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ABSTRACT 
The accurate and safe diagnosis of breast cancer is a significant societal issue, 
with annual disease incidence of 48,000 women and around 370 men in the UK. 
Early diagnosis of the disease allows more conservative treatments and better 
patient outcomes.  
Microcalcifications in breast tissue are an important indicator for breast cancers, 
and often the only sign of their presence. Several studies have suggested that 
the type of calcification formed may act as a marker for malignancy and its 
presence may be of biological significance.  
In this work, breast calcifications are studied with FTIR, synchrotron FTIR, ATR 
FTIR, and Raman mapping to explore their disease specific composition. From 
a comparison between vibrational spectroscopy and routine staining procedures 
it becomes clear that calcium builds up prior to calcification formation. Raman 
and FTIR indicate the same size for calcifications and are in agreement with 
routine staining techniques. From the synchrotron FTIR measurements it can be 
proven that amide is present in the centre of the calcifications and the intensity 
of the bands depends on the pathology. Special attention is paid to the type of 
carbonate substitution in the calcifications relating to different pathology grades.  
In contrast to mammography, Raman spectroscopy has the capability to 
distinguish calcifications based on their chemical composition. The ultimate goal 
is to turn the acquired knowledge from the mapping studies into a clinical tool 
based on deep Raman spectroscopy. Deep Raman techniques have a 
considerable potential to reduce large numbers of normal biopsies, reduce the 
time delay between screening and diagnosis and therefore diminish patient 
anxiety. 
In order to achieve this, a deep Raman system is designed and after evaluation 
of its performance tested on buried calcification standards in porcine soft tissue 
and human mammary tissue. It is shown that, when the calcification is probed 
through tissue, the strong 960 cm-1 phosphate band can be used as a pseudo 
iv 
 
marker for carbonate substitution which is related to the pathology of the 
surrounding tissue. Furthermore, the first study in which human breast 
calcifications are measured in bulk tissue with a thickness of several millimetres 
to centimetres is presented. To date, measurements have been performed at 41 
specimens with a thickness up to 25 mm. Measurements could be performed 
through skin and blue dye.   
The proposed deep Raman technique is promising for probing of calcifications 
through tissue but will need refinement before being adopted in hospitals.  
 
Keywords: Breast cancer, apatite, FTIR (Fourier Transform InfraRed), 
synchrotron FTIR, ATR (attenuated total reflection), Raman mapping, deep 
Raman, Transmission Raman spectroscopy  
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GLOSSARY 
4T1: A mineralising breast cell line. 
ACP: Amorphous calcium phosphate. 
Adipose tissue: fat. 
ALP: alkaline phosphatase. 
Amide I: FTIR amide vibration band in the 1600 - 1700 cm-1 region. 
Amide II: FTIR amide vibration band in the 1500 - 1600 cm-1 region. 
Anti-Stokes: Inelastic scattering event in which the scattered photon has a 
higher energy than the incident photon. 
Apatite: Hydroxyapatite, material type II calcifications are made of, a phosphate 
mineral with chemical composition Ca10(PO4)6(OH)2.  
AR: Alizarin Red staining, a routine stain used in pathology to visualise calcified 
material. Calcium is stained in red. 
ATR FTIR: Attenuated total reflection FTIR, a form of FTIR in which a higher 
spatial resolution is obtained by employing a crystal with a higher refractive 
index than the material that is investigated. 
A-type (substitution): The hydroxygroup of the apatite is substituted by 
carbonate. 
B22: FTIR beamline Diamond synchrotron used for studies. 
βG: betaglycerophosphate. 
B-type (substitution): The phosphate group of the apatite is substituted by 
carbonate. 
Calcifications (breast calcifications): Calcified material in the breast. See 
type I and type II. 
Carcinoma: Cancer arising from the epithelial cells. 
CCD: charge coupled device, a type of detector. 
COD: Calcium oxalate dihydrate (CaC2O4·2H2O), the material type I 
calcifications consist of. 
COHAP: Carbonate substituted HAP. 
COM: Calcium oxalate monohydrate, a standard for COD. 
CW: Continuous wave, a non-pulsed laser. 
DCIS: Ductal carcinoma in situ. Cancer arising in the epithelial cells of the 
ducts. 
Deep Raman: Raman spectroscopy adapted in such a way that photons from 
deeper depths can be measured. 
De-paraffin: The removal of paraffin from slides of a pathology block. In our 
studies this is done by using hexane. 
Elastic scattering: Rayleigh scattering, the energy of the incident photon is 
equal to the energy of the scattered photon. 
Epithelium: Type of cell lining the breast ducts. 
Extracellular matrix: Complex network produced and excreted by cells to 
extracellular space which provides the cells structural support and 
influences their physiology and development.  
Ex vivo (measurements): Measurements done outside an organism, for 
example on excised tissue.  
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xxiv 
 
FPA: Focal plane array, a type of detector. 
FTIR: Fourier transform infrared, a vibrational technique that examines the 
chemical compositions by probing chemical bonds. 
FWHM: Full width half maximum. 
G: glycerol. 
GLREC: Gloucestershire Local Research Ethics Committee. 
HAP: hydroxyapatatite, the material type II calcifications consist of. 
H&E: Haematoxylin and eosin, a routine staining procedure that stains the 
nuclei of the cells purple and the surrounding tissue a range of orange 
hues. 
Horizontal view: Modality during mammography in which the breast is 
compressed top to bottom. 
Inactive breast: No lactation or pregnancy.  
Inelastic scattering: Scattering event in which the energy of the incident and 
the scattered photon differs.   
Invasive cancer: Tumour spreading to other parts of the body. 
Inverse SORS: SORS measurements in which the excitation is done in a ring, 
and the collection in the centre of the ring. 
In vivo (measurements): Measurements done in an intact cell or organism. 
IRENI: FTIR beamline Synchrotron Radiation Center (WI, USA) used for 
studies. 
Kerr gating: A type of deep Raman spectroscopy based on temporal 
differences of signals from different depths.  
LCIS: Lobular carcinoma in situ. Cancer arising in the epithelial cells of the 
lobules. 
L-type (carbonate substitution): The carbonate is within the surface hydration 
layer of the apatite.  
Macrocalcifications: Larger calcifications with a size up to several millimetres. 
Mammography: Screening technique used in the NHSBSP. The breast is 
examined with X-ray after compression from either top to bottom or left to 
right. 
Metastasis: Spread of cancer. 
Mie scattering: Scattering of photons by a sphere. 
MRI: Magnetic resonance imaging, a medical imaging technique in which a 
magnetic field is applied and the alignment of the protons returning to their 
original state is measured when the field is removed. 
mRNA: messenger RNA. 
NBSP: National breast screening programme. 
Near-IR:  Region of the electromagnetic spectrum, ± 780 - 3000 nm.  
NHSBSP: NHS breast screening programme. 
Oblique view: Modality during mammography in which the breast is 
compressed left to right. 
One stop clinic: Triple assessment consisting of mammogram and/or 
ultrasound, family history and clinical examination and a biopsy done in one 
day. 
OPN: Osteopontin, a bone matrix protein expressed by human breast cancer 
cells. 
Glossary 
xxv 
 
Pi: Phosphate. 
PCA: Principal component analysis, a multivariate data analysis used to 
decrease the amount of data. 
PCA-LDA: Principal component analysis linear discriminant analysis 
PCA load: All data is compressed to a smaller amount of loads than spectra. 
Each load shows the next largest variation in the spectrum.  
PCA score: The PCA scores indicate how much of the corresponding load is in 
the original spectrum of the specimen.  
PPi: Pyrophosphate. 
Raman mapping: A combination of microscopy and Raman spectroscopy. By 
measuring a Raman spectrum on every position, a chemical map can be 
created. 
Raman scattering: Inelastic scattering event of photons.  
Raman shift: The shift in wavelength between the incident and scattered 
photon. 
Rayleigh scattering: Elastic scattering event, the energy of the incident photon 
is equal to the energy of the scattered photon (elastic scattering). 
Resonance Raman: A variant of Raman spectroscopy where an excitation 
wavelength close to an absorption band is used to enhance the probability. 
SERS: Surface enhanced Raman spectroscopy. Due to the interactions with a 
roughened metal surface the Raman signal is dramatically improved by 
electromagnetic and chemical enhancement. 
SESORS: Surface enhanced spatially offset Raman spectroscopy, a 
combination of SERS and SORS which will increase the Raman signal 
compared to SORS. 
SNR: Signal to noise ratio. 
SORS: Spatially offset Raman spectroscopy, a distance is introduced between 
the excitation and collection. 
Spatial approach: Discrimination of signals based on position differences. 
Stokes: Inelastic scattering event in which the scattered photon has a lower 
energy than the incident photon. 
Synchrotron: Facility where intense beams of lights are produced by 
accelerating electrons along a circular trajectory. 
Temporal approach: Discrimination of signal based on differences in time. 
TNM: Tumour Node Metastasis staging. 
Transmission Raman: An extreme form of SORS in which the signal is 
collected on the opposite end of the sample. 
Turbid media: highly scattering media. 
Type I calcifications: calcifications consisting of COD 
Type II calcifications: calcifications consisting of HAP. 
US: Ultrasound, a medical imaging technique, US is often used for biopsy 
guidance. 
VK: von Kossa staining, a routine stain which stains calcified material black. 
Whitlockite: calcium phosphate mineral with composition Ca3(PO4)2. 
X-ray: Region of the electromagnetic spectrum, ± 0.1 - 10 nm. 
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1 Introduction 
1.1 Breast disease and anatomy 
1.1.1 Breast disease 
Breast cancer is the most common type of cancer among women and accounts 
for 30.6% of all cancers among women (figure 1.1). In 2009, 48,417 women 
were diagnosed (and 371 men) with breast cancer in the UK alone (Cancer 
Research UK, 2012a).  
 
Figure 1.1: Most common cancers among females in the UK in 2009 (Cancer 
Research UK, 2012b). 
Breast cancer incidence in the UK is 124 per 100,000 women (about 1 in every 
8 women). There is however a strong relation between age and incidence. In 
the 20-24 years old age group, the incidence per 100,000 women is 1.4 while 
for example the incidence in the age group 40-44 years old is 121.4 per 
100,000, and 400.1 in the 65-69 age group (Cancer Research UK, 2012b). The 
incidence numbers per age group are displayed in figure 1.2.  
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Figure 1.2: Number of breast cases per year and age-specific incidence rates per 
100,000 women in the UK (Cancer Research UK, 2012b). 
Other important risk factors are a family history of breast cancer (linked to the 
BRCA1 and BRCA2 genes), previous breast disease, the age at menarche, 
menopause and the first pregnancy (McPherson, 2000), and the 
mammographic density. The mammographic density is a measure for the tissue 
composition. While fat appears dark on a mammogram, epithelium and stroma 
(connective tissue) are radiographically dense and appear light on a 
mammogram. The risk of breast cancer increases four to six times for women 
with dense tissue in 75% or more of the breast compared to women with little or 
no dense tissue in the breast (Boyd et al., 2007).  
Carcinoma, a cancer arising from the epithelial cells, is the most common 
cancer in the breast and can be divided into several classes and grades 
according to the tumour node metastasis staging described in section 1.1.4. 
Carcinoma is often split in ductal and lobular carcinoma named after the 
believed origin of the cancer i.e. the ducts or the lobules. Although it is now 
known that both types originate from the terminal duct lobular unit these names 
are still commonly used (Sainsbury, 2000). Ductal carcinoma is much more 
common than lobular carcinoma and accounts for 90% of the breast carcinomas 
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(Cassidy et al., 2006). As the male breast contains ductal epithelium, carcinoma 
can develop in men as well although the incidence is much lower. Breast cancer 
accounts for only 0.2% of cancers among men (Cancer Research UK, 2012a). 
In situ disease represents the first stage (ductal carcinoma in situ or DCIS and 
lobular carcinoma in situ or LCIS) in which the tumour remains within the 
confines of the ductal basement membrane. It is estimated that the probability 
of development from DCIS into invasive cancer (when the tumour spreads to 
other parts of the human body) is between 30 and 50% (Cassidy et al., 2006). 
Invasive ductal carcinoma (IDC) accounts for 75% of all breast cancers 
(Cassidy et al., 2006). 
 
1.1.2 Breast anatomy 
In women, the breast contains a mammary gland that secretes milk for feeding 
infants. During the lactation stage, milk is produced in the lobules which are 
drained into the ducts towards the nipple. Each lobule consists of circa twenty 
acini which open into the terminal duct. Similar to ducts, the acini are lined with 
a single layer of epithelial cells and an external layer of myoepithelial cells 
around the basal membrane (Guinebretiere et al., 2005). The anatomy of the 
human (female) breast is shown in figure 1.3.  
When the breast is inactive (no pregnancy and lactation) the lobules consist 
almost entirely of branching ducts surrounded by connective and adipose (fat) 
tissue (Kopans, 2007). During pregnancy the glandular tissue increases in size 
by growth, branching of the ducts, and formation of acini from the ducts. 
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Figure 1.3: Anatomy of the human breast (training.seer.cancer.gov accessed 
August 11, 2010). 
 
1.1.3 Detection of breast cancer 
The prognosis of breast cancer patients is strongly correlated with the stage in 
which the disease is detected. Early diagnosis allows more conservative 
treatment and better patient outcomes. Screening will result in detecting cancer 
in an earlier (and more treatable) phase resulting in lower mortality rates. 
Mammography is the standard method to screen for breast cancer, the NHS 
alone screened over 2.1 million women in the year 2009/2010 with this 
technique (Patnick, 2011). There is no evidence that clinical examination, breast 
ultrasound, or teaching self-examination are effective tools for early detection 
(Blamey, 2000). 
The UK National Breast Screening Programme (NBSP) offers three-yearly 
mammography screening. Originally the age range of the women invited for 
screening was 50-64 years which was in 2002-2004 expanded to 50-70 years. 
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Currently the range is further expanded; by the end of 2012 all women between 
47 and 73 years old will be invited (Duffy et al., 2010).  
During mammography, the breast is examined with X-ray after compression 
from top to bottom for the horizontal view, and left to right for the oblique view. 
In general, dense materials such as calcifications (or bone material) would 
absorb more radiation and are typically displayed in white, while less dense 
materials such as breast tissue absorb less radiation and appear dark in 
mammograms. Due to the higher density of breast tissue in breast of young 
women, the contrast is low and mammography is less sensitive which results in 
an age restriction on the applicability of this technique. An overview of the 
techniques that can be applied to improve the contrast is given by Cheng et al. 
(2003). A typical range of density of mammograms is shown in figure 1.4 for the 
horizontal view (upper row) and oblique view (lower row). 
 
Figure 1.4: Example of the range in density visible in mammography. Horizontal 
views are shown in the upper row and oblique views in the lower row. (Images 
kindly provided by Prof. Iain Lyburn, radiologist at Cheltenham General 
Hospital). 
When an abnormality is found during mammography, the patient will be referred 
to the ‘one stop clinic’ where a triple assessment will be carried out consisting of 
the following: 
1. Mammogram and/or ultrasound. The combined use of mammography 
and ultrasound increases the sensitivity (Kuhl et al., 2005; Zonderland et 
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al., 1999). Ultrasound is often used to examine young (or pregnant) 
women who cannot be examined with mammography and can be used to 
target the location of a biopsy (Nover et al., 2009). 
2. Family history and clinical examination by a clinician 
3. Biopsy 
Women who show symptoms of breast disease, such as a lump felt during 
breast self-examination, can be referred to the one stop clinic by their GP. 
Women with a higher-than-average risk of developing breast cancer may be 
offered additional screening and genetic testing. In the future, the use of 
molecular markers as a screening tool may be beneficial for this specific group.  
A technique suitable for younger women, with symptoms or a family history is 
magnetic resonance imaging (MRI) (Kuhl et al., 2005). In figure 1.5, a typical 
example of an MRI image is shown in panel C, alongside the mammogram 
images in panel A and B. 
 
Figure 1.5: Mammogram versus MRI scan; A) Horizontal view mammogram; B) 
Oblique view mammogram; C) MRI scan (images kindly provided by Prof. Iain 
Lyburn, radiologist at Cheltenham General Hospital). 
MRI is based on the alignment of protons to a magnetic field applied. When the 
magnetic field is removed, the alignments of the protons return to their original 
state. A picture is then formed based on the different rates of return to the 
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equilibrium state (Nover et al., 2009). MRI is typically more sensitive than 
mammography and therefore used to obtain extra information after a suspicious 
mammogram (Kriege et al., 2004; Orel and Schnall, 2001). The specificity of 
MRI is limited (in contrast to the sensitivity which is remarkably high), the 
technique is costly and the cost-effectiveness is debated and therefore this 
method is not routinely used in the breast screening programme (Orel and 
Schnall, 2001). 
 
1.1.4 Pathology of breast disease 
When an abnormality is detected, the diagnosis is made based on a tissue 
biopsy which is examined by pathologists. Biopsy is currently the ‘gold standard’ 
for breast cancer diagnosis. Staining of biopsies by a pathologist is a routine 
procedure in order to pick out differences in pathology more easily. H&E 
(haematoxylin and eosin) is the first stain performed on almost all (sectioned) 
specimens in medicine. Haematoxylin stains the cell nuclei blue, the eosin 
counter stain changes the colour of blue-stained nuclei towards purple and 
provides a range of orange hues for the surrounding tissue. By providing the 
different colours to specific elements of the specimen the morphology of cells 
and tissues is more readily defined by the pathologist.  
Pathology samples are staged in order to create a patient specific treatment 
plan. Breast cancer staging can be done with the ‘tumour, node, metastasis’ 
(TNM) staging system. It takes the size of the tumour into account, whether the 
nodes are affected and whether or not the cancer has spread (metastasis). An 
overview of the TNM method is given in table 1.1 (Cassidy et al., 2006). 
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Table 1.1: Overview of TNM (Tumour, Node, Metastasis) staging system, adapted 
from (Cassidy et al., 2006). 
The TNM staging does not take the histological grade into account which is a 
prognostic factor strongly associated with both breast cancer-specific and 
disease-free survival (Rakha et al., 2008). The survival rate of patients with 
grade I tumours is significantly better than that of patients with grade II or III 
tumours (Elston and Ellis, 1991). The Nottingham Prognostic Index (NPI) 
combines tumour size, nodal status and histological grade. The NPI is given by 
the following relationship: 
 
T 
stage 
Tumour size Specifics 
Tis In situ disease only  
T1 ≤ 2 cm  
  
T1mic 
≤0.1 cm  
  T1a 0.1 - 0.5 cm  
  T1b 0.5 - 1.0 cm  
  T1c 1.0 - 2.0 cm  
T2 2.0 - 5.0 cm  
T3 >5.0 cm  
T4 Any size  Involvement of chest wall or skin 
  T4a Any size Spread into chest wall 
  T4b Any size Spread into skin 
  T4c Any size Fixed to chest wall and skin 
  T4d Any size Inflammatory cancer 
N 
stage 
Node assessment  
Nx Not assessed 
N0 Negative lymph nodes 
N1 Positive mobile axillary lymph nodes (armpit) 
N2a Positive fixed axillary lymph nodes 
N2b Internal mammary nodes clinical apparent (behind breast bone) 
N3a Positive lymph node infraclavical (below collarbone) 
N3b Positive axillary and internal mammary nodes 
N3c Positive supraclavicular node (above collarbone) 
M 
stage 
Metastasis assessment  
M0 No sign of metastasis  
M1 Positive evidence of distant metastasis  
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Equation 1: Calculation of the Nottingham Prognostic Index (NPI). 
A lymph node stage of one means that no lymph nodes are involved. A lymph 
node stage of two includes patient with up to three lymph nodes involved. When 
four or more lymph nodes are involved and/ or an internal lymph node the grade 
equals three. The score of the histological grade equals the grade itself i.e. I=1, 
II=2, and III=3 (Lee and Ellis, 2008). A NPI value lower than 2.4 indicates an 
excellent prognosis, between 2.4 and 3.4 equals 'good', 3.4- 5.4 'moderate', and 
above 5.4 a poor prognosis. 
Samples can also be tested for the oestrogen and progesterone receptor status 
and HER2 expression. 60-75% of breast cancers are oestrogen receptor 
positive (Cassidy et al., 2006). Oestrogen and progesterone can stimulate the 
growth of these breast cancers and hormone therapy can block the effect or 
lower the amount of oestrogen and progesterone in the body. HER2 is a protein 
that functions as a growth factor receptor and is expressed in 25-30% of breast 
cancers (Cassidy et al., 2006). When patients are HER2 positive, they can be 
treated with the antibody Herceptin. 
Although pathologists are highly trained and skilled, pathology remains a 
subjective approach that is time consuming and expensive. In a study by 
Parham et al. (2010) fifteen H&E slides were examined by seven general 
pathologists and five pathologists with a special interest in breast pathology. 
The majority diagnosis of the pathologists with a special interest was used as 
the gold standard and compared to the diagnosis of the individual general 
pathologists. The pathologists with a special interest obtained an 85% 
agreement in the first round and 82% in the second round six months later. The 
general pathologists reached 75% agreement in the first round and 72% in the 
second round. An objective and accurate method would clearly mean a leap 
forward in cancer diagnostics. 
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1.2 Breast cancer screening and the clinical need of a new tool 
Upon examination by pathologists, most biopsies turn out to be negative. A 
study by Weaver et al. (2006) done at the seven community-based 
mammography registries located in California, Colorado, New Hampshire, New 
Mexico, North Carolina, and Washington (USA) indicated that from 26,748 
biopsies from the breast cancer surveillance data from 1996-2001, only 8815 
were followed by diagnosis of breast cancer (33%). Of the breast cancers, 81% 
were invasive carcinoma and 19% DCIS. In the UK, the NHSBSP recalled 
89,164 women after mammography in the age group 45-74 (4.2% of the total 
amount of 2,102,870 women) in 2009/2010, of which 16,476 turned out to have 
breast cancer which is 18.5% of the amount of recalls (Patnick, 2011). The 
numbers of recalls are displayed in figure 1.6 in orange, and are split into 
malignant (red) and non-malignant (green). 
 
Figure 1.6: Amount of recalls in NHSBSP 2009/2010 (based upon numbers of 
Patnick 2011). 
Due to the time delay between screening, biopsy, and diagnosis, the current 
procedure is very stressful for the woman involved. A new technique which 
could be used in vivo would not only reduce time delay and stress, but also the 
amount of biopsies and the costs associated with biopsies. It is estimated that a 
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fine needle aspiration cytology costs £35.52, a core biopsy including equipment 
£49.25, and day case and inpatient excision biopsies including pathology costs 
£539 and £812, respectively (Dey et al., 2002). It should be noted that the use 
of fine needle aspiration cytology is not recommended for calcification biopsy as 
it is not possible to confirm representative sampling (Evans et al., 2002). 
Vacuum-assisted biopsy has a higher calcification retrieval yield and is the 
method of choice to biopsy calcifications (Liberman et al., 1998b). Biopsy costs 
in the USA were evaluated by Liberman et al. (2001) who found that the costs 
of a stereotactic biopsy of one site were $764 (with clip) or $695 (without clip) 
and for two sites $1,345 (with clips) or $1,234 (without clips). Needle 
localisation and surgical biopsy costs $1,502 (with margin analysis) or $1,435 
(without margin analysis) for one site and $2195 (with margin analysis) or $ 
2,127 (without margin analysis) for two sites.  
In this thesis, the potential incorporation of deep Raman into the breast 
screening programme is evaluated. Currently, the presence of calcifications in 
the breast is used as a diagnostic marker but the chemical composition of the 
calcification is not taken into account. This chemical composition is however 
related to disease. There is no reliable method to separate different types of 
calcifications with mammography although several algorithms have been 
proposed based on for example size, shape, and number (Fandos-Morera et 
al., 1988; Galkin et al., 1983) but these are not very effective in all situations.  
It is estimated that microcalcifications are the primary indication for 
approximately 50% of the breast biopsies performed for non-palpable 
mammographic abnormalities (Johnson et al., 1999), although retrospectively 
most biopsies contain calcifications. This number is in agreement with Gülsün et 
al. (2003) who state that 30-50% of nonpalpable breast cancers present 
themselves as microcalcifications alone. National figures regarding the 
proportion of breast biopsies due to calcifications are unknown for the UK, but it 
is well known that the recall rate is two times higher in the USA (Elmore et al., 
2005) which is thought to be related to extra investigations of calcifications. The 
number of biopsies due to calcifications in the UK is therefore thought to be 
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lower. Private communication with Miss Sarah Vesty, breast surgeon at 
GHNHSFT, revealed that within Gloucestershire Hospitals 15% of the biopsies 
(group size 400) are solely due to calcifications (Vesty, 2013) which is two times 
less than the USA figures. 
Probing the chemical composition in vivo as an adjunct to mammography would 
reduce the amount of (unnecessary) biopsies and reduce the time delay in 
clinic; especially in the USA where recall rates are higher. Raman spectroscopy 
has shown to have the potential to probe the chemical composition of 
calcifications ex vivo (Haka et al., 2002). In figure 1.7 an overview of the current 
time line is given. 
 
Figure 1.7: Overview of the current screening programme (in case an 
abnormality is detected). 
Over the last few years, breast screening programmes have been criticised in 
the literature (Kalager et al., 2012). It is often claimed that the high rates of 
DCIS found are due to over diagnosis with the associated lesions not 
presenting a clinical problem or threatening patient’s life. Another possibility 
would therefore be to use deep Raman spectroscopy to monitor disease 
progress since not in all cases clinical interference would be beneficial.  
 
1.3 Calcifications in the breast 
The formation of crystalline and semi-crystalline materials occurs extensively 
within many types of biological tissues due to natural biological processes (such 
as bone and tooth growth), but also as a result of disease progression (for 
example prostate and thyroid cancer), drug therapies and implants. The 
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presence of calcifications in breast is one of the features screened for during 
mammographic screening and one of the most common abnormalities identified 
(Purdie and McLean, 2009). The presence of calcifications is related to high 
histological grade in both DCIS (Mun et al., 2013) and invasive breast cancer 
(James et al., 2003). 
A typical example of mammography in which calcifications are found is shown 
in figure 1.8. 
Figure 1.8: Mammography of breast with diffuse calcification in left breast A) 
horizontal view right breast; B) horizontal view left breast; C) Zoom of left breast 
horizontal view; D) oblique view right breast; E) oblique view left breast; F) Zoom 
of oblique view left breast (Images kindly provided by Prof. Iain Lyburn, 
radiologist at Cheltenham General Hospital). 
In panel A and B the horizontal view of the right and left breast are shown, 
followed by an enlarged version of the left breast in panel C. In this panel 
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microcalcifications can be distinguished. In panel D and E an oblique view is 
presented. A zoom of the oblique view of the left breast is shown in panel F in 
which microcalcifications can be observed again. 
The amount of calcifications present in the breast ranges from study to study 
since it is often not the key research question and the methods of estimating the 
amount of calcifications range. As previously mentioned, Johnson et al. (1999) 
estimated that half the biopsies performed after a mammographic abnormality 
are due to the presence of calcifications, while Evans et al. (2002) estimate that 
in 80-90% of mammographic abnormalities in DCIS calcifications are present. 
According to Sickles (1982) 60-80% of cancers are shown to contain 
calcifications upon histology examination. These numbers cannot be compared 
since all of the numbers describe another statistic. Although there might not be 
a standard way of reporting the amount of calcifications in the breast, 
calcifications are currently the primary guide used in radiology, surgery, and 
pathology during the diagnostic evaluation (Johnson et al., 1999).  
While microcalcifications have a typical size ranging from 50-500 micron (Evans 
et al., 2002), calcifications can reach sizes of a few millimetres. Figure 1.9 
shows an example of a macrocalcification in panel A, and of microcalcifications 
in panel B.  
 
Figure 1.9 A) Mammogram with macrocalcification; B) mammogram with 
microcalcifications (images kindly provided by Prof. Iain Lyburn, radiologist 
Cheltenham General Hospital). 
A correlation between such large macrocalcifications and cancer has not been 
found and further monitoring or treatment is not necessary when the 
macrocalcifications are seen on mammograms. Therefore, for the rest of the 
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thesis macrocalcifications are not discussed and the term ‘calcification’ will refer 
specifically to microcalcifications.  
Breast calcifications can also be found in men. These calcifications are typically 
coarser, fewer in number, and more widely scattered than those in female 
breast cancer (Adibelli et al., 2010). Since breast cancer in males is rare and 
not routinely screened for, calcifications in the rest of this thesis will refer to 
calcifications found in the female breast.  
The incidence of calcification in carcinoma in situ is more common in younger 
patients and in higher grade lesions (Tse et al., 2007). In a large study by Tabar 
et al. (2004), the 24-year survival of 714 women with 1-14 mm invasive breast 
carcinoma was studied. In 7% of the cases calcifications were observed (52 
cases) and this was associated with a positive lymph node status (spread to 
lymph node), poorer histologic grade and a decreased survival rate. It has been 
reported that removal of calcifications correlates significantly with a lower rate of 
upgrade from atypical ductal hyperplasia to carcinoma (Nguyen et al., 2010).  
Radiography of biopsy specimens is an integral part of the biopsy process 
(Liberman et al., 1994). In a study of Margolin et al. (2004) it is shown that 
biopsy cores containing calcification (based on specimen radiographs) were 
more likely to enable an accurate diagnosis than cores without calcifications. 
Furthermore, it was less likely to miss a cancer diagnosis in the samples with 
calcifications. Radiography is sometimes used to verify the presence of the 
lesion in the surgical biopsies. If no calcifications are present the surgeon would 
then be informed and a wider excision would be performed immediately instead 
of summoning patients back to theatre at a later time (Johnson et al., 1999; 
Liberman et al., 1994). In figure 1.10 X-ray images are shown of excised tissue 
with a wire to target the correct location (panel A), a typical example of an X-ray 
machine used in theatre (panel B), microcalcifications in a slice (panel C), and 
microcalcifications in core specimens (panel D). 
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Figure 1.10: A) X-ray image of surgical specimen; B) X-ray machine used in 
theatres; C) X-ray image of microcalcifications in slice; and D) X-ray image of 
microcalcifications in core specimens (www.faxitron.com). 
Although microcalcifications are relatively common in breast carcinoma, their 
presence is however also a common feature in benign breast lesions. According 
to Popli (2002) the amount of cases in which calcifications are found steadily 
increases with age up to 86% of the mammograms of women between the age 
of 76 and 79. Since the breast screening programme examines women in the 
age range from 47-73 years old, the presence of microcalcifications is a 
frequent occurrence. 
In order to distinguish calcifications related to benign and malignant surrounding 
tissue, several algorithms have been proposed based on, for example, size, 
shape, and grouping characteristics such as the size and shape of the cluster 
and the amount of calcifications in the cluster.  For example, the shape of most 
calcification clusters surrounded by breast tissue with benign pathology grade 
tend to be round or oval, while the majority of clusters associated with ‘in situ’ 
breast disease have an irregular shape, 80% of the in situ cases, which is 
sometimes V-shaped (10% of the irregular shapes) (Evans et al., 2002). As a 
general rule, the smaller the cluster the less characteristic it is for breast 
disease. In a study by Fondrinier et al. (2002) 44% of the clusters of 25 mm or 
smaller were malignant, whereas of the clusters larger than 25 mm 69% was 
malignant. In the same study 42% of the clusters containing 35 calcifications or 
less were malignant, while 83% of the clusters containing more calcifications 
were malignant. In contrast, Park et al. (2000) demonstrated in a study of 57 
nonpalpable lesions with three different radiologists, that the significance of 
clustering is lower than 50% and does not necessarily suggest malignancy.  
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A study by Buchbinder et al. (2002) evaluated the size of the calcifications in a 
cluster by measuring the length and area of the calcifications. The average 
length of the calcifications in the malignant group was higher than the length in 
the benign control group, 0.44 mm versus 0.38 mm. It is however difficult to use 
this as a tool considering the small size of the calcifications.   
Other important features for differentiating benign from malignant 
mammographic calcifications is the calcification morphology and distribution. 
Linear calcification morphology has a high positive predictive value for 
carcinoma (Liberman et al., 1998a). A study by Stomper et al. (2003) indicated 
that linear calcifications are more often related to invasion than granular 
calcifications. A common feature of DCIS is that the calcifications are aligned in 
a ductal distribution (Evans, 2003). When reanalysing previous mammograms 
from women diagnosed with DCIS, 22% of the mammograms were in retrospect 
abnormal. The mammograms showed more often predominantly punctate 
calcifications and less common rod-shaped calcifications (Evans et al., 1999).  
 
1.3.1 Types of breast calcifications 
In breast, two major types of microcalcifications are found. These are thought to 
be related to disease (Frappart et al., 1986, 1984). Type I (calcium oxalate 
dihydrate, CaC2O4∙2H2O) is mostly present in benign biopsies and type II 
(hydroxyl apatite, Ca10(PO4)6(OH)2) are most often present in proliferative 
lesions including carcinoma (Foschini et al., 1996; Haka et al., 2002; Singh and 
Theaker, 1999). Type II micro calcifications frequently indicate the location of 
the most important abnormality within the breast (Cassidy et al., 2006; Johnson 
et al., 1999).  
Type I calcifications have an amber colour under the microscope and are 
birefringent under polarised light (Frappart et al., 1986). In contrast, type II 
calcifications appear greyish under microscope light and are not birefringent 
under polarised light.  
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Although calcifications have a positive predictive value for breast cancer, it is 
not known how they are formed in mammary tissue and what their exact role in 
breast cancer formation is. Pathologists often state that calcifications are 
formed by calcification in necrotic debris or from mucin in extracellular spaces. 
These claims were however never underscribed by thorough time-studies.  
Recent studies suggest that calcifications play an active role in disease 
development. In a study by Morgan et al. (2001) breast cell lines treated with 
hydroxyapatite crystals were compared to those treated with latex beads of 
similar size and concentration and those with no treatment at all. In all the cell 
lines the addition of hydroxyapatite had a positive effect on mitosis which 
resulted in a higher cell count compared to the latex bead treatment and control. 
In a later study by Cox et al. (2012) scratch wound assays were performed on 
cells treated with hydroxyapatite and controls and an increase in cell migration 
was found for the cell lines treated with hydroxyapatite. The same assay was 
performed with calcium oxalate crystals in which no effect was found. 
Hydroxyapatite crystals were also found to up regulate the production of a 
variety of matrix metallo proteinases (MMPs)(Morgan et al., 2001). MMPs are 
associated with degradation of the extracellular matrix and a good correlation 
between expression of MMPs and the invasive phenotype of tumour cells has 
been shown (Morgan et al., 2005).      
Another indication for the role of calcifications in breast disease is given by a 
study by Vestergaard (2011) which reported a decreased risk of breast cancer 
among patients given bisphosphonates. In medicine bisphosphonate 
medication is used as drugs for various diseases of bone, tooth, and calcium 
metabolism. 
Cox et al. (2012) investigated the effect of several factors on the 4T1 
mineralising breast cell line. Inorganic phosphate promotes stabilization of 
formed hydroxyapatite and inhibits the formation of some other calcium-
containing crystals such as calcium oxalate (Terkeltaub, 2001). 4T1 cells 
stained positively for calcium after treatment with inorganic phosphate. 
Phosphonoforbic acid inhibited mineralisation with and without inorganic 
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phosphate. When two inorganic phosphate molecules are joined by an ester 
bond, inorganic pyrophosphate is formed which is a known inhibitor mineral 
deposition and growth (Fleisch, 1998; Thouverey et al., 2009). Inorganic 
pyrophosphate did not have an effect on the 4T1 cell line (Cox et al., 2012).  
The ratio of pyrophosphate to phosphate is interlinked with alkaline 
phosphatase which hydrolyzes phosphate esters. Alkaline phosphatise is 
suggested to have an important role in the calcification formation mechanism 
(Bonucci, 2007) and was found to enhance 4T1 cell mineralisation (Cox et al., 
2012). Levamisole is a known inhibitor for alkaline phosphatise (Cox et al., 
2012). Other regulators in breast calcification formation are osteonectin, bone 
sialoprotein II and osteopontin (OPN) which are all bone matrix proteins 
expressed by human breast cancer cells (Bellahcène and Castronovo, 1997, 
1995; Pampena et al., 2004). Cox et al. (2012) also evaluated the role of OPN 
on the 4T1 cell line. Similar to the addition of pyrophosphate to the medium, the 
addition of OPN did not have an effect on the cell line. There was however an 
increase in OPN mRNA in the 4T1 cell line grown in osteogenic cocktail. 
The experiments done by Cox et al. (2011; 2012) resulted in the mammary 
mineralisation mechanism shown in figure 1.11. Betaglycerophosphate (βG) of 
the osteogenic cocktail in which the cell line is grown is hydrolysed to glycerol 
(G) and phosphate (Pi) by alkaline phosphatise (ALP). Phosphate is then 
transported into the cell and apatite is formed by combining calcium and 
phosphate in the cell. ALP mRNA is up regulated and the formed apatite enters 
the extracellular matrix. Pyrophosphate (PPi) acts as an inhibitor of apatite 
formation, but the increased ALP may result in PPi hydrolysis to Pi, which can 
be incorporated in the apatite. OPN is also an inhibitor but does not affect an 
effect on the 4T1 cell line which might be due to the ALP taking of a phosphate 
group and thus making it inactive. The apatite crystals in the extracellular matrix 
enhance the proliferation and migration of the surrounding cells. 
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Figure 1.11: Mammary mineralisation model proposed by Cox et al. 
Betaglycerophosphate (βG) of the osteogenic cocktail is hydrolysed to glycerol 
(G) and phosphate (Pi) by alkaline phosphatise (ALP). Pi is transported into the 
cell and apatite is formed and up regulation of ALP mRNA takes place. 
Hydroxyapatite enters the extracellular matrix. Pyrophosphate (PPi) acts as an 
inhibitor of apatite formation, but the increased ALP may result in PPi hydrolysis 
to Pi, which can be incorporated in the apatite. Osteopontin (OPN) is also an 
inhibitor but ALP may take of a phosphate group whereby making it inactive. The 
apatite crystals in the extracellular matrix enhance the proliferation and 
migration of the surrounding cells (Cox et al., 2012). 
 
1.3.2 Carbonate incorporation in apatites and its relationship to 
disease 
Biological apatites are usually described as carbonate substituted 
hydroxyapatite. Research by Haka (2002) using principal component analysis 
(PCA) indicated that further subtle differences could be found between type II 
calcifications associated with benign and malignant tissue. Benign proliferative 
lesions have shown to have type II calcifications with higher carbonate levels 
than the more pure hydroxyapatite (HAP) crystals found in malignant lesions.  
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A recent infrared study performed by Baker et al. (2010) confirmed that the 
correlation between carbonate substitutions of type II calcifications (and 
therefore the chemical composition) and different types of breast lesions is very 
strong. In this study 236 calcifications on paraffinised pathology samples were 
measured (10 µm thickness mounted on calcium fluoride). These were 
separated into three groups; invasive (n=112), in situ (n=64), and benign 
(n=60). These  three groups within the cancer spectrum could be separated 
from each other by the percentage of carbonate substitution and the amide to 
phosphate infrared band intensity ratio (figure 1.12).  
 
Figure 1.12: Relationship between the different pathology groups and the 
carbonate percentage (Baker et al., 2010). 
Substitution in the apatite lattice slightly changes the structure and often has 
critical effects on mineral properties such as hardness, strain, crystal size and 
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dissolution rate. The apatite in bone (7 wt% CO3) is amenable to dissolution, 
whereas the slightly different apatite in enamel (3.5 wt% CO3) resists dissolution 
(Wopenka and Pasteris, 2005). 
Carbonate can be incorporated in the apatite lattice (Ca10(PO4)6(OH)2) in 
several ways;  
 A-type: the hydroxygroup is substituted by carbonate (Peroos et al., 
2006) 
 B-type: the phosphate group is substituted by carbonate (Peroos et al., 
2006)  
 L-type (labile); the CO3
2- is within the surface hydration layer of the 
apatite crystals (Wopenka and Pasteris, 2005) 
A representation of the apatite lattice and the apatite lattice with A-type and B-
type substitution is given in figure 1.13. The location of substitution is indicated 
with a black circle. 
 
Figure 1.13: Incorporation of carbonate in the HAP lattice. The location of the 
carbonate substitution is indicated with a black circle. Oxygen atoms are 
depicted in red, calcium in green, phosphorus in pink, hydrogen in white, and 
carbon in yellow. (Peroos et al., 2006).  
Synthetic and high-temperature apatites often contain A-type defects or a 
mixture of A- and B-type defects in their lattice. Since the synthesis of A-type 
carbonated substituted apatites in industry requires high temperatures, it was 
always thought that apatites in breast tissue (and more general biological 
apatites) mostly type B would be observed (Baker et al., 2010; Nishino et al., 
1981). Although A-type substitution in biological apatites has previously been 
considered negligible (Wopenka and Pasteris, 2005), more recent studies by 
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Fleet and Liu (2007) indicate that biological apatites are Na-bearing A-B 
carbonate apatites, with significant B-type substitution. Calculations of Peroos 
et al. (2006) showed that type A is the most stable defect structure, but that the 
B-type defect is also energetically feasible. In a study by Shimoda et al. (1990) 
a link was found between pH and the type of carbonate inclusion. Apatites were 
prepared in aqueous systems with a pH of 7.5 or 10.5 at 80°C. At neutral pH the 
carbonate was incorporated at both the A- and B-positions, while at the alkaline 
pH the carbonate was only included as B-type.  
 
1.4 The use of vibrational spectroscopy to detect breast 
calcification and cancer 
Probing microcalcifications with Fourier transform infrared (FTIR) can give 
insight in the disease status of the surrounding tissue (Baker et al., 2010).  FTIR 
is a form of vibrational spectroscopy.  
 
1.4.1 Vibrational spectroscopy 
In vibrational spectroscopy, typically, the periodic oscillations of atoms within a 
molecule (or lattice oscillations) are probed by the absorption (i.e. FTIR 
spectroscopy) or inelastic scattering of photons (i.e. Raman spectroscopy). 
 
1.4.1.1 FTIR 
In an infrared experiment a range of (infrared) frequencies are directed onto the 
sample and absorption occurs where the energy of the incident radiation 
matches that of a vibrational mode of the molecule of the sample. The loss of 
photons from the incident beam after the interaction with the sample is then 
monitored at different spectral components. Infrared spectroscopy can be done 
in either transmission (beam passes through the sample), reflection (beam is 
reflected from the sample), or transflection mode (beam passes through the 
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sample, is reflected from the substrate, and then passes back through the 
sample). Water strongly absorbs in the IR fingerprint region, which is why it is 
not typically possible to apply IR directly in vivo. (An exception is NIR which is 
monitoring overtone and combination vibrational modes which are much 
weaker.) 
FTIR imaging is however a valuable technique to examine the chemical 
composition of pathology slides on a microscopic scale for its high chemical 
specificity and high sensitivity. However, work to date has been severely limited 
by the spatial resolution of the benchtop systems used to study the interface 
between the calcifications and the breast tissue. To improve spatial resolution 
synchrotron FTIR can be used to a better effect.  
 
1.4.1.2 Synchrotron IR 
In a synchrotron facility, intense beams of lights are produced by accelerating 
electrons along a circular trajectory (e.g. several tens or hundreds of meters). 
Synchrotron light is typically 100 – 1000 times brighter than a conventional 
source and the brightness of the source allows small regions to be probed with 
an acceptable signal to noise ratio (SNR). Using a synchrotron source instead 
of a conventional source radically improves the spatial resolution (Miller and 
Smith, 2005). In figure 1.14, an aerial photo of the Diamond Light Source 
(Oxfordshire, UK) is shown where part of the synchrotron work described in this 
thesis was performed.   
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Figure 1.14: Photo of the Diamond Light Source (www.diamond.ac.uk, accessed 
7 December 2010). 
The FTIR beam line at Diamond uses conventional confocal arrangements with 
apertures and a single point collection. When using this type of setup, the 
aperture dimension determines the spatial resolution (Hirschmugl and Gough, 
2012). Apertures only deliver diffraction-limited resolution when the wavelength 
of the light is larger or equal to the aperture. When a small aperture is used, the 
signal for the longest wavelengths is below the detection limit since the signal is 
reduced over the bandwidth. On the other hand, when a larger aperture is 
chosen the spatial resolution for the shorter wavelengths is sacrificed. The trade 
off between spatial resolution and SNR may result in long acquisition times 
(Hirschmugl and Gough, 2012). At the IRENI beamline (Synchrotron Radiation 
Center, University of Wisconsin, USA), where some measurements presented 
in this thesis were also performed, a wide field approach is used. 
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1.4.1.3 Attenuated total reflection (ATR)  FTIR 
Another way to improve spatial resolution in z-direction (depth) in FTIR is to use 
attenuated total reflection (ATR). ATR is a form of FTIR in which a higher spatial 
resolution is obtained by employing a crystal with a higher refractive index than 
the material that is investigated; commonly used are germanium, silicon, 
diamond, and zinc selenide with refractive indexes of 4.00, 3.41, 2.41, and 2.40, 
respectively (Griffiths and De Haseth, 2007). When the angle of incidence is 
larger than the critical angle total internal reflection takes place. Part of the light 
penetrates into the sample, the evanescent wave. The penetration depth 
depends on the wavelength of the light, the incidence angle, and the refractive 
indexes. Because the penetration depth is independent of the sample thickness, 
ATR is a suitable technique to measure samples with strong water contributions 
(Kazarian and Chan, 2006). Due to the wavelength dependence the ATR 
spectra differ from transmission spectra; the intensity at the high wavenumber 
end of the spectra is typically lower due to a shorter penetration depth.  
 
1.4.1.4 Raman Spectroscopy 
In contrast to FTIR, Raman spectroscopy is based upon inelastic scattering. 
When light is shone on a sample it can be transmitted, absorbed, or scattered. 
Most of the scattered light is scattered elastically (no energy is exchanged 
between the incident photon and the sample) which means the scattered light 
has the same energy (and therefore wavelength) as the incident light. However, 
typically, one out of every 109 scattered photons or less is shifted inelastically to 
a longer wavelength (Stokes, the photon transfers a portion of its energy to the 
sample activating typically a molecular vibrational motion or phonon (crystal 
lattice) vibration) or to a lower wavelength (anti-Stokes, the photon gains energy 
from already active vibrational or lattice motion in the sample) as a result of 
interaction with sample. This effect is called Raman scattering, named after 
C.V. Raman who first reported the effect (Raman and Krishnan, 1928). On the 
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theoretical side, the Raman effect was already predicted earlier by Smekal 
(1923).  
During a Raman experiment the incident photons typically raise the energy 
state of a molecule (the Stokes process) to a so-called ‘virtual state’ (figure 
1.15). This is not a stationary state in a quantum mechanical sense but merely a 
distortion in the electron distribution. A resonant variant of the Raman scattering 
process exists with a hugely enhanced probability of the Raman scattering 
(resonance Raman spectroscopy) where a real electronic absorption state of 
the molecule coincides with the incident photon energy. This process is 
however not used in the studies described due to associated absorption and 
consequently limited penetration depth and therefore not further discussed.  
 
Figure 1.15: The principle of Raman scattering. S0 and S1 correspond to the two 
lowest electronic states. After excitation (↑), the scattered photon (↓) can have an 
energy similar (Rayleigh), higher (Anti-Stokes), or lower (Stokes) than the 
incident photon. 
The shift in wavelength (Raman shift) is normally given in wavenumbers (cm-1) 
and directly related to the frequency of the activated mode within the molecule. 
The frequencies of the modes are highly specific of the chemical constitution. 
Therefore, molecules can be identified by their spectral pattern, ‘Raman 
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fingerprint’. Raman mapping combines spatial information (from the 
microscope) with spectral information. This spectral information can then be 
used to derive chemical information and the location of individual sample 
constituents. 
 
1.4.2 Infrared spectroscopy on calcifications 
Baker et al. (2010; 2009) extensively studied breast calcifications in pathology 
slides with FTIR. As mentioned earlier, Baker et al. (2010) reported a significant 
correlation between the chemical composition (carbonate content and 
protein/mineral ratio) of microcalcifications and the pathology grade of the 
surrounding tissue. Representative spectra for calcifications in tissue with 
different pathology, benign, in situ, and invasive breast disease, are shown in 
figure 1.16.  
 
Figure 1.16: Average FTIR spectra of calcifications from samples with benign, in-
situ and invasive pathology, figure modified from (Baker, 2009). 
All breast calcifications show a strong band around 1026 cm-1 (phosphate) with 
shoulders ~1091 cm-1 and ~1110 cm-1. Furthermore bands can be found ~1550 
cm-1 (amide II protein) and ~1660 cm-1 (amide I protein) for all groups, although 
the intensity differs with pathology. The strong bands around 1464 cm-1 and 
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1472 cm-1 are due to paraffin. Weaker bands can be found in the 870-880 cm-1 
region (carbonate), ~961 cm-1 (phosphate), ~1245 cm-1 (amide III), and ~1417 
cm-1 which is ascribed to carbonate.  
A study by Eckel et al. (2001) found that the amide bands in spectra of breast 
tissue change with pathology. Other FTIR studies evaluate calcified materials 
such as synthetic standards (Apfelbaum et al., 1992; Fleet, 2009; Gadaleta et 
al., 1996a, 1996b; Rehman and Bonfield, 1997; Ślósarczyk et al., 1997), urinary 
stones (Estepa and Daudon, 1997; Maurice-Estepa et al., 2000; Volmer et al., 
1993; Wilson et al., 2010), and mineralised tissues (Boskey and Mendelsohn, 
2005) such as bone and enamel (Aydin et al., 2011; Miller et al., 2001; Rey et 
al., 1991a, 1991b). 
A synchrotron FTIR study consisting of three maps on frozen breast specimens 
was performed by Baker (2009). In this study, a lower concentration of amide I 
and amide II was found in the calcified tissue than in the surrounding tissue. 
Dessombz et al. (2011) published a synchrotron FTIR study on kidney 
calcifications. 
Both Rehman et al. (2010) and Walsh et al. (2012) performed an ATR study on 
breast tissue. Increased spatial resolution and reduction of scattering artefacts 
were reported, but clinical applications are limited due to the required physical 
contact with tissue and the limited sampling area. When studying bone, Furedi 
and Walton (1968) found that the mineral component of bones in whole bone 
sample could be studied without further sample pre-treatment. Gulley-Stahl et 
al. (2009) used ATR for quantitative analysis of kidney stones which flagged up 
an important problem using ATR for calcified materials. Linear calibration 
curves could only be obtained if the particle sizes of the analytes were 
comparable and considerably less than the sampling area of the ATR crystal. 
The particle sizes of hydroxyapatite and calcium oxalate monohydrate were 
measured to be 76 and 20 µm, respectively (Gulley-Stahl et al., 2009).  
A detailed list of IR bands in mineralized materials and their assignments can 
be found in appendix A. 
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1.4.3 Raman spectroscopy on breast calcifications 
It has been shown that type I and type II calcification can be separated with 
Raman spectroscopy in both fixed tissue samples (Haka et al., 2002) and 
freshly excised needle biopsy cores (Saha et al., 2011). Baker (2009) 
performed a Raman mapping study on two areas of a frozen breast tissue 
sample which indicated protein was present at low concentration in the 
calcification region compared to the surrounding tissue.  
Raman studies with different excitation wavelengths were done by Frank et al. 
(1994) who found that background luminescence was significantly lower when 
using an excitation wavelength in the near-IR (691-830 nm used). At these 
wavelengths, lipid bands were more pronounced and oleic acid appears to be 
the main component. In a subsequent study by Frank et al. (1995), Raman 
spectra of normal breast specimens were compared to benign and invasive 
carcinoma. In this study, a different lipid/protein ratio was found for the 
pathology groups of which the intensity of the 1439 cm-1 band is a marker. The 
band also shifts to higher wavenumbers (1450 cm-1) for invasive cancer. The 
intensity of the amide I band (1654 cm-1) changes with the degree of 
unsaturated fatty acid and Frank et al. (1995) use the 1654/1439 band ratio as a 
marker for disease.  
Shafer-Peltier et al. (2002) modelled the components of human breast tissue of 
different pathology grades by comparing the spectra of the specimens to 
chemical components. They found that the amount of fat decreases from 
normal breast tissue to invasive cancer; the fit coefficient was 83% and 2%, 
respectively. In contrast, the amount of collagen in the fit increased from normal 
breast tissue (1%) to invasive breast cancer (40%). Calcifications were not 
commonly found in their study and only played a minor role in their model. In 
later studies by the same group the chemical differences of both types of 
calcifications are probed (Haka et al., 2002), both types of calcifications are 
incorporated in their biochemical fitting model (Haka et al., 2005), and tested for 
margin assessment (Haka et al., 2006), freshly excised surgical specimens 
(Haka et al., 2009) and needle biopsies (Dingari et al., 2012). Deep Raman 
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studies on breast tissue will be discussed in the relevant technique sections in 
1.5. 
Most studies on carbonated hydroxyaptites (the material type II calcifications 
consist of) have been done on bone, dentin enamel, dentine, or synthetic 
materials (Penel et al., 1998, 2005; Leroy et al., 2002; Antonakos et al., 2007). 
It is not known to which extent these studies can be used as a basis for breast 
calcification studies. Spectra of similar materials are expected to be comparable 
due to the alike chemical composition and therefore similar vibration modes. 
However, the different properties of the materials indicate different chemical 
composition which could result in spectral differences. 
Wopenka and Pasteris (2005) studied the spectral differences of four different 
types of apatite; a cross section of a mouse femur, human enamel, geological 
apatite and synthetic apatite. After exclusion of the bands characteristic for 
collagen, the spectra looked remarkably similar. However, when spectral 
regions were enlarged differences could be observed in band position, width, 
and intensity.  
The general shape of the breast calcification spectra will be similar to that of 
synthetic standards. In figure 1.17, Raman spectra of synthetic standards of 
calcium oxalate monohydrate (green), and 0.5 (blue), and 6.0% (red) carbonate 
substituted HAP. 
Figure 1.17: Raman spectra of calcium oxalate monohydrate and 0.5 and 6% 
carbonated HAP. 
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Calcium oxalate monohydrate (COM) is used as a model for calcium oxalate 
dihydrate (COD) since the latter cannot easily be obtained as a standard due to 
its instability (in other studies it is either freshly synthesized or obtained from 
crushed renal stones). The overall shape of the Raman spectra of COM and 
COD are very similar due to their chemical similarity. The characteristic Raman 
bands from COM are observed at 502, 896, 1462, 1489, and 1629 cm-1, and for 
COD at 508, 912, 1477, and 1632 cm-1 (Kontoyannis et al., 1997).  
The spectrum of HAP consists of a bands at 430, 448, 591, and 608 cm-1, a 
strong peak around 960 cm-1, and two broader weaker features at 1047 and 
1072 cm-1 (Awonusi et al., 2007). The intensity of the 1074 cm-1 band increases 
with increasing carbonate substitution (Awonusi et al., 2007; Penel et al., 1997; 
Peroos et al., 2006). As a result, the relative intensity of that band and for 
example the 960 cm-1 band (which is a phosphate band) reveals the percentage 
of phosphate replaced by carbonate (COHAP). As work of Baker et al. (2010) 
revealed, the percentage of carbonate substitution indicates the state of the 
disease. Therefore the relative intensities in the spectra can be used to make 
an indication of the amount of CO3 substitution, which is related to the state of 
disease. 
An overview of characteristic Raman bands in breast tissue and calcified 
materials can be found in appendix B.  
 
1.5 Utilizing deep Raman spectroscopy to detect breast 
calcifications in vivo 
In order to use Raman spectroscopy for the detection of microcalcifications in 
vivo difficulties concerning depth penetration have to be first overcome, for 
example measuring through skin and breast tissue. Traditionally Raman is a 
near-surface technique (Moreira et al., 2008) and cannot be typically applied at 
depths on more than several hundred micrometers in tissue (Matousek and 
Stone, 2007). The penetration depth depends in some extent on the wavelength 
(Stolik et al., 2000) but the choice in wavelength is restricted by the detector 
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(typically CCD) sensitivity, spectral cut off, and water absorption which 
increases significantly above 1000 nm. The clinically relevant depth ranges from 
a few millimetres used for margin evaluation (Keller et al., 2009) to centimetres 
for probing of calcifications (Stone and Matousek, 2008).  
Discrimination of signals with their origin in different layers of a turbid media can 
be achieved by either a temporal or a spatial approach (Matousek, 2007). With 
both methods, the relative signal level from the surface is suppressed which 
enhances the relative signal from the depth of interest (Stone and Matousek, 
2008).  
Temporal approaches are usually done in backscatter mode (signal collection at 
the same side of the sample as excitation) which means that photons arriving 
from greater depths have to travel a larger distance (Matousek, 2007). This will 
result in a time difference between signals from the surface and deeper layers 
(figure 1.18). Normally, time differences like these cannot be detected easily 
since light travels in tissue with a velocity of ~2·108 m/s and the differences in 
distance are minimal. However, due to the diffuse scattering of tissue the path 
lengths are many times greater than the direct distances and the time 
differences larger. The time difference can be detected with state-of-the-art 
equipment such as picosecond Kerr gating (section 1.5.1). 
 
Figure 1.18: Schematic representation of a temporal approach in deep Raman. 
The time difference between the photons emerging from the different layers is 
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used by only accumulating a fraction of the time. By choosing the delay time 
between the trigger to start the gating and opening the gate, it is possible to 
selectively detect one of the signals without a large contribution from another 
one (Ariese 2009). 
Spatial approaches (for example spatially offset Raman spectroscopy (SORS), 
section 1.5.2) are based on the fact that photons emerging from deeper depth 
are spread more sideways than photons emerging from regions closer to the 
surface (Matousek and Stone, 2009; Matousek, 2007). As a result, the distance 
between the excitation and the spot where the Raman signal is measured is 
related to the depth of the origin.  
 
1.5.1 Kerr gating 
Kerr gating is based upon sampling light with temporal differences from the 
illumination pulse. These temporal differences originate from the differences in 
depth where the Raman signals are originating from. As shown in figure 1.19, 
the setup consists of two polarisers in crossed orientation. When the gate is 
closed, all light from the sample is blocked and will not reach the spectrometer. 
However, when the gate is switched on with the gating pulse (between the 
polarisers, drawn in red) a transient anisotropy in the Kerr media can be set to 
act as a half-wave plate. The Kerr media will therefore rotate the polarisation of 
the Raman signal by 90° and enable it to pass through the cross polariser and 
reach the detector. The anisotropy is transient, lasting around 4 ps, and 
consequently the gate automatically closes (due to collisional randomisation of 
the orientation imposed on molecules of CS2 by the intense gating pulse) after 
the passage of the gating pulse. By changing the time delay between the 
Raman excitation pulse and the gating pulse, different fractions of the Raman 
spectra (e.g. photons from different depths of the sample) can be measured 
(Baker et al., 2007; Matousek and Stone, 2009). 
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Figure 1.19: Schematic representation of the Kerr gated setup. Kerr gating is 
based upon temporal differences. When the 'gate' is opened, the Kerr medium 
acts as a half-wave plate. As a result, light can enter the spectrometer. When the 
gate is closed, light cannot reach the spectrometer due to crossed polarizers 
(Matousek and Stone 2009). 
Baker et al. (2007) demonstrated that this technique can distinguish synthetic 
type I and type II material through a layer of both fatty and protein rich tissues. 
However, the 1 picosecond pulsed laser (490 nm) used combined with a 4 ps 
Kerr-gate (equal to resolution) was only able to measure through 1 mm of 
tissue. The combination of the high peak intensity and shallow depth are 
serious limitations to the use of this technique in vivo. 
 
1.5.2 Spatially Offset Raman Spectroscopy  
SORS is based upon spatial instead of temporal gating. Spatial gating is 
achieved by introducing a certain distance between the excitation and collection 
points of the Raman signals. Photons emerging from deeper areas have to 
travel a larger distance to the surface and on their way diffuse more sideways 
than photons from a shallower depth (figure 1.20). 
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Figure 1.20: Principle of SORS. Photons with their origin deeper in the tissue will 
have a higher chance to travel sideways during their route towards the surface. 
(See for comparison red (shallow depth) and blue (deeper depth) arrow above 
each other) By introducing a distance between the excitation and collection it is 
possible to discriminate between photons from different depths. 
With this concept, low power continuous wave (CW) lasers can be used instead 
of short laser pulses, which reduces not only the risk of photo degradation but 
also makes the device instrumentally much simpler and safer. In comparison to 
the Kerr gated work, the signal quality is typically also higher. This is a result of 
the fact that the spatial technique integrates scattered light across the entire 
time domain, unlike the temporal approach (Matousek, 2007). The SORS setup 
evaluated by Stone et al. (2007) could probe calcified material up to a depth of 
10 mm of tissue, which is clinically considerably more relevant than a depth of 1 
mm. In addition, with a small modification of the SORS technique it is viable to 
apply higher laser powers and achieve even higher penetration depths (figure 
1.21): in contrast to the conventional SORS setup where the Raman signal is 
accumulated in a ring around the central excitation fibre, the excitation is within 
a ring (and thus the light is spread over a larger area) and the Raman signal is 
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collected in the centre of the ring (Matousek and Stone, 2009). This concept is 
termed inverse SORS. 
 
Figure 1.21: SORS and inverse SORS probe. SORS measurements are applied by 
exciting in the middle and collecting in a ring with offset Δs around the excitation 
point. In inverse SORS the excitation and collection positions are swapped 
around, which means excitation is in the ring and collection in the middle. In this 
case, the average power can be higher since the beam is spread over a larger 
surface (Matousek and Stone 2009). 
Until recently, SORS was only used to detect strong Raman scatterers deep 
within tissue with a specific fingerprint (for example, microcalcifications and 
breast tissue have a completely different Raman spectrum) underneath a layer 
of soft tissue. Keller et al. (2009) recently published a proof of principle study for 
the use of SORS on layered soft tissue. The authors were able to detect Raman 
signal of a breast tumour sample based underneath normal breast tissue 
through up to two millimetres of soft tissue based upon the spectral differences 
between breast tissue and breast tumour tissue. In figure 1.22, Raman spectra 
of an experimental run are given. The top spectrum is the pure tumour spectrum 
and the bottom spectrum a characteristic breast tissue spectrum. The spectra in 
between are measured on different distances from the excitation fibre and the 
light grey boxes indicate the spectral regions used for discrimination. In contrast 
to previous studies (Frank et al., 1995) not the intensity of the 1439 cm-1 band is 
used for the lipid to protein ratio but the ratio of the 1303 to 1265 cm-1 band. In a 
later study (Keller et al., 2011) a SORS probe with multiple offsets was 
designed and tested.  
laserRaman
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laser Raman
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Figure 1.22: Raman spectra SORS experiment of 0.5 mm normal breast tissue 
layer with tumour underneath (Keller 2009). The main changes in the spectra are 
highlighted in grey. 
 
1.5.3 Transmission Raman 
Transmission Raman can be considered to be an extreme form of SORS in 
which the signal is not collected in backscatter mode, but at the other side of the 
tissue - in transmission mode. In this orientation, the overall bulk content is 
measured instead of an individual layer or microstructure of sample (Matousek, 
2007). This issue is illustrated, by figure 1.23 in which the transmission Raman 
setup used in this thesis is depicted with a breast phantom. The phantom is a 
triple modality biopsy training phantom (18-229, Imaging Equipment Ltd, Bristol, 
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UK). Models like this are normally used for needle biopsy training and can be 
imaged with mammography, MRI, and ultrasound imaging. 
The phantom is opaque when it is not illuminated by the laser (upper panel). In 
the lower panel the same breast phantom is shown during five minutes of 
illumination (5 minutes shuttertime, ISO 1600, f=2.8) and it can be seen that the 
light travels through the whole of the breast phantom although the transmission 
Raman signal has shown to have a moderate bias toward the centre of the 
sample, diminishing outward toward each face (Matousek et al., 2011).  
 
Figure 1.23: Transmission setup with breast model. Upper panel) Not illuminated, 
Lower panel) When illuminated by laser scattering can be seen in the whole of 
the breast (Photography by Hans van Schoot).  
Stone and Matousek (2007) demonstrated that calcified material at a depth of 
up to 16 mm in chicken tissue could be detected with transmission Raman, 
which was about twice the depth that could be achieved with SORS. Only one 
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year later, with an improved methodology, (Stone and Matousek, 2008) calcified 
material within mammalian tissue could be detected through 27 mm with 
transmission Raman. Furthermore, they were able to detect a clinical relevant 
calcification concentration levels (0.125% volume density ratio HAP, 
approximately 0.14% relates to benign and 0.05% to malignant) through 20 mm 
of porcine tissue.  
 
1.5.4 Surface Enhanced Raman scattering (SERS) combined with 
SORS (SESORS) 
The main challenge of Raman spectroscopy, and especially deep Raman, is its 
low intensity. Only one of every 109 photons is typically scattered inelastically. 
Raman signals can be dramatically improved by using surface enhanced 
Raman scattering (SERS). The exact mechanism behind SERS is still being 
discussed although SERS was already observed in the 1970’s (Fleischmann et 
al., 1974). However, it is widely accepted that the major mechanisms are both 
electromagnetic and chemical enhancement due to interactions with the 
roughened metal surface (Lin et al., 2009). Electromagnetic enhancement takes 
place when the exciting radiation interacts with the surface electrons to form a 
plasmon, a quasiparticle resulting from the quantisation of plasma, essentially 
an oscillating electron wave on the surface (McNay et al., 2011). Chemical 
enhancement is sometimes called charge-transfer enhancement because the 
analyte is bound to the metal surface to form a charge-transfer complex. It is 
generally acknowledged that that the electromagnetic enhancement is typically 
much larger than the chemical enhancement. 
An enhancement factor up to 106 or more can be achieved for silver, copper, 
and gold nanoparticles. Also other metals such as aluminium and a range of 
transition metals are reported to obtain the surface enhanced Raman effect but 
these give lower enhancement (Ren et al., 2007). Disease specific signals can 
be achieved by using specific antibodies to target molecules. This approach is 
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not entirely non-invasive as it relies on introducing metal nanoparticles into the 
tissue. 
By combining SERS and SORS (SESORS) the SERS signals can be read from 
deep areas of tissue directly. The first experimental demonstration of SESORS 
was recently published by Stone et al. (2010). The concept was demonstrated 
through 25 mm of mammalian tissue in Raman transmission geometry. 
Disadvantages of this approach include the requirement for injection of metal 
nanoparticles into tissue and yet unanswered issues about their toxicity. In a 
later study by Xie et al. (2012) experiments were performed with a tag 
(bisphosphonate) specific for calcium hydroxyapatite.  
 
1.6 Summary and outlook 
Microcalcifications in the breast are related to breast disease. Type I 
microcalcifications (COD) are mostly present in benign breast disease, while 
type II calcifications (HAP) are mostly present in proliferative lesions including 
carcinoma. It has been shown that the level of carbonate substitution in HAP is 
related to the pathology of the surrounding tissue.   
Mammography cannot reliably distinguish between type I and type II 
calcifications. Raman spectroscopy has the ability to distinguish both types, but 
is originally a (sub)surface technique. In contrast, Raman spectroscopy has 
such inherent capability but until recently it could only be applied to the surface 
or near surface of the specimen of interest. With the introduction of deep 
Raman techniques there is the potential capability of identifying the lesion type 
from outside the breast non-invasively. A new generation of non-invasive 
methods for diagnosis based around transmission Raman and SORS (both 
deep Raman techniques) have a potential to reduce large numbers of normal 
biopsies, reduce the time delay between screening and diagnosis and therefore 
diminish patient anxiety.  
The aim of this PhD project is to explore the mechanism of calcification 
formation, the disease specific composition, and the biochemical interface of the 
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calcification and the tissue. The ultimate goal is to turn this knowledge into a 
clinical tool based on deep Raman spectroscopy (especially SORS and 
transmission Raman) to detect breast disease in vivo and thus reduce the 
amount of false negatives (which result in a high biopsy rate) and patient stress. 
An overview of the deep Raman approach and how this could be incorporated 
in the NHS breast screening programme can be found in figure 1.24. 
 
Figure 1.24: Time line of the current screening programme (in case an 
abnormality is detected) and where a deep Raman approach would fit in. 
 
1.7 Aims and objectives of the study 
All work in this thesis can be divided into three categories; 1) study of breast 
calcifications, 2) study of deep Raman techniques, and 3) deep Raman on 
breast calcifications. In the first category the following aims are explored: 
calcification formation, disease specific composition, and biochemical interface 
of the calcification and the tissue. The other two sections will evaluate the 
development of a clinical tool for breast cancer diagnosis based around deep 
Raman spectroscopy.  
1) Study of breast calcifications (chapter 3) 
 Study known calcification standards to understand the relationship 
between chemical differences and spectral differences (section 3.1). 
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o Infrared experiments (3.1.1) 
o Raman experiments (3.1.2) 
 Compare spectroscopic techniques (FTIR & Raman) to von Kossa (VK), 
Alizarin Red (AR), and H&E staining to understand how well 
spectroscopic techniques pick up calcifications in pathology samples 
(3.2). 
 Detailed mapping of calcifications and surroundings with synchrotron 
FTIR (section 3.3). Also, an ATR FTIR study is shown (3.4) and a 
preliminary Raman mapping study (3.5). 
 
2) Deep Raman system evaluation (chapter 4) 
 To build a deep Raman setup which can be used for proof of principle 
studies (2.2.5). 
 To evaluate the performance of the system in clinical use by evaluating 
o Sample thickness (4.2) 
o Lateral spreading of Raman signals (4.3) 
o Originating depth of the Raman signals (4.4) 
o Measurements through skin (4.5) 
 
3) Deep Raman spectroscopy on breast calcification (chapter 5) 
 To test whether the amount of carbonate substitution of calcification 
standards can be evaluated through tissue (5.1). 
 To detect calcification standards buried in human breast tissue (5.2). 
 To measure fresh human breast tissue with deep Raman system and 
compare findings with X-ray images of the sample to evaluate detection 
of microcalcifications (5.3). 
45 
 
2 Materials and methods 
2.1 Materials and sample collection 
2.1.1 Calcification standards 
Standards of 0.5, 1.4, 2.0, 2.3, 3.5, 6.0, and 11.0% COHAP (defined by 
manufacturer (±1%) with FTIR) were obtained from Clarkson Chromatography 
(South Williamsport, PA, USA). Calcium carbonate and amorphous calcium 
phosphate was provided by Prof. Keith Rogers. Calcium oxalate monohydrate 
was obtained from Aldrich.  
Prof. Mary Tecklenburg (Central Michigan University) kindly supplied samples 
with different amounts and types of carbonate substitution which was monitored 
with Raman, FTIR, and elemental analysis. The following samples were 
supplied: type A carbonate substituted apatite (4.4 wt% A-type, 0.6 wt% B-
type), AB carbonated apatite (4.3 wt% A-type, 2.1 wt% B-type), and 0.2, 1.1, 
2.0, 2.3, 3.5, 5.7, 7.7, and 10.3 wt% B-type substituted apatite.   
All samples were used without further sample pre-treatment, except during the 
IR Diamond experiments and the dilution series for which KBr tablets were 
pressed. For the diamond experiments 1 wt% tablets were pressed and for the 
dilution series 0.3, 0.7, 0.8, 1.3, 1.8, and 2.2 wt%. 
 
2.1.2 Pathology slides for (synchrotron) FTIR mapping 
Specimens were stored from patients who had undergone biopsy for 
mammographically suspicious breast lesions at Gloucestershire Royal Hospital 
between 1996 and 2007. Specimens that were known to contain calcifications, 
from histopathology reports, were retrieved from storage. Mammographic 
reports would have been more appropriate, since it is mammographically visible 
calcifications we are interested in. Unfortunately, mammographic data was not 
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available. It should be noted that the resolution of histology for calcification 
detection is higher than that of mammography.  
The paraffin-set biopsy blocks were microtomed to 10 µm thickness and 
mounted onto calcium fluoride windows (CaF2) with a thickness of one 
millimetre (Crystran Ltd, Poole, UK) for the first beam time allocation (Diamond, 
SM6123).  
Four types of substrates were obtained from Crystran Ltd to test for further 
experiments: calcium fluoride (1mm thickness), barium fluoride (0.5mm), zinc 
sulphide (0.4mm), and zinc selenide (0.5mm). From these samples the 
transmittance was measured over the wavelength area of interest. 
All the subsequent synchrotron work (SM6605 Diamond synchrotron and direct 
access IRENI beamline) was carried out with tissue samples microtomed to 6 
µm thickness mounted on 0.5 mm barium fluoride windows (Crystran Ltd, 
Poole, UK).  
An ethical approval for this study was obtained from the Gloucestershire Local 
Research Ethics Committee (GLREC). 
 
2.1.3 Stained pathology slides 
Contiguous sections of twelve samples selected for synchrotron work, benign 
(n=3), in situ (n=4), and invasive breast disease (n=5), were stained with H&E, 
AR, and VK by the pathology department of the Gloucestershire Hospitals. As 
discussed in chapter 1, H&E stains the cell nuclei purple and the surrounding 
tissue a range of orange hues.  
AR stains specific minerals, a complex with calcium needs to be formed in order 
to stain. AR forms a salt with calcium and the polarizing effect of the calcium ion 
results in the colour change (Puchtler et al., 1969). AR staining is affected by 
the pH of the solution used. Calcium oxalate crystals stain with AR at a pH of 
7.0, but not at a pH of 4.2 (Proia and Brinn, 1985). AR staining was performed 
at a pH of 4.2, which will positively stain apatites red.  
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 VK staining localizes calcium deposits indirectly, it stains the counter ions; 
normally carbonate or phosphate (Kumar and Kiernan, 2010). For the VK 
staining, van Gieson was used as a counterstain. The optimal pH for 
hydroxyapatite is between pH 4.0 and 6.0 (Shoji, 1993). During VK staining 
calcium cations are replaced by silver, the silver salts are reduced by a light 
reaction and calcified material is blackened out (Kumar and Kiernan, 2010).  
Ethical approval for this study was obtained from the GLREC.  
 
2.1.4 Pathology slide for ATR imaging and Raman mapping 
Samples used for the first experiments at the Diamond synchrotron (10 µm 
thickness mounted on 1 mm CaF2, Crystran, Poole, UK) were used for initial 
ATR experiments. For the Raman mapping and the ATR data presented in this 
thesis, a sample known to contain calcifications in the ducts was retrieved back 
from storage and cut to 6 micron thickness and mounted on calcium fluoride (1 
mm thickness, Crystran, Poole, UK). 
Paraffin was removed by placing paraffin oil on top of the sample for 1 hour and 
subsequently washed off with 0.5 ml hexane. The protocol was applied twice in 
order to remove all paraffin and is evaluated in Appendix D. Ethical approval for 
this study was obtained from the GLREC. 
 
2.1.5 Mineralising breast cell line 
A novel in vitro model of mammary cell mineralization has previously been 
established and characterised using the murine mammary adenocarcinoma 4T1 
cell line (ATCC). A detailed description of the protocol has been published 
previously (Cox et al., 2012). Briefly, 4T1 cells were grown on calcium fluoride 
windows (1 mm thickness, Crystran, Poole, UK) in either osteogenic cocktail 
(50µg/ml ascorbic acid and 10mM beta glycerophosphate) or control media for 
7, 11, 14, 17, or 21 days after which they were fixed with 4% paraformaldehyde 
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by Dr Maria Morgan and Dr Rachel Cox of the Royal College of Surgeons in 
Ireland. Replicates were stained with AR and VK. 
 
2.1.6 Breast tissue models for preliminary deep Raman studies 
Porcine soft tissue was used to mimic human mammary tissue. All models were 
used fresh and without further sample pre-treatment. For measurements 
through skin, porcine soft tissue was used with attached skin since porcine skin 
is known to be similar to human skin (Vardaxis et al., 1997). The epidermis of 
the porcine skin has been quoted to be in a range similar to that in human, the 
dermal-epidermal ratio of porcine skin is in the same range as in human skin, 
and the turnover of the epidermis and the kinetics of epidermal proliferation are 
similar as well. Porcine tissue has however a large amount of striated muscle 
which is different than the fibroglandular tissue which makes up the breast.  
 
2.1.7 Nanoparticles 
Four different SERS nanoparticles were kindly provided by Cabot (Boston, 
Massachusetts); x403, x420, x421, and x440. Each nanoparticle consisted of a 
gold core (~100 nm diameter) surrounded by a reporter molecule (dye) and the 
whole was encapsulated in a thin silica layer. The nanoparticles were used as a 
target for several experiments concerning the sample thickness, signal depth 
and detecting several different analytes (multiplexing). In figure 2.1, the Raman 
spectra of all nanoparticles are shown. The crosses depict the bands used as 
marker bands in non-invasive experiments.  
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Figure 2.1: Raman spectra of the four different SERS particles. The crosses 
depict the characteristic bands used in non-invasive experiments (Stone et al., 
2011). 
 
2.1.8 Breast tissue for preliminary deep Raman studies 
For initial experiments, human tissue collection was done by Mr. J. Horsnell and 
C. Chan during mammoplasty reduction procedures in Cheltenham General 
Hospital. Tissue was snap frozen in liquid nitrogen and transported back to 
Gloucester Royal Hospital and stored at -80°C until used. Ethical approval was 
obtained from GLREC.  
 
2.1.9 Fresh human breast tissue for transmission Raman study 
Breast tissue specimens were collected from 41 patients who underwent a wide 
local excision or a wire guided local excision at Gloucestershire Royal Hospital 
during breast lists of Miss Sarah Vesty and Mrs Clare Fowler between March 
and July 2012. The patients had an age ranging from 35 to 84, with a mean age 
of 61.  
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During local excision the affected area and some of the surroundings were 
removed. For a wire guided local excision a wire is inserted in the breast to 
mark the location of the breast abnormality which is checked with 
mammography. In panel A of figure 2.2, a mammogram is shown of a breast 
with an inserted wire and in panel B the X-ray image of the excised specimen of 
the same patient.  
 
Figure 2.2: Example of wire localisation A) Mammogram made after wire 
insertion; B) excised breast specimen with wire. 
As a routine procedure, X-ray images were captured of each breast specimen in 
theatre using a faxitron device. X-ray images of every specimen are shown in 
appendix E3. Four of the 41 specimens had skin attached (specimens 18, 23, 
39, and 40) and seven specimens had blue dye in them (specimens 8, 12, 18, 
21, 27, 30, and 39). Blue dye is normally injected in combination with 
technicium near the tumour to locate the sentinel lymph nodes. A range of 
‘blueness’ was found which is illustrated in figure 2.3. The presence of blue dye 
did not appear to hinder the Raman measurements, although it has been 
reported it yields a Raman spectrum on its own (Horsnell, 2012). 
Ethical approval was obtained from the GLREC and informed written consent 
was given by the patients involved. A copy of the consent form and patient 
information leaflet can be found in appendix E1 and E2.  
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Figure 2.3: Some of the specimens had blue dye in them and a range of 
‘blueness’ was observed. In the left panel a specimen without blue dye is shown, 
while in the right panel the most extreme case is shown.  
 
2.2 Experimental setups 
2.2.1 Benchtop Fourier Transform InfraRed (FTIR) 
FTIR measurements for the staining study and the targeting of calcifications for 
synchrotron experiments were performed on a Spotlight 400 (Perkin Elmer, 
figure 2.4) at Gloucestershire Hospitals.  
 
Figure 2.4: Illustration of the Perkin Elmer Spotlight 400 (www.perkinelmer.de, 
accessed 11 October 2012). 
The dilution experiments were performed at the Cranfield Forensic Institute at 
the Shrivenham campus. For these experiments a Spotlight 200 (Perkin Elmer) 
was used. 
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In contrast to the Spotlight 400, a Spotlight 200 cannot be used for imaging. The 
difference between the two systems lies in the choice of detector; the spotlight 
200 has a single element detector while the Spotlight 400 has an 16x1 linear 
array detector. Both the systems are cooled with liquid nitrogen and have a 
detection wavelength range of 4000 – 720 cm-1.  
 
2.2.2 Raman microscope and imaging 
Measurements were performed on a Renishaw System 1000 using 830 nm as 
the excitation wavelength. The system is equipped with a xyz-stage and 
streamline technology which enables Raman mapping. A schematic overview of 
the system is shown in figure 2.5 below. The laser beam enters the system at 
the laser turning mirror after which it is directed to the microscope using other 
mirrors. The scattered light is directed through a filter, removing the spurious 
laserline, onto a slit. The grating (300 lines/mm) splits the different spectral 
components of the Raman light before it reaches the CCD detector.  
 
Figure 2.5: Schematic overview of the Renishaw 1000 system (Clark, 2002). 
The Raman system is calibrated daily to ensure reproducible measurements. 
Calibration is performed with an offset calibration based on a measurement of 
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silicon which has a well defined peak position of 520 cm-1. Furthermore, every 
day the system is used, standard measurements are performed on a cuvette 
filled with cyclohexane and a polymer standard (pipette tip) which both have 
bands over the entire active spectrum. When blocking the laser, a full calibration 
can be obtained by measuring a neon argon emission spectrum. A 
measurement done on a piece of green glass is used as a tertiary fluorescent 
standard. This has been calibrated using a National Physical Laboratory 
tungsten (W) filament secondary standard calibration lamp.  
 
2.2.3 Synchrotron beam lines 
Synchrotron experiments were performed at beam line B22, MIRIAM 
(Multimode InfraRed Imaging And Microspectroscopy) at the Diamond light 
source (Harwell Science and Innovation Campus, Oxfordshire, UK) and IRENI 
(IR ENvironmental Imaging) at the Synchrotron Radiation Center (SRC, 
University of Wisconsin, USA).  
At both the end stations of the B22 beam line, Hyperion 3000 microscopes were 
used coupled to Bruker Vertex 80V FTIR spectrometers. Synchrotron light is 
supplied to the beam line by the storage ring.  Diamond operates in a ‘top up’-
mode which means the electron beam is topped up through the day, in contrast 
to the SRC which gets injected only four times a day.  
The IRENI beam line at SRC combines multiple synchrotron beams (3x4) with 
wide-field detection using a focal plane array (FPA) detector (Nasse et al., 
2011). Light is supplied by the Aladdin electron storage ring and mirrors create 
a 3x4 bundle of synchrotron beams which are directed to the Vertex 70 FTIR 
spectrometer and FPA detector (Bruker Hyperion 3000). A schematic overview 
is shown in figure 2.6. 
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Figure 2.6: Overview IRENI beamline A) Schematic of the experimental setup; B) 
FPA image (128x128 pixels) of the 12 beams illuminating an area of ~50x50 µm. 
Scale bar 40 µm. C) Visible light photograph of the 12 beams projected on a 
screen in the beam path, dashed box in A, the scale bar has a size of ~1.5 cm; D) 
Long time exposure photograph showing the combination of the 12 individual 
beams into the beam bundle (Nasse et al., 2011). 
 
2.2.4 ATR FTIR setup 
ATR experiments on the deparaffinated sample were performed in collaboration 
with Dr Alina Zoladek and Prof Sergei Kazarian at Imperial College (London, 
UK). The system comprised a germanium ATR crystal, a Varian 7000 FTIR 
spectrometer, and a Varian 600 UMA microscope with a 64x64 pixel FPA 
detector. 
 
2.2.5 Transmission Raman setup 
A scheme of the experimental setup is shown in figure 2.7. The emission from a 
frequency stabilized laser module (830 nm, Innovative Photonics Solutions) is 
sent from a fibre to a fibre-export collimator (Thorlabs) and passed through a 
laserline filter (FL830-10, Thorlabs) to suppress off-centre spectral emission 
from the laser. The generated Raman signal was collected in transmission 
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mode using an anti reflective coated lens (f = 60 mm, dia = 50 mm, INGRYS 
Laser Systems). The collimated scattered light was passed through a 
holographic super notch filter (HSPF-830.0 AR-2.0, Kaiser Optical Systems) to 
remove the elastically scattered light and imaged onto an optical fibre bundle by 
a second lens of the identical parameters to the collection lens. The output end 
of the fibre probe was placed at the entrance port of a Holospec VPH system 
spectrograph (Kaiser Optical systems Inc, HSG-917.4 custom, f-number = 1.8) 
and a CCD detector cooled to -70°C (Andor Technology, DU420A-BR-DD, 1024 
x 255 pixels).  
 
Figure 2.7: Experimental setup used for the transmission Raman study. 
During this project, the deep Raman setup was modified to permit both the 
inverse SORS and transmission Raman modes of operation (figure 2.8 and 
2.9). First, a different Innovative Photonics solutions laser was installed for the 
transmission measurements, with similar excitation wavelength (830 nm), but 
the output power at the sample was 220 mW. Later this laser was used for the 
inverse SORS measurement and for the transmission measurements a 830 nm 
Renishaw laser with an output of 140 mW was utilised. 
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Figure 2.8: Photograph of the deep Raman setup, with the different components 
indicated. 
In figure 2.9, the beam alignments for both SORS and transmission Raman are 
indicated. The beam used for the transmission Raman (depicted in blue) is 
steered to the sample using a periscope to adjust the height and mirrors leading 
the beam to a lens (f= 7.0 cm) which focuses the beam onto the sample. 
 
Figure 2.9: Detail of the combination of SORS and transmission Raman on one 
setup. The path of the laser is depicted in the photograph for both the SORS 
(orange arrows) and transmission Raman (blue arrows). 
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A collimated laser  beam of the SORS laser (path depicted in orange in figure 
2.9) was passed through an axicon (fused silica conical lens, 25.4 mm 
diameter, 170° apex angle, Topag Lasertechnik, Darmstadt, Germany) 
transforming the beam into a ring. By changing the separation of the axicon 
from the sample, the size of the ring could be controlled. In figure 2.10 a 
schematic overview of the workings of an axicon is shown together with an 
example of the output. 
 
Figure 2.10: A) Schematic view of the workings of an axicon with the apex angle 
indicated in red (adapted from www.thorlabs.de, last accessed 11 October 2012); 
B) Photograph of the output of the axicon used, the point in the middle of the 
circle is the output of the transmission laser. 
The system was calibrated using an aspirin tablet (acetylsalicylic acid), using 
values provided by Boczar et al. (2003). On each day the system was used, an 
aspirin spectrum was first measured (1 s acquisition time). The pixels relating to 
the 291, 425, 551, 751, 1045, 1191, 1293, 1606, and 1752 cm-1 bands were 
selected, assigned, and then used to calibrate the system. 
 
2.3 Methods 
2.3.1 Study of breast calcifications (Chapter 3) 
2.3.1.1 Study of calcification standards 
Tablets were pressed from all available standards (KBr, 1wt% analyt) and 
measured with the MIR light source at Diamond Light Source beamline B22. 
Measurements were performed without an aperture, 4 cm-1 spectral resolution 
and 256 scans in transmission mode with a blank KBr tablet as background 
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(n=3). Data was loaded into Matlab, where the average of each group was 
taken.  
To test what effect the saturation has on the peak shape, KBr tablets were 
pressed with different amounts of 2% carbonate substituted apatite in them. 
These tablets were measured on the Spotlight 200 in transmission mode in the 
4000-750 cm-1 range, 120 scans, 1 cm-1 interval, and a 200x200 micron 
aperture. Measurements were done at five locations on the tablet. This part of 
the study was performed at the Cranfield Forensic Institute at Shrivenham. 
A comparison between ATR and transmission FTIR was made by measuring a 
2.0% carbonate substituted HAP sample with both settings. These 
measurements were performed by Dr Alina Zoladek at Imperial College. All 
measurements were performed with a 40x objective, but due to the different 
nature of the measurements the interrogated area differs. ATR measurements 
were performed at a 64x64 µm area with 64x64 data grid, in contrast to 
transmission FTIR measurements which interrogated a 350x350 µm area with a 
64x64 data grid. For the ATR measurements 50 scans were used and for the 
transmission FTIR 25 scans. 
Raman measurements were performed on a Renishaw 1000 Raman 
microscope. Powders were measured on a calcium fluoride slide without further 
sample preparation. Five areas were measured with an acquisition time of 60 
seconds and a 50x magnification.  
 
2.3.1.2 Comparison of spectroscopic techniques with pathology staining 
The unstained, AR stained, H&E stained, and VK stained sections of all 
specimens were registered on the Perkin Elmer Spotlight 400 system and 
corresponding areas were selected. Obtaining a white light image with the FTIR 
setup results in intensity discrepancies which are visible as ‘tiles’ in the 
montaged image. An example is shown in figure 2.11A.  
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Figure 2.11: A) Original white light obtained with FTIR setup; B) same figure 
corrected for unequal distribution of light over each tile. 
This tiling can be removed by using a blending algorithm (Rankov, 2005). By 
selecting a blank area of the size of one tile on the slide, a Gaussian filter can 
be created which reduces the differences in lighting conditions. This filter is then 
applied to the whole of the image. In panel B of figure 2.11 the image is shown 
after applying the algorithm. 
All FTIR measurements were done on the unstained slides in transmission 
mode, with a spatial resolution of 4 cm-1 and pixel size of 6.25 µm. The FTIR 
data was loaded into Matlab and biochemical component spectra were fitted 
against the spectral maps of the samples using ordinary least squares. The 
simplest approach to detect calcifications with FTIR, would be to plot the 
intensities of a characteristic apatite band, such as the ~1030 cm-1 band, over 
all the maps. However, due to the complexity of the spectra, a fit would be more 
appropriate to identify calcifications. Biochemical fitting enabled estimations of 
the relative concentrations of these components at each location in the 
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measured map. Hydroxyapatite (0.5% carbonate), DNA, RNA, actin, collagen 
IV, oleic acid, palmitic acid, paraffin, and triolein were fitted and the first 
derivative was used because previous research shows that works best (Baker, 
2009). The false colour map indicating the fit coefficient (or relative level) of the 
hydroxyapatite was compared to the images of the different stains on adjacent 
slides of the sample. 
 
Raman and IR mapping of cell lines 
Samples grown in osteogenic cocktail for 7, 11, 14, 17, and 21 days, and 
samples grown for 11 and 14 days in control media were measured at the B22 
beamline of Diamond Light Source Ltd (Harwell Science and Innovation 
Campus, Oxfordshire, UK) with a Bruker 80 V Fourier Transform IR 
Interferometer coupled to a Hyperion 3000 microscope. A grid of 145x145 
micron was evaluated (10x10 point measurements) on the samples grown in 
osteogenic cocktail in order to capture different phases in calcification growth. 
Measurements consisted of 128 scans with a resolution of 4 cm-1 performed in 
transmission mode with a 15 µm aperture and a 36x objective. The background 
was measured every 10 measurements. Additional FTIR measurements were 
performed on a Perkin Elmer Spotlight 400 system on larger areas with a 
spectral resolution of 4 cm-1, pixel size of 6.25 µm and 120 scans per pixel. 
Raman maps were acquired with a step size of 2.2 µm and an 15s exposure 
time on a Renishaw System 1000 with streamline technology using 830 nm 
excitation on samples grown for 14, 17, and 21 days.  
 
2.3.1.3 Synchrotron FTIR imaging of breast calcifications 
Localisation of calcifications 
White light images of the pathology samples were taken on an IR Spotlight 400 
system (Perkin Elmer). Sections which were thought to contain 
microcalcifications were subsequently mapped. All the measurements were 
carried out in transmission mode, with a resolution of 4 cm-1, pixel size of 6.25 
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µm, and up to 16 scans per pixel. Background measurements (120 scans per 
pixel) were taken on a blank piece of slide. The location of microcalcifications 
was then marked on the white light image in order to find these regions back 
easily during synchrotron experiments. Biochemical fitting was used in order to 
investigate whether a sample contained calcifications. Once the data was 
loaded into Matlab, biochemical component spectra were fitted against the 
spectral maps of the samples as described in section 2.3.1.2.A fit of one 
indicates the spectrum is purely that compound. A mixture of at least protein, 
paraffin, and apatite is expected for a calcification. The threshold set for the 
apatite signal was 0.1 to ensure the spectra relating to the pixels do show 
apatite features. An overview is shown in figure 2.12. 
 
Figure 2.12 Screening procedure of pathology samples A) A white light image 
was taken; B) Area which is thought to contain microcalcifications was mapped 
and subsequently a biochemical fit of hydroxyl apatite (0.5% carbonate) 
performed; C) pixels with a calcification signal higher than threshold are 
coloured white, and D) Spectra matching to the white pixels. 
 
Diamond experiments 
During the first beamtime allocation at Diamond (SM6123) regions of interest 
were mapped in transmission mode with a 36x objective, 15x15 micron 
aperture, 128 scans, and a 4 cm-1 spectral resolution. During the second 
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allocation (SM6605) both line maps and maps were taken using a 36x objective, 
aperture of 10x10 µm, 4 cm-1 spectral resolution, 128 scans and 10 µm steps 
except for the last map which was measured in a step sizes of 3.5 µm. Data 
collection at Diamond is performed with OPUS software. In order to load these 
measurements into Matlab, ‘ImportOpus’ can be used (modified by Dr Jacob 
Filik, B22 beamline, Diamond Light Source) and free to use and distribute. 
When loaded into Matlab, the spectra were analysed and the amount of 
phosphate and carbonate was evaluated using the area under the curve. In 
order to test the feasibility of using thinner samples, pathology samples were 
cut to 1, 2, and 5 µm thickness and mounted on calcium fluoride. The samples 
were then mapped with the Spotlight benchtop system in transmission mode 
with a spectral resolution of 4 cm-1, pixel size of 6.25 µm and the background 
measured on a blank piece of the slide. A biochemical fit was then performed 
on the datasets. 
 
IRENI experiments  
At the IRENI beamline, measurements were performed in transmission mode. 
For initial experiments (to target locations) a lower amount of scans was used, 
but for the maps obtained measurements were performed with 128 scans and a 
spectral resolution of 6 cm-1. 
Due to the vast size of the data, original maps had to be compressed using self 
organising maps (SOMs) before loading into Matlab. In Matlab, PCA was 
applied and regions with calcifications were selected and saved for further 
analysis. 
Additional measurements were performed in September-October 2012 in 
transmission mode with 128 scans and a spectral resolution of 6 cm-1. 
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2.3.1.4 ATR imaging of breast calcifications 
ATR measurements were performed by Dr Alina Zoladek (Imperial College, 
London, UK) on deparaffinised tissue samples. The locations of the 
measurements are indicated in figure 2.13  the transmission FTIR locations are 
indicated by the red boxes and the ATR FTIR measurements with the orange 
boxes. Raw data was provided for measurements at position 3,4,8, and 9 which 
was loaded into Matlab. The data was interpolated from 900 to 1200 cm-1, using 
a 1 cm-1 step size. PCA was then performed in order to distinguish the 
calcification area from the surrounding tissue in the 64x64 pixel maps. Line 
scans were then carried out over the calcified area and the area under the 
curve for the phosphate and amide I band was analysed.   
 
 
Figure 2.13: White light image of the deparaffinated sample with the ATR FTIR 
measurement locations indicated with orange boxes and the transmission FTIR 
locations with red boxes. 
 
2.3.1.5 Raman imaging of breast calcifications 
Measurements were performed on a Renishaw 1000 system (830 nm laser, 50x 
objective, stepsize 6.3 micron) equipped with a xyz stage and Streamline 
software which enabled mapping experiments. The y-bin was set to 6 and the 
measurements done with 15s exposure time, ‘slalom setting’ on and centred 
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around 1250 cm-1. A higher resolution map was taken on a smaller area on the 
same sample with stepsize 1 µm, the y-bin set to 1 and a 15s exposure time. 
Cosmic rays were removed by applying a median filter over all spectra. The 
Raman measurements were compared to the FTIR measurements taken on the 
same area. The FTIR map was performed with a spectral resolution of 4 cm-1, 
pixel size of 6.25 µm, scan speed of 1 cm/s and two scans per pixel. As a 
background measurement a blank piece of slide was measured 120 times with 
the same settings.  
 
2.3.2 Deep Raman system evaluation (Chapter 4) 
2.3.2.1 Comparison porcine soft tissue and human mammary tissue 
For a study comparing porcine soft tissue and human mammary tissue, stored 
breast tissue was retrieved from the freezer and left at room temperature to 
defrost. To provide stability the tissue was placed inside a polymer tube with a 
diameter of 2.5 cm. Raman spectra were taken in transmission mode with 
accumulation times 5x60s (cosmic ray removal on) on the transmission Raman 
setup. Measurements of sample with comparable thicknesses (see sample 
thickness section below) were used to compare porcine soft tissue and human 
breast tissue. 
 
2.3.2.2 Sample thickness limits when using transmission Raman setup 
Freshly frozen breast specimens and porcine soft tissue specimens of different 
thicknesses were measured on the transmission Raman setup with the same 
setting described in the section above. The breast specimens had a thickness 
of 8, 10, 12, 15, 20, 22, and 25 mm and the porcine soft tissue specimens had 
thicknesses of 10, 18, 27, 40, and 49 mm, respectively. 
During the measurements done on freshly excised breast pathology specimens 
the thickness of each specimen was recorded (section 2.3.3.3). This data was 
analysed to investigate the effect of sample thickness. The SNR was calculated 
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by taking the height of the Gaussian fit to the 1440 cm-1 band as the signal and 
taking the noise as being half the difference of the highest and lowest point 
between 350 and 450 cm-1. 
For extended depth measurements, nanoparticle x403 (described in section 
2.1.7) was injected (approximately 3x 1010 particles) in the centre of the porcine 
muscle tissue block of 45-50x50x50mm (approximate thickness 47mm) shown 
in figure 2.14. Raman spectra were collected over 5x60s (cosmic rays removal 
on) in transmission mode.   
 
Figure 2.14:Tissue block (45-50x50x50mm, average thickness 47mm) used for 
the extended Raman depth measurements. 
 
2.3.2.3 Lateral spreading in transmission Raman measurements 
To study the spread of Raman signal through the specimens of a certain 
thickness, one microliter of x403 nanoparticle suspension was pipetted in the 
middle of a piece of porcine soft tissue with a thickness of 5 mm. Translational 
x-y stages were used in a range of 20 mm to translate the sample in steps of 2 
mm, to construct an image of 11x11 data points. Raman spectra were collected 
for 10s at each of these points. After construction of this image, an extra layer of 
porcine soft tissue was attached to the sample with surgical pins which made 
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the total thickness of the sample 20mm. Again an image of 11x11 data points 
was created. Both images were loaded into Matlab where an image was 
created based on the baseline corrected (1152 cm-1) most prominent band 
(1016 cm-1) of the x403 spectrum. A 2D Gaussian function was fitted to this 
data to indicate how much the intensity spread over the pixels depends on the 
thickness of the sample.  
 
2.3.2.4 The originating depth and spatial resolution of transmission 
Raman signal 
To understand the effect the depths of the calcifications have on the Raman 
signal quality, measurements were performed with analytes on different depths 
while keeping the thickness and the size of the analyte static.  
Porcine soft tissue of 15-20 mm thick (average 18 mm, figure 2.15) was carved 
the size of a large microscope slide. It was wrapped into cling film to provide 
stability needed to mount it upright. Then a microliter of x403 was injected into 
the tissue block. 
 
Figure 2.15: Sample orientation in the originating depth experiment. 
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Translational x-y stages were used in a range of 20 mm to translate the sample 
in steps of 1 mm, to construct an image 21x21 datapoints. Raman spectra were 
collected for 10s at each point. Then the sample was unwrapped, rotated 180 
degrees, wrapped again and an image of 21x21 datapoints was constructed 
while the sample was translated in steps of 1 mm. By doing this, the thickness 
of the sample is exactly the same, and only the depth of the signal is changed. 
All data was loaded into Matlab were an image was created based on the most 
prominent peak of the x403 (1016 cm-1, baseline corrected) spectrum. A 2D 
Gaussian was then fitted to this data in order to investigate the effect of the 
depth from which the signals originate on the lateral spreading of the Raman 
signals. 
 
2.3.2.5 Measurements through skin 
In order to use transmission Raman as a non-invasive tool, it should be possible 
to do measurements through skin. In order to test the capability of the system to 
achieve this, measurements were performed on porcine soft tissue with skin 
and human breast tissue with attached skin. 
Porcine soft tissue was sectioned to a thickness of 0.5 cm, placed against a 
large microscope slide and then wrapped in cling film to provide enough stability 
to position the sample upright. One microliter x403 dye was pipetted into the 
centre of the sample. A volume of one microliter corresponds to a sphere with a 
diameter of 0.6 mm, assuming no leeching into the surrounding tissue (see 
equation below for calculation of radius r).  
       
 
 
    
Equation 2: Volume of a sphere. 
Translational xy-stages were used in a range of 20 mm to translate the sample 
in steps of 2 mm, to construct an image 11x11 data points. Raman spectra were 
collected for 10s at each point. Then, porcine skin and fat was attached to the 
sample with surgical pins, which forced the two parts to be in contact. The 
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thickness was 15 mm. Again, a 11x11 measurement grid was created in order 
to construct an image. All data was loaded into Matlab where an image was 
created using colour scale of one of the prominent peaks of x403. Furthermore, 
a 2D Gaussian was fitted to this data matrix in order to estimate how much the 
signal spreads through the sample. 
Measurements through skin were also performed on the fresh human breast 
specimens. During the theatre experiments, four samples had skin attached. 
The specimens were wrapped in cling film and placed between two large silica 
microscope slides as described in section 2.3.3.3. In figure 2.16, photographs of 
the first specimen (10 mm thickness) are shown.  
 
Figure 2.16: Pathology sample with skin A) photograph of sample; B) sample 
mounted for deep Raman measurements. 
The blue colour of the specimen is due to blue dye used in theatre, as explained 
in material section 2.1.9. On this specimen three measurements were done 
through skin and five through tissue only. 
The second specimen with attached skin had a thickness of 23 mm and did not 
contain blue dye (figure 2.17). On this specimen six measurements were 
performed; three on the skin patch and three on an area without skin.  
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Figure 2.17: Pathology sample with skin A) Front view, the arrow indicates the 
skin patch; B) Side view of mounted sample (thickness 23 mm). 
The third specimen with attached skin had a thickness of 10 mm and blue dye 
was visible (image not shown). All measurements on this sample were 
performed through skin. The fourth specimen had a thickness of 21 mm and 
had no visible blue dye (image not shown), on this specimen two 
measurements were performed on skin and on the tissue alone.   
During all Raman measurements performed on the fresh tissue samples the 
experimental settings were similar to those of the other measurements in the 
theatre study (Section 2.3.3.3); all measurements were done in transmission 
mode with an accumulation time of 3x60 seconds and the cosmic ray removal 
function on. 
 
2.3.3 Deep Raman spectroscopy on breast calcifications and tissue 
(Chapter 5) 
2.3.3.1 Use of a pseudo marker to estimate the amount of carbonate 
substitution 
Calcification standards with 0.5, 1.4, 2.0, 2.3, 3.5, 6.0, and 11.0% carbonate 
substitution were placed in quartz cuvettes with a path length of 2 mm (Starna, 
Hainault, UK). The samples were each measured five times in random order for 
20 seconds and these measurements were used as standards. 
For a non-invasive proof-of-principle feasibility study the cuvettes were wrapped 
in porcine tissue (figure 2.18) to evaluate the carbonate substitution through a 
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layer of tissue. Tissue with a mix of fat and protein was chosen to mimic bulk 
human breast tissue. The thickness of the porcine tissue was 1.8 mm for the 
proof of principle experiments on both sides of the cuvettes (overall thickness 
porcine tissue 3.6 mm + 2 mm cuvette = 5.6 mm). The measurement was also 
performed with an overall thickness of 16 mm in order to evaluate the clinical 
relevance of the method. During all measurements (n=3 for each standard) the 
signal was accumulated over 5x60 seconds and the cosmic ray removal option 
of the detector software was used.  
 
Figure 2.18: Detail of the experimental setup. Left panel: porcine soft tissue 
wrapped around an optical cell as used in feasibility experiment; right panel: a 
graphical representation (Kerssens et al., 2010). 
All data was loaded into Matlab7 in which an in-house written tool fitted a 
Gaussian function to the peak located at 960 cm-1 after which the 
characteristics of this fit were evaluated. This yielded four parameters to 
analyse; the position of the Gaussian, the height of the baseline, the sigma of 
the Gaussian, and the maximum of the Gaussian. In our analysis the position 
and the sigma of the fitted Gaussian were used to separate the different 
samples. The σ is related to the width of the peak: 
             
Equation 3: Full-width-half maximum calculation. 
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In a later stage of the project, apatite standards were kindly provided by Prof. 
Mary Tecklenburg (section 2.1.1). All apatite samples were measured on the 
Raman microscope (n=5) with an accumulation time of 60 seconds to test the 
effect of substitution type on the position of the apatite band. Since elemental 
analysis was performed on the new samples, the amount of carbonate 
substitution could be defined with a higher accuracy. The samples were used to 
validate measurements performed on the samples from Clarkson 
Chromatography and the Rogers lab.  
 
2.3.3.2 SNR limits for using the pseudo marker 
For the spatial resolution measurements two cuvettes filled with calcification 
standards with a carbonate substiution range found in breast calcifications 
(Baker et al., 2010). One standard had a carbonate substitution of 1.4%, 
which would be a breast calcification relating to invasive breast cancer, and 
the other calcification standard a carbonate substitution of 2.0%, which would 
relate to a benign breast calcification. The standards were oriented next to 
each other and wrapped in porcine soft tissue (figure 2.19).  
 
Figure 2.19: Graphical representation of the spatial resolution experiment. 
The xy-translational stage was used to move the sample in steps of 1 mm. The 
overall sample thickness was 7 mm and the sample was measured five times 
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(60 s accumulation time) on every location. A signal to noise tool was employed 
to estimate the SNR. The height of the fitted Gaussian was taken as the signal 
and the noise was estimated as half the difference between the highest and 
lowest signal between 800 and 900 cm-1.  
Human breast tissue was retrieved from the freezer and left in room 
temperature to slowly defrost. After defrosting the tissue did not maintain its 
shape, so stability was provided by mounting the tissue in a syringe tube. A 
calcification standard containing 2% carbonate substitution was measured with 
different amounts of breast tissue around it (varying from 5 mm to 20 mm). 
To get an idea about the SNR needed for an accurate estimation of the amount 
of carbonate substitution the study described below was designed and 
performed. 
Human breast tissue was retrieved from the freezer and left in room 
temperature to slowly defrost. After defrosting the tissue was positioned on top 
of a glass plate and wrapped in cling film to provide stability. A calcification 
standard (0.5, 1.4, or 6% COHAP) was put in front of the sample. Figure 2.20 
shows a photograph of the sample mounting. 
 
Figure 2.20: Photograph of the SNR experimental setup. 
Each sample was measured 12 times (accumulation time 2x30s, cosmic ray 
removal on). The data was loaded into Matlab, where a matrix was constructed 
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with all combinations of the spectra. For n=3 the combinations would be: 0 0 0 
(none of the spectra), 1 0 0 (only the first spectrum), 0 1 0 (only the second 
spectrum), 0 0 1 (only the third spectrum), 1 1 0 (spectrum 1 and 2), 1 0 1 
(spectrum 1 and 3), 0 1 1 (spectrum 2 and 3), and 1 1 1 (all three spectra). 
With twelve measurements, 212 (4096) combinations can be constructed since 
there are two options for each of the twelve measurements; incorporation or 
not. The combination of none of the spectra is removed, and from all the other 
(4095) combinations the mean spectra of every combination is calculated. The 
Gaussian fitting routine is applied over all new spectra and the amount of 
carbonate substitution is calculated (the range of each group, mean, and 
standard deviation) and the SNR. 
The SNR is calculated by using the highest intensity between 940 and 980 cm-1 
as a measure for the signal which is lowered by the lowest intensity in this 
region as a method of background subtraction. The noise is calculated by taking 
the highest and lowest intensity between 760 and 800 cm-1, which is an area of 
the spectrum which does not show Raman bands. The difference between the 
highest and the lowest intensity is than calculated and divided by two, to give an 
indication of the noise level. The signal is then divided by the noise to obtain the 
SNR. 
 
2.3.3.3 Theatre project deep Raman on breast 
Specimens were collected from theatre and transported to the Biophotonics 
Research Unit. As a routine procedure, patients might get injected with a 
radioactive tracer (99mTc) which is why radiation protection advice was sought 
from the GlosRad team and local rules were set up. In short, the lab was 
designated as a ‘supervised area’ when a radioactive breast specimen is 
present. Warning signs were fitted to the door whilst the sample was in the 
room or waste was stored with a measured activity level exceeding the disposal 
limits. Radiation was measured with a Thermo Type 44A scintillation monitor 
SN5023 and records of the measurements retained.  
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At the Biophotonics lab, the breast specimens were placed in cling film and 
mounted between two 51x76x1.2-1.5 mm microscope slides (Logitech Ltd, 
Glasgow, UK). The sample was then mounted in the sample holder and the 
thickness of the sample was recorded which ranged from 3-25 mm. Five 
measurements were taken from each sample (different positions) with an 
accumulation time of 3x60s with the cosmic ray removal function on. After the 
measurements the specimens were brought back into the standard clinical 
pathway. Records of the whereabouts of each sample were kept in both theatre 
and the lab.  
All data was loaded into Matlab and interpolated in order to have the same x-
axis for each sample in the dataset and background subtracted. All specimens 
were coded for the presence of calcification; ‘0’ when no calcifications were 
clearly seen on the image and ‘1’ when calcifications were present. The 
presence of the calcifications was evaluated by X-ray images of all specimens. 
Access to the original data has not been secured yet, but low resolution images 
are depicted in appendix E3 for all specimens used in the study together with 
the raw Raman data per sample. It should be noted that this was not done by a 
radiologist and not based on the high quality images. As a result the 
classifications of both groups is limited. Calcifications were present in 19 
specimens and 22 specimens did not have calcifications.  
PCA was performed and the scores for each component were plotted versus 
the scores for the next principal component for both groups. The model was 
then changed to four groups: specimens with many calcifications (n=6), 
specimens with calcifications (n=11), specimens without calcifications (n=8), 
and an ‘unknown’ group in which specimens were put with unclear X-ray 
images. By introducing the ‘unknown’ group all specimens which were 
previously borderline calcification/ no calcification will be treated as a separate 
group which decreases the subjectivity. 
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3 Results: study of breast calcifications 
3.1 Study of calcification standards 
In this section, a study involving hydroxyapatites in a range of carbonate 
substitution (0-11%) with transmission FTIR and Raman spectroscopy, as well 
as calcium carbonate and amorphous calcium phosphate is presented. By 
studying the spectra of samples with known chemical composition the effect this 
composition has on the spectra can be derived. This knowledge can then be 
used to translate spectral differences to chemical information within tissue 
specimens. Furthermore, the effect of dilution is studied with transmission FTIR 
to assess the effect of signal saturation on the measured spectra and a 
comparison is made between transmission FTIR and ATR FTIR and Raman 
spectroscopy. 
 
3.1.1 Infrared experiments on calcification standards 
Transmission FTIR experiments were performed on the standards as described 
in section 2.3.1.1. The mean spectra of the samples provided by the 
Tecklenburg lab (Michigan University) are shown in figure 3.1.  
For clarity, the spectra are offset. Key band positions are indicated with blue 
lines (873, 878, 1030, 1410, 1470, and 1537 cm-1).  
The key signature of the apatite spectrum consists of a intense broad band 
~1030 cm-1 with a shoulder ~1070 cm-1 and a lower intensity band at 960 cm-1. 
The position of the band in the 870 cm-1 - 880cm-1 region is different for both 
types of carbonate inclusion, type A and B. Samples with A-type substitution 
show a band ~878 cm-1, and samples with B-type substitution show a band 
~873 cm-1 which is in agreement with previous studies (Antonakos et al., 2007; 
Fleet and Liu, 2007; Fleet, 2009). 
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Figure 3.1: Mean FTIR spectra from samples prepared by Tecklenburg lab 
(Central Michigan University). Measurements are normalised and for clarity 
shown with offset. The blue vertical lines indicate the key positions at 873, 878, 
1030, 1410, 1470, and 1537 cm-1. 
Samples with (partly) A-type substitution showed furthermore bands at 1134 
cm-1 and 1537 cm-1, which were not observed for B-type substituted apatite 
samples. The phosphate region (900 cm-1 -1200 cm-1) shows subtle differences 
due to environment of the phosphate due to for example pH differences during 
formation, maturation, carbonate substitution. Rey et al. (1991b) observed a 
band ~1134 cm-1 in a brushite spectrum. Brushite, CaHPO4∙2H2O, is a mineral 
with a chemical composition fairly similar to hydroxyapatite (Ca10(PO4)6(OH)2). 
The band located ~1537 cm-1 can be assigned to A-type carbonate substitution. 
According to literature, A-type substitution is characterised by a doublet ~1545 
cm-1 and 1450 cm-1 (Fleet, 2009), although in the same manuscript several 
orientations of A-type substitution are discussed which alter the band positions 
to 1540 cm-1 (a band was observed ~1537 cm-1 in the spectrum above) and 
1449 cm-1 and 1569 cm-1 and 1507 cm-1. An additional band ~1470 cm-1 was 
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observed in the A-type substituted samples, which was not observed in the B-
type substituted samples, which is most likely a combination of the 1450 and 
1545 cm-1 doublet described by Fleet.  
In figure 3.2 the mean spectra of the samples provided by Prof. Rogers and 
Clarkson Chromatography are shown. For clarity, the spectra are normalised 
and shown with offset. Again, key band positions are indicated with blue vertical 
lines positioned at 873, 878, 960, 1030, 1410, 1455, and 1550 cm-1.  
Figure 3.2: Infrared spectra measured from Clarkson Chromatography samples 
and samples provided by Prof. Keith Rogers (Cranfield University, Shrivenham). 
Measurements are normalised and for clarity shown with offset. The blue vertical 
lines indicate the key positions at 873, 878, 960, 1030, 1410, 1455, and 1550 cm-1. 
All apatites are said to be B-type carbonated. However, the band between 870 
cm-1 and 880 cm-1 contains features for both A- and B-type carbonate 
substitution. Although the relative amount of both substitution mechanisms 
cannot be evaluated with FTIR,  it is clear that the samples do not contain solely 
B-type substituted carbonate as claimed by the manufacturer.  
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The phosphate band (~1030 cm-1) is slightly broader for amorphous calcium 
phosphate (ACP) and hydroxyapatites in which a larger amount of carbonate is 
incorporated which is due to distortion of the lattice. In contrast to the samples 
prepared in the Tecklenburg lab, no bands were observed ~1134 cm-1. Bands 
characteristic for B-type carbonated substituted apatite are observed ~1410 cm-
1 and ~1455 cm-1 (Fleet, 2009), although also a small band ~1550 cm-1 which 
can be assigned to A-type carbonate substitution. Although carbonate 
substituted HAP and calcium carbonate (CaCO3) both contain calcium and 
carbonate, it can be seen that the FTIR spectra do not show the same bands 
and therefore not the same chemical bonds are probed with FTIR.  
In appendix A an overview of FTIR band assignments of calcified materials can 
be found.  
 
3.1.1.1 Dilution experiments 
The effect of sample dilution upon the shape of the spectral bands was tested 
by pressing KBr tablets with different amounts of apatite in them and measuring 
the FTIR spectrum. In figure 3.3, the measurements are shown for the 0.3 wt% 
and 1.8 wt% samples. Similar results were obtained from the samples with 
different amounts of calcification standard (data not shown).  
Both samples show the characteristic phosphate band shape in the 1000-1200 
cm-1 region. In the lower panel (1.8 wt% sample), a signal saturation artefact is 
seen in the spectrum displayed in cyan. The top of the band is flat with noise on 
top, and the bands in the 1400-1600 cm-1 region are much stronger than the 
other measurements on the same sample. The broadening of the phosphate 
band of the purple spectrum indicates saturation as well, although not in the 
same amount as the cyan spectrum. 
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Figure 3.3: Results dilution experiments; Upper panel) Measurements on 0.3 wt% 
sample; Lower panel) Measurements on 1.8 wt% sample. Data is not normalised. 
All spectra, when not saturated, showed the characteristic phosphate band 
shape consisting of one band ~ 1030 cm-1 with a strong shoulder ~1090 cm-1. 
During analysis it should be kept in mind that a spectrum is saturated in case 
this characteristic shape is lost. 
 
3.1.1.2 Transmission FTIR versus ATR FTIR 
In figure 3.4, the mean spectra of the transmission FTIR and ATR 
measurements on a 2.0% carbonate substituted apatite standards are shown. 
The carbonate bands in the 1400-1500 cm-1 region of the transmission FTIR 
spectrum are much stronger than those in the ATR FTIR measurements. This 
could indicate that saturation is present in the transmission FTIR 
measurements. In the raw data, saturation is indeed visible (data not shown). 
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However, it should be noted that the intensity at higher wavenumbers is lower 
for ATR due to the wavelength dependence. 
Figure 3.4: Mean ATR measurements (green) versus mean transmission FTIR 
(blue) on 2.0% carbonate substituted HAP standard. Spectra are not normalised. 
Saturation would also explain the difference in the phosphate bandwidth (900-
1200 cm-1). During transmission FTIR measurements, light goes through the 
whole of the sample while the penetration depth during an ATR experiments is 
typically between 0.5 and 2 µm. The difference in penetration depth is related to 
the presence or absence of signal saturation. 
ATR FTIR measurements were performed on the A- and B-type substituted 
samples, mean spectra are shown in figure 3.5.  
Figure 3.5: Mean spectra of ATR FTIR measurements performed on A- and B-type 
substituted calcification standards. Measurements are normalised. 
900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Wavenumber (cm
-1
)
A
b
s
o
rb
a
n
c
e
 (
A
U
)
 
 
Transmission FTIR
ATR FTIR
900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000
0
0.05
0.10
0.15
0.20
0.25
Wavenumber (cm
-1
)
A
bs
or
ba
nc
e 
(n
or
m
al
is
ed
)
 
 
4.4 wt% A, 0.6 wt% B
4.3 wt% A, 2.1 wt% B
5.7 wt% B
Chapter 3 
81 
 
The location of the phosphate band shifts position depending on the type of 
carbonate substitution. The phosphate band of the fully B-type substituted 
sample is positioned ~1027 cm-1 (same as previous observed in 2.0% 
carbonate substituted sample), while the position of the partly A-type substituted 
sample is ~1008 cm-1 for the red spectrum and ~1010 cm-1 for the blue 
spectrum.  
Considering the different ratio of A- and B-type substitution of both mixed 
samples (red and blue, respectively) one would expect a more pronounced 
difference in location of the phosphate band. This is however not visible in the 
mean spectra.  
When plotting the different data sets, two for 4.4 wt% A and 0.6 wt% B (red) and 
three for 4.3 wt% A and 2.1 wt % B (blue), significant differences in band 
locations are found between measurements of the same sample (figure 3.6). 
 
Figure 3.6: Mean spectra of each dataset performed on the A- and B-type 
carbonate substituted calcification standards. Measurements are normalised. 
The band shift between the different samples seems to be a real phenomenon 
when plotting all data (figure 3.7).  
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Figure 3.7: All ATR measurements on standards. A) Standard with 4.4 wt% A-
type and 0.6 wt% B-type substitution; B) Standard with 4.3 wt% A-type and 2.1 
wt% B-type substitution; C) Standard with 5.7 wt% B-type substitution.  
However, when plotting the position and the area under the curve of the 
phosphate band over a line scan across a calcification (figure 3.8), it can be 
seen that the shift is related to the position of the measurement on the 
calcification.  
Figure 3.8: ATR FTIR measurements on calcification standard with 
predominantly A-type substitution. In blue the area under the phosphate curve 
along the line scan is depicted and in green the position of this band.  
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3.1.2 Raman microscope measurements on calcification standards 
The Raman spectra of the samples prepared by the Tecklenburg lab were 
loaded into Matlab and the mean was plotted in figure 3.9. The percentages in 
the legend indicate the amount of B-type carbonate substitution, except for the 
samples depicted by the dotted red and blue line for which first the total amount 
of carbonate substitution is given followed by the amount of B- and A-type 
carbonate substitution.  
Figure 3.9: Mean Raman spectra (n=5) of samples Tecklenburg lab, 830 nm laser, 
60s accumulation time. Measurements are normalised and for clarity shown with 
offset. The blue vertical lines indicate the prominent bands discussed in the text 
located at 432, 440, 445, 960, 1018, 1046, 1071, 1076, and 1106 cm-1. 
The most prominent band is the phosphate band in the 960 cm-1 region. The 
amount of calcium substitution for the B-type carbonate (carbonate for 
phosphate) substituted apatites reflects in the relative intensities of bands 
relating to carbonate and phosphate. The relative intensity of the 1046 cm-1 
(phosphate) and ~1071 cm-1 (carbonate and phosphate) strongly depends on 
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the amount of carbonate substitution. For samples with a low amount of 
carbonate substitution the 1046 cm-1 band is the strongest, while for samples 
with higher amounts of carbonate substitution the intensity levels of the two 
bands are reversed.  
Furthermore, a peak shift can be observed due to a change in intensity of 
underlying carbonate (1070 cm-1) and phosphate (1076 cm-1) modes (Awonusi 
et al., 2007). The samples with A-type substitution (CO3 for OH, spectra with 
dotted lines) show an additional band ~1106 cm-1, which is a carbonate mode 
characteristic for A-type substitution (Penel et al., 1998) and ~1018 cm-1 which 
is a characteristic phosphate mode for A-type substituted apatite. In the lower 
wavenumber regions the phosphate band shifts depending on the type of 
substitution, the maximum for B-type substitution is located ~432 and ~445   
cm-1, while the maximum for A-type substitution would be ~440 cm-1. 
Furthermore, it can be seen that the maximum of the sample with 4.4% A-type 
substitution with 0.6% B-type substitution (red dotted spectrum) is more shifted 
towards the maximum characteristic for A-type substitution in this region, than 
the sample with 4.3% A-type substitution and 2.1% B-type substitution.  
Another batch of samples was prepared by Clarkson Chromatography and 
kindly provided by Prof. Keith Rogers. The apatites (all spectra except 
amorphous calcium phosphate (ACP) and CaCO3) all exhibit B-type carbonate 
substitution and the mean (normalised) spectra are shown in figure 3.10. For 
clarity, the spectra are shown with offset. Again, key band positions are 
indicated with blue vertical lines. These lines are located at 432, 445, 960, 
1046, and 1076 cm-1. These positions are similar to those in the previous plot, 
although positions related to the A-type substitution are not displayed.  
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Figure 3.10: Mean Raman spectrum (n=5) for samples Rogers lab and Clarkson 
Chromatography. Key band positions are indicated with blue vertical lines 
positioned at 432, 445, 960, 1046, and 1076 cm-1. 
Amorphous calcium phosphate (ACP, depicted with solid green line) has bands 
very similar to apatite, while calcium carbonate (depicted with red solid line) 
does not show any of the characteristic apatite bands. Similar to the previous 
bands the relative intensities of the carbonate and phosphate bands change 
with increasing amount of (B-type) carbonate substitution. Although from the 
FTIR experiment it is known that these standards contain A-type substitution, 
this is less readily derived from the Raman experiments. 
 
3.2 Comparison of spectroscopic techniques with pathology 
samples staining 
In this study H&E, VK and AR staining is compared with FTIR mapping on 
pathology samples. FTIR provides both molecular and crystalline identification 
of calcified materials such as urinary stones (Volmer et al., 1993; Wilson et al., 
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2010), kidney crystal deposits (Estepa and Daudon, 1997), and breast 
calcifications (Baker et al., 2010). A comparison between FTIR, Raman and the 
different stains could not be made here since the paraffin embedded tissue 
samples exhibited sufficient background signals in the Raman to prevent 
detailed analysis. Therefore, the performance of Raman spectroscopy is 
compared to FTIR, VK and AR staining on samples from a 4T1 mammary 
adenocarcinoma cell line in which calcifications are formed. Since these 
samples are grown for a specific amount of days, the calcifications are ‘time 
stamped’ and it can be investigated how soon the different techniques pick up 
the presence of calcifications.  
FTIR imaging picked up additional calcification in all benign samples, in one 
case no positive staining was obtained with both AR and VK while calcifications 
were visible in the score plot of hydroxyapatite (figure 3.11). At these positions 
were indeed calcification spectra found in the original FTIR map (spectra 
depicted in figure 3.11). Additional measurements on benign samples can be 
found in appendix C.  
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Figure 3.11: A) White light image of benign sample with overlaid the intensity fit 
of hydroxyapatite. Two calcifications are visible which are highlighted by a circle 
and spectral information is shown; B) Alizarin Red staining of adjacent slide; C) 
H&E staining of adjacent slide; D) von Kossa staining adjacent slide. 
More calcifications were found within the in situ pathology samples than in the 
benign samples, although one sample was excluded from the dataset since it 
did not contain calcifications. In figure 3.12, an example of one of the in situ 
pathology samples is shown.  
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Figure 3.12: Measurements on sample with in situ pathology. A) White light 
image of sample, overlaid is the chemical component map for hydroxyapatite; B) 
Adjacent slide stained with Alizarin Red; C) Adjacent slide stained with H&E; D) 
Adjacent slide stained with von Kossa. 
Calcifications were stained positively by both AR (panel B) and VK (panel D) 
and were demonstrated in the score plot of HAP (panel A, yellow/white). In all in 
situ samples the calcifications are more readily recognized in the AR staining 
than VK, which is mainly due to the area stained. Calcifications which appear as 
one larger calcification in AR are displayed as a cluster of smaller calcifications 
when stained with VK. In the FTIR map the calcifications are also a cluster of 
smaller inclusions. 
In figure 3.13, a pronounced example of the extended stained area in AR 
staining is shown. The AR staining fills the whole of the ducts while von Kossa 
staining and FTIR show more localized calcifications.  
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Figure 3.13: Sample with in situ pathology. A) Score plot of the hydroxyapatite; 
B) Alizarin Red staining of adjacent slide; C) H&E staining of adjacent slide; D) 
Von Kossa staining of adjacent slide.  
The calcifications are stained by the H&E (purple) as well, but it should be noted 
that H&E only gives structural and no chemical information – the walls of the 
ducts are stained purple as well (figure 3.13). Most of the calcifications within 
the in situ pathology samples are located in the ducts of the breast and are 
more clearly visible by AR staining and FTIR imaging than VK staining. 
Additional measurements on samples with in situ pathology can be found in 
appendix C.  
In the set of invasive samples studied here (additional measurements in 
appendix C), the number of calcifications was larger than in the samples with in 
situ or benign pathology. Furthermore, the calcifications were not located solely 
in the ducts but distributed across the whole of the sample (figure 3.14).  
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Figure 3.14: Invasive sample A) Scores of the chemical component map of 
hydroxyapatite; B) Alizarin Red staining on adjacent slide; C) H&E staining of 
adjacent slide; D) Von Kossa staining of adjacent slide. 
In figure 3.15, the displaying method of the FTIR maps (biochemical fit) is 
compared to simply displaying the intensity of the characteristic apatite band 
centred ~1030 cm-1 for the benign (panel A and B) and in situ sample (panel C 
and D) shown in figure 3.11 and 3.13. In general, displaying the intensity will be 
sufficient when the calcification signals have a high intensity. With lower 
intensity artefacts such as scattering on the edge of the sample and slightly 
varying background signals will dominate and result in a large number of false 
positives.  
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Figure 3.15: Comparison of intensity of the 1030 cm-1 phosphate band 
characteristic for apatite to biochemical fit of apatite. A) Intensity of the apatite 
band on benign sample; B) Biochemical fit of apatite on benign sample (same as 
in A); C) Intensity of the apatite band on in situ sample; D) Biochemical fit of 
apatite on in situ sample (same as in C). 
The 4T1 in vitro mineralisation model allows temporal analysis of mammary cell 
mineralisation to take place. Positive AR staining was first observed in 
osteogenic cocktail treated  4T1 cells after 11 days and the intensity and extent 
of staining increased with time (figure 3.16 A). Positive VK staining of replicate 
samples was consistently more discrete and less extensive than AR staining. 
However, when replicate samples were analyzed using the B22 beamline, no 
calcifications were detected at 11 or 14 days. One very small calcification was 
present in the area measured of the cells grown for 17 days and calcifications 
were also present in samples grown for 21 days in osteogenic cocktail (figure 
3.16 B).  
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Figure 3.16: Mineralization of mammary 4T1 cells. A) Alizarin red and von Kossa 
staining of 4T1 cells grown in the osteogenic cocktail for 14 and 21 days; B) 
Measurements Diamond synchrotron on 4T1 cells grown for 14, 17, or 21 days in 
osteogenic cocktail. The blue line indicates the position of the 1026 cm-1 band 
characteristic for apatite. One spectrum displaying apatite was found on the 
sample that matured for 17 days, while apatite was abundant in the sample 
matured for 21 days. No apatite was found in the sample matured for 14 days. 
Additional measurements were undertaken on the FTIR Spotlight system. 
Measurements on the sample grown for 17 days (figure 3.17 A) showed only 
one pixel with the characteristic calcification band ~1030 cm-1. On the map 
taken on a sample grown for 21 days large numbers of calcifications were found 
(figure 3.17 B).  
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Figure 3.17: FTIR mapping 4T1 cell line grown in osteogenic cocktail. A) Apatite 
fit on map of sample grown for 17 days; B) Apatite fit of map of sample grown for 
21 days. 
Raman imaging (figure 3.18) was consistent with FTIR imaging, although no 
calcifications were found on samples grown for 17 days. This is probably due to 
the low density of calcifications in the samples (in IR mapping experiment 1 
pixel in a map-size of 51840 pixels). In the 21 days matured sample, abundant 
calcifications were also found with Raman. 
 
Figure 3.18: Intensity of the phosphate band in the Raman maps of 4T1 cell line 
grown in osteogenic cocktail for 14, 17, and 21 days.  
An overview of the different techniques and their outcome is shown in table 3.1.  
 14 days 17 days 21 days 
Alizarin Red stain ++ +++ ++++ 
Von Kossa stain + ++ +++ 
Raman mapping N N Y 
FTIR N Y Y 
Synchrotron FTIR (Diamond) N Y Y 
Table 3.1: Overview of the techniques used to analyse the time course of 4T1 cell 
mineralisation and their ability to detect calcifications in the different samples. 
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Staining: + = sparse, ++ = moderate, +++ =extensive, ++++ = very extensive. 
Detection of calcification: Y = yes, N= no.  
 
3.3 Synchrotron FTIR imaging of breast calcifications 
In this study the composition of breast calcifications in tissue from different 
ranges from the pathology spectrum (benign, in situ, and invasive) and their 
surroundings are studied with synchrotron FTIR. Synchrotron FTIR provides a 
higher signal intensity (and thus higher  sensitivity) and spatial resolution than 
that available from a benchtop FTIR system.  
 
3.3.1 General observations and challenges 
Targeting of calcifications for the synchrotron studies proved difficult. It was 
attempted to localise calcifications on the FTIR benchtop system and marking 
their position in the white light images before samples were taken over to 
synchrotron facilities. The distance between the calcification and different 
features of the pathology slides, for example ducts, could then be used to find 
the calcifications on a different system. Especially for the pathology samples 
mounted on barium fluoride this is difficult, due to the circular shape of the 
substrate which makes it harder to mount the sample in the same orientation 
every single measurement. Furthermore, it was hard to distinguish paraffin 
deposits from calcifications, since both resulted in darker areas when using the 
transmission illumination and glowing areas in the reflection illumination. 
Recently, the illumination at the IRENI beam line has been adapted to fibre 
optics. This enhanced the contrast significantly and when the reflection mode is 
applied paraffin patches glow up (depending on thickness) while the 
calcification patches did not. When taking white light images with both the 
transmission and the reflection settings, paraffin can thus be distinguished from 
calcification patches.  
Another challenge was that all systems obtained slightly different white light 
images. In figure 3.19, an example of the differences is shown. The white light 
Chapter 3 
95 
 
images of one of the used pathology samples (in situ pathology) are shown. 
The same region is shown in each panel which is measured on the Spotlight 
benchtop system (panel A), UK’s Diamond synchrotron (Bruker system, panel 
B), and USA’s IRENI beamline (Bruker system, panel C). Again, the new 
illumination at the IRENI beamline improved the contrast significantly compared 
to the data shown in figure 3.19. 
 
Figure 3.19: White light image of the same area on three different setups A) 
Spectrum Spotlight 400 microscope and Spectrum One; B) Bruker 80V FTIR and 
Hyperion 3000 microscope B22 beamline, Diamond Light Source Ltd 
(Oxfordshire, UK); C) Vertex 70 FTIR spectrometer and Hyperion 3000 IR/VIS 
microsope from Bruker, IRENI beamline, Synchrotron Radiation Center 
(University of Wisconsin, USA). 
One of the other drawbacks of using white light images measured on the 
benchtop system as a reference is that the samples degrade over time which 
means the sample is not always in the same condition as it was when 
previously mapped. In figure 3.20, the same in situ sample is shown measured 
twice with nine months in between. In this time the sample was shown to lose 
substantial calcification content, likely due to mechanical vibrations from 
handling and transportation.  
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Figure 3.20: Illustration of sample degradation over a nine month period A) 
sample in April 2011; B) sample in January 2012. 
 
3.3.2 Results from Diamond beamtime allocation SM6123 
Larger patches of calcifications were found to be extremely dense in terms of IR 
transmission and saturated the FTIR absorption. This feature was not observed 
in the measurements done on the benchtop IR imaging system which is likely 
due to the use of an aperture at the Diamond beam line while measurements at 
the benchtop system are done without an aperture and light can potentially by-
pass the calcification and consequently not provide a true account of its 
absorption on the benchtop system.  
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It was therefore attempted to measure some of the less dense calcifications 
which would show less saturation, shown in figure 3.21. PCA was applied to this 
dataset and line scans were analysed on this map based on principal 
component 3 which showed a characteristic apatite band in the positive 
direction (calcification intensity high in red on score plot shown in panel C).  
Figure 3.21: Area sample 4694 (in situ pathology) measured on the B22 beam line 
of Diamond Light Source Ltd and Principal Component Analysis of this 
measurement. A) White light image of the sample measured; B) Load PC3; C) 
Score PC3. 
One feature of interest is the mineral content which is commonly given by the 
phosphate: amide I ratio (Faibish et al., 2005). In benchtop studies by Baker 
(2010) an increase in amide:phosphate ratio was observed in calcifications from 
increasingly malignant tissue. When the different grades were grouped 
together, the mean amide:phosphate ratio were 0.8278, 0.3717, and 0.1114 for 
‘invasive’, ‘in situ’, and ‘ benign’, respectively. However, it is unknown whether 
the observed differences in amide intensity are due to higher amide 
concentration in the calcification or to higher contributions of amide from the 
surrounding tissue (Baker et al., 2010; Haka et al., 2002).  
A linescan (row 7) was selected from the map and broken into two linescans, 
pixel 1-12 and pixel 14-23, each covering one calcification area. Both the 
phosphate band and the amide I band were selected in Matlab and the area 
under the curve was calculated for each pixel. In figure 3.22, the raw data of 
both lines (panel A and C) are shown together with the area under the curve for 
both the phosphate and the amide I band (panel B and D). The maxima of the 
phosphate bands are visible at pixel 9 and 16. The phosphate band of the 
second calcification (panel C) is heavily saturated and a reliable area under the 
curve cannot be obtained. The score plot in figure 3.21 shows that the first 
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calcification is less dense, and the spectra in panel A from figure 3.22 are 
indeed less saturated. From the area under the curve calculation can be seen 
that at the position of the calcification a local minimum is found for the area 
under the amide I curve. There is however amide present in all calcification 
spectra. 
 
Figure 3.22: Measurements sample 4694 (in situ pathology) on B22 beamline 
Diamond Lightsource Ltd. A) Spectra of pixel 1:12 of row 7; B) Area under the 
phosphate (blue) and amide I (green) curve; C) Spectra of pixel 13:23 of row 7; D) 
Area under the phosphate (blue) and amide I (green) curve. 
The data resulting from the first beam time allocation was rather limited, as was 
the quality. Therefore, the calcification/tissue interface could not be studied and 
a new proposal was submitted. To improve the quality of future data the 
transparency of different windows was tested. The transmission of zinc selenide 
(ZnSe), barium fluoride (BaF2), calcium fluoride (CaF2), and zinc sulphide (ZnS) 
were tested on the Perkin Elmer Spotlight benchtop system for use in a new 
sample batch. All measurements were done in transmission and point mode 
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(120 scans) with the auto correction function on, and an interval of two 
wavenumbers. Measurements on the slides are shown in figure 3.23. 
Figure 3.23: Transmission of the tested substrates (an air measurement is taken 
as background). Note that the thickness of the substrates is not equal.  
From the experiments on the different windows it became clear that calcium 
fluoride (dark blue line) absorbs strongly under 1000 cm-1. Therefore, it was 
decided that for future experiments barium fluoride windows with a thickness of 
0.5 mm would be used which have a greater transparency over the calcification 
region (~1030 cm-1). Furthermore, the pathology samples themselves would be 
cut thinner (6 µm) in order to enhance the light intensity transmitted throughput 
of the sample.  
When using the imaging mode of the Spotlight benchtop system no aperture 
was applied. On the experiments carried out at the Diamond synchrotron an 
aperture of 15x15 µm (in later experiments 10x10 µm) was used, which yielded 
a saturated signal on most of the studied calcifications. Experiments were done 
on the Spotlight benchtop system to investigate the signal quality when similar 
aperture settings were performed. Brightness of the synchrotron is not due to 
higher total power but due to a higher flux density (higher power/area) which is 
due to the small effective source size and the narrow range of angles the light is 
emitted into. Therefore, a higher throughput is measured through a small 
aperture compared to a globar source with a comparable aperture. 
In figure 3.24, spectra are shown which are measured on the Spotlight 
benchtop system with a 10x10 µm and 100x100 µm apertures. The spectra 
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obtained with a 10x10 µm aperture on the Spotlight benchtop system show 
saturation in the phosphate region, albeit not in the same degree as the 
measurements performed at the Diamond synchrotron, while when the same 
area is measured with a 100x100 µm aperture on the same instrument no 
saturation is observed. 
 
Figure 3.24: Comparison of a 10x10µm (top panel) and a 100x100µm aperture 
(bottom panel). The same 200x500µm area was measured with both settings on 
the Perkin Elmer Spotlight. 
 
3.3.3 Results from Diamond beamtime allocation SM6605 
During the second beam time allocation samples from different range of the 
pathology spectrum (benign, in situ, and invasive) and their could be studied. 
Two calcifications from a patient with benign breast disease (pathology report: 
fibroadipose connective tissue with focal microcalcifications) were mapped. The 
white light image of the first calcification is depicted in panel A of figure 3.25. In 
800 1000 1200 1400 1600 1800 2000
0  
0.5
1.0
1.5
2.0
2.5
3.0
Wavenumber (cm
-1
)
A
b
s
o
rb
a
n
c
e
 (
A
U
)
800 1000 1200 1400 1600 1800 2000
0  
0.5
1.0 
1.5 
2.0 
A
b
s
o
rb
a
n
c
e
 (
A
U
)
Wavenumber (cm
-1
)
Chapter 3 
101 
 
panel B and C the intensity plot of the phosphate band (characteristic for 
apatite) and the amide I band are depicted, respectively. 
Figure 3.25: Sample with benign pathology measured at Diamond Light Source 
Ltd A) White light image of the sample; B) Intensity plot of the phosphate band 
(background corrected); C) Intensity plot of the amide I band (background 
corrected). 
It can be seen that the intensity (absorption) of the amide band is highest 
directly next to the calcification patch, although not all around it. From the 
biochemical fitting of paraffin and line scans through the map it becomes clear 
that all other sides of the calcification patch are surrounded by paraffin (figure 
3.26).  
Figure 3.26: Sample with benign pathology measured at Diamond Light Source 
Ltd A) score plot of paraffin fit; B) Line scan (row 14) over the calcification. 
In panel B, the line scan over row 14 is shown. The first seven pixels only show 
the characteristic paraffin spectrum; a single band ~1378 cm-1 and a doublet 
~1462 cm-1 and ~1472 cm-1. Amide I and amide II bands (~1660 cm-1 and 
~1550 cm-1, respectively) were only observed on the edges of the calcification, 
in the interior a band was observed ~1624 cm-1.  This band is one of the 
characteristic COM (calcium oxalate monohydrate) peaks (Maurice-Estepa et 
al., 2000) or OH vibration due to water inclusion in apatite (Seregin and Coffer, 
2006; Wilson et al., 2010). The latter seems more probable, considering none of 
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the other characteristic COM peaks; such as the 1316 cm-1 band (Maurice-
Estepa et al., 2000) are observed and water bands are observed in the 3000 
cm-1 region. The characteristic phosphate band has its maximum ~1110 cm-1 in 
the middle of the calcification area, but the phosphate maxima of the outermost 
spectra of the calcification region are found more towards lower wavenumbers. 
According to Rey (1991b) bands at 1110 and 1125 cm-1 are present in newly 
precipitated apatite, which will disappear progressively during maturation. 
Furthermore, a strong band ~1440 cm-1 is found in the calcification spectra. 
Biological apatites are usually described as carbonate substituted 
hydroxypatite. Carbonate can be included in the lattice in several ways; in type 
A the hydroxygroup is substituted by carbonate and in type B the phosphate 
groups is substituted by carbonate (Peroos et al., 2006). According to Akonakos 
et al. (2007) a band ~1444 cm-1 is characteristic for A-type carbonate 
substitution, while bands ~1409 and ~1427 cm-1 are characteristic for B-type 
substitution. 
The second calcification in the benign specimen is found in the area shown in 
panel A of figure 3.27. The spectra corresponding to the calcifications and the 
rest of the (10x13) map are shown in panel B. The calcification is surrounded by 
paraffin and no interface with tissue can be studied. The 1010-1020 cm-1 
phosphate band is assigned to non-stoichiometric apatite in the formative phase 
(Chiou et al., 2010). 
 
Figure 3.27 Sample with benign pathology measured at Diamond Light Source 
Ltd. A) White light image of the sample; B) Spectra corresponding to the 
calcification (top) and its surroundings (bottom panel). 
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During the beam time allocation three maps were taken on samples DCIS. Two 
maps were taken on a sample with low grade DCIS and one on a sample with 
high grade DCIS. Furthermore, line scans were done on four other calcifications 
in the high grade DCIS sample.  
The first map on the low grade DCIS is shown in figure 3.28A. On this map 
several calcifications are present, but they are quite small and scattered all over 
the map. A line scan which consisted calcifications (row 3) is shown in panel B. 
Figure 3.28: Sample with in situ pathology (low grade) pathology measured at 
Diamond Light Source Ltd. A) White light image of the sample; B) Line scan (row 
3) over the map. 
The spectra corresponding to pixel 16-20 are shown in figure 3.29. These 
spectra do show amide I and amide II bands. The phosphate bands are all 
distorted which indicates that the edge of the calcification is measured which 
results in an artefact due to the scattering of the light on a sphere with a size 
very similar to the wavelength of the light (Mohlenhoff et al., 2005). When 
measuring both tissue and calcification a mix of both signals is expected. 
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Figure 3.29: Sample with in situ (low grade) pathology measured at Diamond 
Light Source Ltd. Spectra of pixel 16-19 of row 3 of the map shown in figure 2.28.  
A strong band is visible left of the paraffin doublet. In contrast to the previous 
sample, the position is not ~1440 cm-1 but ~1408 cm-1 which is characteristic for 
B-type carbonate substitution (Antonakos et al., 2007). 
Findings from the second map measured (16x22) on the sample with low grade 
in situ pathology were similar to the previous map; a strong band ~1408 cm-1 is 
found in spectra showing a phosphate band. Again the phosphate bands are 
distorted and pixels corresponding to calcifications are spread over the map 
(data not shown).  
The third map was measured on a sample with high grade in situ pathology. 
The white light image of the calcification is shown in panel A of figure 3.30. In 
contrast to the other in situ samples, this is a localized larger calcification or 
cluster of smaller ones which results in less distortion in the spectra. The score 
plot of the biochemical fit of apatite over the map is shown in panel B of the 
same figure.  
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Figure 3.30: Sample with in situ pathology (high grade) measured at the Diamond 
Light Source Ltd. A) White light image of the studied calcification; B) Score plot 
of the apatite biochemical fit. 
Line scans were selected from the map and the area under the curve for the 
phosphate and amide I band were plotted. In contrast to the benign samples, all 
spectra in which the phosphate band was present also showed the amide I and 
amide II bands. An example of one of the line scans (row 9) is shown in the 
figure below. The area under the curve is given for both the phosphate (blue) 
and amide I (green) band in panel B. The area under the curve for the 
phosphate band is not reliable in all cases, due to saturation of the phosphate 
band which influences the area under the curve. 
Figure 3.31: Example of line scan over sample with in situ (high grade) 
pathology. A) Spectra of row 9; B) Area under the curve for phosphate (blue) and 
amide I (green) band. 
A ratio plot of the amide and phosphate is shown in figure 3.32 which will 
compensate for variations in sample thickness and scattering artefacts of the 
background.  
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Figure 3.32: Ratio plot of the phosphate: amide of the data shown in figure 3.31 
B. 
The amount of spectra showing saturation in the characteristic phosphate band 
is significant; which is more clearly displayed in figure 3.33A where the spectra 
of row 9 are shown. In panel B of the same figure the spectra of pixel five to 
thirteen are shown which correspond to the first calcification area and only show 
minor saturation in the phosphate region. The shape of the phosphate band 
seems to be different at the edges of the calcifications compared to the middle, 
although it is unclear at this point in time whether this is genuine or an artefact. 
The band in the 1410-1420 cm-1 region is characteristic for B-type carbonate 
substitution. In contrast, the spectra of the second calcification area also show a 
band (1440 cm-1) characteristic for A-type carbonate substitution.  
Figure 3.33: Line scan over sample with in situ (high grade) pathology A) All 
spectra of row 9; B) Spectra 5:13 of row 9. 
Additional line scans were done on four calcifications in the last sample. White 
light images of these calcifications are shown in figure 3.34.   
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Figure 3.34: White light images of the line scans done over calcifications with in 
situ pathology A) White light image corresponding to data in figure 3.35 an d 
3.36; B) White light image corresponding to data in figure 3.37 and 3.38; C) White 
light image corresponding to data in figure 3.39 and 3.40; D) White light image 
corresponding to data shown in figure3.41 and 3.42. 
The first line scan is shown in figure 3.35 below. The spectra are shown in 
panel A and the area under the curve for the phosphate (blue) and amide I 
(green) band in panel B. The area under the curve for the phosphate band 
shows a maximum between pixel 25 and 35, which indicates the position of the 
calcification area. Again, the phosphate band is saturated on multiple occasions 
so the value of the area under the curve should not be used for quantitative 
purposes. On both sides of the calcifications of the calcification patch (pixel 10-
25, and pixel 35-40, respectively) a minimum can be found for the area under 
the curve of the amide I band. When investigating the spectra in panel A, it 
becomes clear that these pixels only show a paraffin spectrum and no tissue 
contribution is present. The area under the curve for the amide I band at the 
calcification path (pixel 25-35) is similar to the intensities found at the tissue 
(pixel 0-10, and pixel 40-50, respectively).  
Figure 3.35: A) Spectra correlating to the line scan sample with in situ pathology; 
B) Area under the curve for phosphate band (blue) and the amide I band (green) 
over the line map. 
In figure 3.36 the phosphate:amide ratio of the data is displayed.  
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Figure 3.36: Ratio plat of the data shown in figure 3.35 B. 
Both bands characteristic for A- and B-type carbonate substitution were present 
in the calcification spectra, although the intensity of the bands characteristic for 
B-type were higher than those characteristic for A-type carbonate substitution.  
Similar results were found in the second line scan. The spectra of this line scan 
and the area under the curve for the phosphate (blue) and amide I (green) 
curve are shown in figure 3.37 and the relative intensity (phosphate:amide ratio) 
in figure 3.38. Again the calcification was surrounded by paraffin and not by 
tissue which resulted in the minimum value found for the area under the amide I 
curve both left and right of the calcification (pixel 12-24, and pixel 36-38, 
respectively).  
Figure 3.37: A) Spectra correlating to line scan with in situ pathology; B) Area 
under the curve for phosphate (blue) and amide I (green) band over the line map. 
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Figure 3.38: Ratio plot of the data shown in figure 3.37 B. 
The third line scan is taken over a calcification embedded in tissue. The spectra 
of this line scan (panel A) and the area under the curve for the phosphate (blue) 
and amide I (green) curve (panel B) are shown in figure 3.39 and the 
phosphate:amide ratio in figure 3.40. The calcification is located at pixel 30:70. 
Unfortunately, most of the phosphate bands are saturated so the area under the 
curve for the phosphate band cannot be used quantitatively. The area under the 
curve of the amide I is very similar in the area of the calcification and the 
surrounding tissue.  
Figure 3.39: A) Spectra correlating to the line scan with in situ pathology; B) Area 
under the curve for phosphate (blue) and amide I (green) band over the line map. 
Figure 3.40: Ratio plot of data shown in figure 3.38 B. 
The spectra and the area under the curve for the phosphate (blue) and amide I 
(green) band of the last line scan are shown in figure 3.41. In this line scan, two 
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calcification areas are visible, the first from pixel 7 to 34, the second from pixel 
58 onwards, with in the middle one weak calcification (pixel 42:51). The 
phosphate:amide ratio is shown in figure 3.42. Unfortunately all calcifications 
are surrounded by paraffin, most likely due to the calcifications keeping their 
size during paraffin embedding while the tissue does not. As a result, the empty 
space between calcifications and tissue is filled by paraffin and the 
tissue/calcification interface is distorted. 
Figure 3.41: A) Spectra correlating to the line scan with in situ pathology; B) Area 
under the curve for phosphate (blue) and amide I (green) band over the line map. 
Figure 3.42: Ratio plot of the data shown in figure 3.41 B. 
In contrast to the benign calcifications, the in situ calcifications do show amide 
bands. The 1444 cm-1 band is visible as a shoulder of the paraffin peak and a 
new band ~1414 cm-1 is observed. This band is a combination of the 1409 and 
1427 cm-1 band which are both specific for B-type carbonate substitution. 
During the beam time allocation four maps were taken on samples with invasive 
pathology and six line scans. The white light image of the first calcification is 
shown in figure 3.43. On this calcification with invasive lobular carcinoma a line 
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scan and a map were measured. In panel B the spectra corresponding to pixel 
7 to 15 from the line scan are shown.  
Figure 3.43: Sample with invasive pathology A) White light image of the 
measured calcification; B) Spectra corresponding to pixel 7:15 of the line scan. 
Similar to the data obtained from the samples with in situ pathology, most of the 
phosphate bands are saturated. Furthermore, amide bands (1500 - 1700 cm-1 
region) can be seen in the spectra corresponding to the calcification. However, 
the amide I and II band seem to have merged into one band with a maximum 
around 1590 cm-1 in the centre of the calcification. In the 1410 – 1460 cm-1 
region two bands can be observed, related to both A- and B-type carbonate 
substitution. On the same calcification a map was taken, data not shown, which 
had a data quality similar to the line scan shown. 
The second map was measured on the same sample (other calcification). 
Again, line maps were analysed of which an example is shown in figure 3.44. In 
panel A, the spectra of line 6 are shown, and in panel B the area under the 
curve for the phosphate (blue) and amide I (green) band. The area under the 
amide I curve is significantly higher for the spectra corresponding to the 
surrounding tissue than for those corresponding to calcification. To emphasise 
this is a real phenomenon and not due to inconsistencies in the area under the 
curve routine used, the spectra in panel A are colour coded so differences in 
signal intensities are more readily picked up. Spectra correlated to tissue are 
depicted in blue, spectra showing the characteristic apatite band are depicted in 
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red, and spectra correlating to the calcification tissue interface (Mie scattered) in 
green. The phosphate: amide ratio is displayed in figure 3.45. 
Figure 3.44: Line scan (row 6) over sample with invasive pathology A) Colour 
coded spectra of the row: tissue depicted in blue, calcification in red, and tissue 
calcification interface in green; B) Area under the curve of phosphate (blue) and 
amide I (green) band over the line scan. 
Figure 3.45: Ratio plot of the data shown in figure 3.44 B. 
A third map was measured over a new sample with invasive pathology. The 
white light image of the sample is shown in figure 3.46 with the area of the map 
indicated in red. In panel B the score plot for the biochemical fit of apatite is 
shown. From this figure it becomes clear that the map consist of several smaller 
calcifications.  
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Figure 3.46: Sample with invasive pathology A) White light image of the map 
measured; B) Score plot of the apatite biochemical fit. 
When the spectra relating to one calcification are selected, figure 3.47, it can be 
seen that the shape of the characteristic phosphate band changes over the 
calcification patch. In all previous samples the 960 cm-1 band characteristic for 
phosphate is present as a relatively weak band compared to the phosphate 
moiety ~1030 cm-1. In contrast, in the spectra shown in figure 3.47 the 960 cm-1 
is much stronger and in most cases even stronger than the phosphate moiety 
~1030 cm-1. Furthermore, there is a doublet, one band is located ~960 cm-1 and 
the other ~972 cm-1, instead of a single band. No information about a band 
positioned ~972 cm-1 could be found in literature, and it is likely this 
phenomenon is due to saturation.  
Figure 3.47: Selection of data related to one calcification; Left) Selected pixels 
are indicated by red box; Right) Spectra of the selected pixels. 
On a separate calcification, white light image not shown, a horizontal and 
vertical line scan was done. Colour coded spectra of the horizontal line are 
shown in panel A of figure 3.48. The spectra correlating to apatite are depicted 
in red and the spectra correlating to the surrounding tissue in blue. The area 
under the curve for the amide I (blue) and phosphate curve (green) was 
Chapter 3 
114 
 
calculated and plotted against each other in panel B. Both line scans show a 
local minimum in the area under the amide I curve on the location of the 
calcification, and a local maximum directly next to the calcification which would 
suggest a protein rich capsule around the calcification.  
Figure 3.48: Horizontal line scan over calcification with invasive pathology A) 
Colour coded spectra of line scan; red is related to calcification and blue with 
surrounding tissue; B) Area under the curve for phosphate (blue) and amide I 
(green) band over the line scan. 
The phosphate: amide ratio is displayed in figure 3.49. From the ratio can be 
seen (lower than one) that the area under the amide curve larger is than the 
area under the phosphate curve even though the amide has a local minimum in 
figure 3.48 B at the pixel (number eight) of the maximum of the area under the 
phosphate curve.  
Figure 3.49: Ratio plot of the data shown in figure 3.48 B. 
Findings were similar for the vertical line scan. The spectra of the vertical line 
scan are shown in panel A of figure 3.50. Again the spectra are colour coded; 
the spectra correlating to the calcifications are depicted in red and the spectra 
relating to the surrounding tissue in blue. The area under the curve for the 
phosphate (blue) and amide I curve (green) are shown in panel B. Similar to the 
horizontal line scan, the spectra relating to the calcification contain less amide I 
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than the surrounding tissue and the calcification seems to be surrounded by a 
protein dense capsule.  
 
Figure 3.50: Vertical line scan over invasive calcification; A) Spectra of the line 
scan; spectra correlating to the calcification are colour coded with red and 
spectra of the surrounding tissue with blue; B) Area under the curve of the 
phosphate (blue) and amide I (green) band. 
In figure 3.51 is the phosphate:amide ratio displayed. In the figure can be seen 
that the area under the curve for the amide band larger is than that of the 
phosphate curve (phosphate:amide ratio lower than one).  
Figure 3.51: Ratio plot of the data shown in figure 3.50 B. 
Another line scan was done on the same sample but on a different calcification 
(white light image not shown). The phosphate bands in the spectra relating to 
the calcification were heavily saturated and the intensity of the amide I bands 
was similar over the line scan (data not shown).  
On a new sample two line scans were performed on a calcification (horizontal 
and vertical), followed by a map over the same calcification. In both line scans 
the area under the curve for the amide I band is constant over the line. When 
line scans are derived from the map the same is observed. Furthermore no 
carbonate bands were visible in the 1400 cm-1 region of both line scans and line 
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scans on the map. Similar to the calcification shown in figure 3.52, the intensity 
of the 960 cm-1 band is very high, and the position changes dramatically over 
the map. As an example an intensity plot is shown of row 10 on which the shift 
is indicated with a black circle in panel A, and the corresponding spectra are 
shown in panel B. As can be seen, the location of the band changes; from ~990 
cm-1 in the centre to ~970 cm-1 at the edges of the calcification. 
Figure 3.52: Line scan (row 10) through sample with invasive pathology A) 
Intensity plot of the phosphate region of the spectra on the line scan; B) Spectra 
relating to the calcification (position 10-20 along the line scan). 
In the centre of the calcifications no spectra could be obtained due to the high 
absorbance leading to saturation. This could be avoided by reducing the 
thickness of the samples by thinner slicing of the biopsy blocks. It was feared 
that thinner slicing of pathology samples would force the calcifications out, but 
as can seen in figure 3.53 calcifications are still present in a 1 µm thick slice.  
Figure 3.53: Biochemical fit for apatite on invasive breast pathology sample (1 
micron thickness mounted on 1 mm calcium fluoride). 
 
Pixel (#)
P
ix
el
 (#
)
Biochemical fit apatite
 
 
400 500 600 700 800 900
50
100
150
200
-0.2
0
0.2
0.4
0.6
Chapter 3 
117 
 
3.3.4 Results IRENI beam time 
During this PhD project, beam time was obtained at the IRENI beam line at 
SRC, Wisconsin, USA. Due to the vast amount of data, analysis of all maps 
taken is beyond the scope of this PhD project and a new PhD project is planned 
to continue this line of research.  
Two maps of calcifications are shown to get an idea about the capabilities of 
this synchrotron facility. In figure 3.54, a map of a calcification within a sample 
with invasive pathology is shown.  
 
Figure 3.54: Example of a calcification measured at the IRENI beamline. A) 
Principal component with the line scans analysed indicated in red. B) Data 
corresponding to the line scans; C) Area under the phosphate (blue) and amide I 
(green) curve for each line scan (upper panel) and the amide:phosphate ratio 
(lower panel). 
On this calcification several line scans are performed, which are indicated in 
panel A. In panel B the data corresponding to these line scans are displayed. 
For every spectrum of the line scans, the area under the curve of the phosphate 
and the amide I band are calculated. These values are plotted versus the 
position along the line. In contrast to the measurements on the B22 beamline, 
the amount of amide does not decrease over the line scan.   
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In figure 3.55, the same analysis is shown for a larger calcification in a sample 
with invasive pathology. On this calcification, four line scans were performed, of 
which the locations are indicated in panel A. In panel B, the data corresponding 
to the line scans is shown. Panel C shows the area under the phosphate (blue) 
and amide I (green) curve. Similar to the smaller calcification, the amount of 
amide I does not decrease over the calcification as it did for the Diamond 
measurements.  
Figure 3.55: Example of calcification measured at IRENI beamline. A) PC2 with 
the locations of the line scans; B) Data corresponding to the line scans; C) Line 
scans with the area under the curve for phosphate (blue) and amide I (green) per 
pixel (upper panel) and the amide:phosphate ratio (lower panel). 
 
3.4 ATR imaging of breast calcifications 
In this section, the ATR experiments performed on a deparaffinised breast 
pathology sample are discussed. The effect of the paraffin removal protocol is 
discussed in appendix D.  
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Data was obtained from the measurements at location 3,4,8, and 9. No 
calcifications were present in the ATR and transmission FTIR measurements of 
area 3 (data not shown).  
In figure 3.56, the transmission and ATR FTIR measurements of area 4 are 
shown. In panel A, the intensity of the phosphate band over the transmission 
FTIR map is displayed and in panel B the intensity of the phosphate band over 
the ATR FTIR map. In both transmission and ATR FTIR measurements the 
area measured consist of 64x64 pixels, which correspond to an area of 
~350x350 µm for the transmission FTIR and ~64x64 µm for the ATR FTIR 
measurements. In panels C and D, spectra of both the calcification (depicted in 
red) and the surrounding breast tissue (blue) are shown for the transmission 
FTIR (panel C) and ATR FTIR measurements (panel D). 
It can be seen that the relative intensity of the lower wave number region is 
higher in ATR measurements than that of the higher wave numbers. 
Figure 3.56: Transmission FTIR and ATR FTIR measurements on area 4. A) 
Intensity of apatite band over transmission FTIR map; B) Intensity of apatite over 
ATR FTIR map; C) Transmission FTIR spectra of calcification (red) and 
surrounding tissue transmission (blue); D) ATR FTIR spectra of calcification 
(red) and surrounding tissue (blue). 
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A line scan was performed over the ATR FTIR data. The location of the line 
scan is depicted in panel A of figure 3.57. In panel B, the area under the curve 
are depicted for the phosphate band (blue) and amide I band (green). It can be 
seen that the amount of amide I decreases in the calcification and has a 
minimum in the centre of the calcification. The spectra of the pixels on the line 
scan are depicted in panel C and a band shift can be observed. In panel D, the 
location of the phosphate band over the line scan is shown and it can be seen 
that the position in the centre of the calcification is close to 1020 cm-1 and shifts 
towards higher wavenumbers when increasing the distance to the centre of the 
calcification. A similar finding was observed in the ATR measurements of 
standards. In the case of breast calcifications the shift is larger which is 
probably caused by mixing in the tissue band located ~1060 cm-1. 
Figure 3.57: Line scan over calcification in area 4. A) PC 2 of area 4 and the 
location of the line scan; B) Area under the curve for the phosphate band (blue) 
and amide I band (green) over the line scan; C) Spectra relating to the line scan; 
D) Band shift of the phosphate band over the line scan.  
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In the ATR FTIR measurements of area 8 similar findings were observed (figure 
3.58). The amide I decreased over the calcification and had a minimum in the 
centre of the calcifications.  
Figure 3.58: Line scan over calcification in area 8. A) PC 2 and the location of the 
line scan; B) Area under the phosphate curve (blue) and amide I curve (green) 
over the line scan.  
The phosphate band shift was observed as well (data not shown). The position 
of the phosphate band in the spectra corresponding to the centre of the 
calcification was ~1023 cm-1 and shifted towards higher wavenumbers in 
measurements relating to position more outwards from the centre.   
A similar analysis was done on the calcification in area 9. Also in this 
measurement the intensity of the amide I band decreases over the calcification, 
with a minimum in the centre (figure 3.59).  
 
Figure 3.59: Line scan over calcification in area 9. A) PC 4 and the location of the 
line scan; B) Area under the phosphate curve (blue) and amide I curve (green) 
over the line scan.  
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3.5 Raman imaging of breast calcifications 
In this section, a proof of principle Raman mapping study is performed on a 
paraffin embedded sample of which the paraffin is removed with the protocol 
discussed in section 2.1.4. The effect of the de-paraffin protocol is discussed in 
the appendix D.  
The same area was measured on the Raman Streamline setup and compared 
to the FTIR measurements (similar pixel size) by plotting the chemical fit of the 
apatite of the FTIR map versus the intensity of the characteristic ~960 cm-1 
phosphate band (background subtracted) of the Raman map (figure 3.60). 
Figure 3.60: FTIR and Raman mapping on same sample. A) Apatite chemical fit 
on FTIR map; B) Intensity of the 960 cm-1 phosphate band on Raman map; C) 
Example of Raman spectra of the intensity map showed in panel B. For both 
measurements a pixel size of ~6 micron was chosen. 
Although the locations do not match exactly, due to alignment differences, it can 
be seen the shape and size of the calcified areas is the same on both maps. In 
the Raman map it can be seen that the calcification patch is made up from 
several smaller calcification, a feature that could not be distinguished in the 
FTIR mapping due to lower spatial resolution.  
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Raman mapping can be done with smaller pixel sizes than FTIR imaging. In 
figure 3.61, a Raman map is shown on the left calcification of the previous 
figure. In panel A, the white light image is displayed, followed by principal 
component two and the location of the line map in panel B, in panel C the 
spectra corresponding to the pixels of the line scan are shown. In panel D, a 
Gaussian fit of the intensity of the 960 cm-1 band is shown. The presence of 
several smaller calcifications instead of one larger one is obvious in both panel 
B and D. 
Figure 3.61: Raman mapping with 1 µm steps. A) White light image of the 
calcification; B) Principal component two with the location of the line map 
indicated with a red line; C) Spectra corresponding to the pixels on the line scan; 
D) Amplitude of a fitted Gaussian to the 960 cm-1 band. 
In figure 3.62, the area of the Raman measurement is shown together with the 
corresponding area of the FTIR measurement to give an indication of the 
resolution enhancement that can be obtained. The same calcification is 
measured with ATR FTIR (area one and two) and measurements should be 
compared as soon as the raw data is available. 
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Figure 3.62 Comparison of benchtop transmission FTIR and Raman mapping. A) 
Benchtop FTIR; B) Raman mapping (1 µm stepsize) on same area. 
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4 Results: Deep Raman system evaluation 
One of the aims of this PhD project is to translate knowledge obtained about 
breast calcification to the development of a new clinical tool that could be used 
in vivo. To facilitate this, a transmission Raman setup was built (described in the 
materials and method chapter) and its performance is tested in this chapter. 
 
4.1 Comparison porcine soft tissue and human mammary 
tissue 
In this chapter, porcine soft tissue is routinely used as a model for human 
mammary tissue. From literature it is known that the biochemical composition, 
such as the protein to lipid ratio, of porcine and human tissue is very similar 
(Vardaxis et al., 1997) and the Raman spectra of porcine soft tissue and fresh 
frozen human breast tissue are therefore expected to be similar too. 
In order to test the validity of using porcine soft tissue as a model for human 
breast tissue, similar thicknesses of porcine soft tissue and snap frozen human 
breast tissue were measured on the transmission Raman system (figure 4.1). 
Figure 4.1: Comparison Raman spectra of human mammary tissue (blue) and 
porcine soft tissue (green). 
When comparing the Raman spectra of both samples (figure 4.1), it can be 
seen that the overall shape of the spectra are very similar although the relative 
peak intensities can differ.  
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This makes porcine soft tissue a suitable model for human breast tissue during 
the first phases of our deep Raman experiments. 
 
4.2 Sample thickness limits when using transmission Raman 
setup 
In the case of using deep Raman spectroscopy as an adjunct to mammography, 
it would be ideal if the thicknesses to which it could be applied were at least as 
high as the thickness of the breast during mammography. During 
mammography the breast is compressed to reduce the radiation absorbed by 
the tissue and to improve the quality of the image taken by reducing for 
example the overlap of structures and improve image sharpness (Poulos et al., 
2003). Since compression of the breast may be experienced as painful, it is 
important to push the penetration depth limits of the new screening techniques. 
However, when compressing the breast locally instead of compressing the 
whole of the breast lower thicknesses can be readily achieved. 
Initial experiments concerning the sample thickness, and the effect this has on 
the Raman spectra measured, were performed on porcine soft tissue and 
freshly frozen human breast tissue. It was thought that freshly frozen breast 
tissue could be used as a model for fresh human breast tissue. Candefjord et al. 
(2009) tested the effect of snap freezing on porcine prostate tissue. They found 
several subtle changes when comparing the principal component scores, but 
these were not visible when comparing the mean spectra. However, in our initial 
experiments a striking difference in structural integrity was observed between 
freshly frozen and fresh breast tissue. The snap frozen tissue did not keep its 
shape and structure after defrosting and mounting of the tissue was therefore 
problematic. This is most likely due to the volume of the snap frozen specimens. 
In large specimens, the outer layers will freeze first after which the freezing 
rates are unpredictably slow due to insulation. When crystals start to expand the 
tissue inside the frozen shell, the whole specimen is damaged (Scouten and 
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Cunningham, 2012). Ice crystals will form in the interior of any piece of tissue 
over 10 mm from the cold source. 
As expected, the amount of light coming through both the porcine and the 
freshly frozen samples decreases with the sample thickness (data not shown). 
However, it is not known how the transmission through the affected breast 
tissue is related to measurements on fresh human breast tissue. Therefore, the 
measurements on the freshly excised breast specimens with different 
thicknesses were analysed too. 
The freshly excised breast specimens had a thickness ranging from 2 mm to 25 
mm. In the whole range it was possible to measure a spectrum of the specimen 
in transmission mode with the accumulation time used (raw data shown in 
appendix E3) although the amount of signal decreases with increasing 
thickness, as does the fluorescence background shape.  
In figure 4.2, the SNR is displayed for the range of thicknesses with the error 
bars indicating the standard deviation. In section 5.2 the SNR needed for 
correct estimation of the amount of carbonate substitution is evaluated which is 
6.5 and thus relating to a maximum tissue thickness of 10 mm.  
 
Figure 4.2: Plot of the SNR versus the thickness of the sample. Measurements 
were done during 3x60s with the cosmic removal function on. The error bars 
indicate the standard deviation.  
For calcification vs. no calcification or type I vs. type II a lower SNR will be 
sufficient and thus a larger tissue thickness range could be used.   
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When plotting the log of the data, a linear trend is observed which indicates the 
decrease in signal is exponential. A similar link between the tissue thickness 
and the transmission Raman signal was observed in Monte Carlo simulations of 
Raman photons in breast performed by Matousek and Stone (2007).  
The existing setup does not yet permit reaching 50 mm penetration depth – for 
this further optimisation is required (e.g. higher laser power, higher collecting 
power). A possible further improvement of detectable Raman intensity by more 
than two orders of magnitude was identified (Matousek and Stone, 2007). 
 
4.2.1 SESORS 
In the following exploratory study we also looked at the performance of our 
technique with SERS labels within tissue. Although this approach poses 
challenges stemming from the potential toxicity of nanoparticles it offers 
extremely high sensitivity providing high penetration depth and ability to detect 
low level bio-analytes. Here we used these nanoparticles only as a test target 
instead of calcifications to test the performance of our technique in thick tissue 
samples in an easy and reproducible way with our current Raman benchtop 
instrument. In an exploratory study, dye was injected in a breast model and 
measured. In figure 4.3, the spectra of nanoparticles x403 can be seen detected 
through both 20 and 47 mm thick samples. It should be noted that at the 
extended depth ~20 times more nanoparticles were used and a longer 
collection time. 
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Figure 4.3: upper panel: x403 (3x1010 particles in 50 µl) through 45-50 mm tissue; 
lower panel: x403 (1.8x109 particles in 3 µl) through 20 mm tissue. 
The spectrum measured through 47 mm tissue showed significant signal loss at 
higher wavenumbers (above 1250 cm-1), which was not observed previously 
with tissue. It is suggested that at these wavelengths both water and myoglobin 
absorb significantly light passing through the tissue. The 1250-1600 cm-1 region 
correspond to light of 925-957 nm with the excitation wavelength used (830 
nm). This covers the range where a strong lipid absorption band (930 nm) is 
located (Kukreti et al., 2008) and water absorption band (970 nm). The 
myoglobin may be specific to the porcine model used which has a high amount 
of striated muscle content. In contrast, breast tissue only has a small amount of 
smooth muscle near the nipple so contributions of myoglobin are unlikely in 
breast tissue.  
 
4.3 Lateral spreading in transmission Raman measurements 
The spectra obtained during transmission Raman spectroscopy give a biological 
fingerprint of the bulk sample. This is due to the random direction of the 
scattering in transmission Raman experiments. The thicker the sample, the 
more scattering events the photon undergoes before reaching the detector on 
the other side of the sample. In order to understand the spread of signal through 
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the thickness of the sample, measurements are performed on a porcine tissue 
breast model with a buried analyte which rule out inter patient variability fresh 
human breast tissue would have.  
In figure 4.4, the intensity of the x403 SERS signal over the map is shown. Due 
to the fixed location of the input fibre, the sample has to be moved in order to 
collect signals from another area, which is done in translation steps of 2 mm. 
Each measurement, and therefore each pixel, gives information about the bulk 
tissue the photons travelled through. In panel A, measurements were performed 
on a specimen with 5 mm thickness and in panel B on a specimen with 20 mm 
thickness. In both specimens the same amount of dye was injected at roughly 
the same depth, which means the target has a similar size in both experiments.   
 
Figure 4.4: Mapping of porcine soft tissue breast models with 1µl x403 dye 
injected as an analyte.  A) 5 mm sample thickness; B) 20 mm sample thickness.  
When comparing the signal of the 5 and 20 mm thick specimen, a difference of 
~10 times is observed in the intensity levels. This results in a decrease of the 
SNR of ~3 times. This is a smaller difference than would be expected based on 
the experiments on freshly excised human breast tissue shown in figure 4.2, but 
in those experiments it becomes clear that the SNR does not decrease linearly 
with increasing sample thickness. Furthermore, large standard deviations were 
obtained in samples with low thicknesses due to the limited amount of samples.  
To study the spread of signal over both maps, 2D Gaussians were fitted to both 
datasets (figure 4.5). The original data points are indicated with green dots, and 
Chapter 4 
131 
 
the fitted functions as surface plots. In case no lateral spreading of photons 
would occur, all of the x403 signal would be located in a small area depending 
on the size of the beam and the size of the analyte. The more lateral spreading 
occurs, the more pixels show traces of the x403 signal. As a result, the 2D 
Gaussian would have a larger full width half maximum (FWHM) when more 
lateral spreading occurs.  
 
Figure 4.5: 2D Gaussian fitted to the intensity levels of x403 dye. A) 5 mm thick 
sample; B) 20 mm thick sample. 
In a Gaussian function the FWHM is related to the sigma (σ) of the function.  
             
Equation 4: FWHM of a Gaussian function.  
The sigma was calculated for both 2D Gaussians and was 1.14 pixels for the 5 
mm thick sample, and 1.62 pixels for the 20 mm thick sample. This would result 
in a FWHM of 5.4 and 7.6 mm, respectively.  
In general, an increased sample thickness will result in lower signal intensities 
and more spread of the signal. This is beneficial for screening purposes, since 
larger areas can be interrogated during a measurement. However, for different 
clinical purposes, for example interrogating a designated cluster of 
microcalcifications or an attempt to measure the amount of carbonate 
substitution, it might be beneficial to compress the breast locally in order to 
decrease the sample thickness and lateral spreading and increase the signal 
levels.  
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4.4 The originating depth and spatial resolution of 
transmission Raman signal 
In the previous sections, the effect of the sample thickness on the signal quality 
is explored. Other factors important in localising the analyte are for example its 
physical size, whether it is a strong Raman scatterer or not, and the actual 
location. In this section the effect of the originating depth (location of the analyte 
in the z-direction) is tested. 
In a study by Everall et al (2010) it is shown that the resolution near either 
surface is improved compared to the bulk. When the analyte is on the surface 
the laser beam directly hits the object, so the beam size determines the 
resolution. On the collection surface the collection aperture limits the resolution 
since detected photons do not undergo significant migration anymore. In the 
experiment performed the analyte is almost at the same distance from the 
surface in both measurements, since the sample was rotated by 180o. X403 dye 
was injected in an 18 mm thick breast model and the sample is translated in 1 
mm steps on the transmission Raman setup (figure 4.6). 
Figure 4.6: mapping of samples with same thickness but different injection depth 
analyte A) Analyte injected at the front of the 18 mm thick sample; B) Analyte 
injected at the back of the 18 mm thick sample. 
 Panel A of figure 4.6 shows the intensity of the x403 signal over the map. The 
sample was then rotated 180˚ so that the dye is no longer positioned at the front 
of the sample (where the beam comes in) but at the back of the sample where 
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the collection fibre is located. The intensity of the x403 signal over the map in 
this second alignment is depicted in panel B of figure 4.6. 
A 2D Gaussian is fitted to both maps (figure 4.7). The original data points are 
indicated with green asterisks, and the fitted function is shown as a surface plot. 
The amplitude of the 2D Gaussian is slightly higher for the dye at the front of the 
sample (panel A) than for the dye at the back at the sample; 24.3 versus 27.6, 
respectively. A difference in signal spreading is observed in both figure 4.6 and 
4.7. The 2D Gaussian has a sigma of 3.4 pixels for the dye at the front of the 
sample and 4.2 pixels for the dye at the sample. This results with a pixel size of 
1 mm in a FWHM of 8.1 and 9.9 mm.  
 
Figure 4.7: 2D Gaussian fitted to the intensity levels of the 1016 cm-1 band of 
x403 in 18 mm thick sample injected in front or back (baseline corrected). 
In the transmission Raman measurements, signals are collected from all depths 
and there is no depth discrimination in the measurements. In the experiment 
described in this section, the size of the analyte was known, as was the 
thickness of the specimen. From a mapping experiment it could then be 
attempted to estimate the depth of origin of the analyte signal. However, from a 
single measurement the originating depth of the analyte signal cannot be 
calculated. Raman spectroscopy should thus be used as an adjunct to a 
traditional imaging technique such as mammography – if the depth information 
is required.  
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4.5 Measurements through skin  
In order to use the deep Raman setup non-invasively, measurements through 
skin should be feasible. As a first step, measurements were performed through 
porcine soft tissue with attached skin.  
In figure 4.8, measurements through a 15 mm porcine soft tissue sample with 
skin are shown. The intensity of the x403 over the translated sample is shown in 
panel A, and the 2D Gaussian fitted to these data points in panel B.  
Figure 4.8: Intensity map of x403 dye in a porcine soft tissue sample of 15 mm 
thick including skin. 
In the thickness experiments (4.3) expanding the depth from 5 to 20 mm led to 
a 10x signal decrease. The intensity through the 15 mm thick sample with skin 
is ~7 times lower compared to the 5 mm thick sample without skin in section 
4.3, which is in the expected range. The fitted 2D Gaussian had a FWHM of 5.4 
mm for the 5 mm thick sample, and 10.4 mm for the 15 mm thick sample 
including skin. The FWHM of the sample with skin was higher than that of the 
20 mm thick sample, indicating that skin introduces more dispersion than tissue. 
During the deep Raman theatre project (results found in Chapter 5), 41 
specimens were measured of which four had skin attached. In figure 4.9, the 
Raman measurements on one of the fresh breast specimens with attached skin 
are shown. In the upper panel measurements through skin are shown and in the 
lower panel measurements through tissue on the same specimen. 
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Figure 4.9: Measurements though skin and through tissue only on a fresh human 
breast specimen. 
The sample thickness is equal for the area with and without skin and 
measurements could be obtained from both. However, the measurements 
through tissue clearly show a higher SNR than measurements through skin; 
3.44, 4.77, 5.42, 5.75, and 7.24 compared to 2.98, 3.07, and 3.55. The SNR is 
calculated by taking the amplitude of the Gaussian fit to the band as the signal 
and devide this by the noise observed between 350 and 450 cm-1. 
In figure 4.10, measurements on a second breast specimen with attached skin 
are shown. In the upper panel, measurements through skin are shown, and in 
the lower panel measurements through tissue. Through both sets the 
characteristic Raman bands of breast tissue are shown although it should be 
noted that in the measurements without skin a higher SNR was obtained; 5.78, 
6.20, and 6.31 for the measurements through skin and 4.50, 9.82, and 12.58 for 
the measurements through tissue only.  
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Figure 4.10: Measurements through skin (n=3) and through tissue only (n=3) on a 
fresh breast specimen.   
Similar results were observed in the third specimen with skin attached. The two 
measurements through skin had a SNR of 3.9 and 4.0, while the measurements 
through tissue on the same sample had a SNR of 3.4, 6.3, 7.6, 8.8, and 9.7 
(figure 4.11).  
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Figure 4.11: Measurements through skin (n=2) and through tissue only (n-4) on a 
fresh human breast specimen. 
The last specimen had skin over the whole of the top and measurements 
comparing the signal with and without skin could not be performed. 
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5 Deep Raman spectroscopy on breast calcifications 
and tissue 
In this chapter the use of the deep Raman system is tested on breast 
calcification standards and fresh human breast tissue. The feasibility of using a 
pseudo marker for the amount of carbonate substitution is tested with bare 
samples and samples buried in breast models. Furthermore, a proof of principle 
study is presented in which transmission Raman is applied on freshly excised 
human breast specimens. 
 
5.1 Use of a pseudo marker to estimate the amount of 
carbonate substitution 
The amount of CO3 substitution in the lattice can be deduced from the relative 
intensities of the corresponding bands. Unfortunately, the CO3 band at 1074  
cm-1 is relatively weak and often obscured by photon shot-noise (predominantly 
from fluorescence) which makes it difficult to characterise, especially by non 
invasive means. Haka et al. (2002) found a linear relationship between the 
FWHM of the 960 cm-1 phosphate stretching mode and the calcium carbonate 
content. In dentin samples a shift was observed (Xu et al., 2009).  If a shift or 
broadening of this peak was correlated to the carbonate concentration too it 
would make the development of a diagnostic tool substantially easier since this 
peak is much stronger than the features around 1042 and 1074 cm-1. The goal 
of this study was to investigate if the 960 cm-1 band could be used as a pseudo 
marker for the amount of carbonate substitution. 
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5.1.1 Position of the 960 cm-1 band 
Calcifications standards with different amounts of carbonate substitution were 
measured on the transmission Raman setup. A Gaussian band was fitted to the 
960 cm-1 phosphate band of the apatite, as shown in figure 5.1. The 
interpolated data is shown in blue and the fitted Gaussian in red.  
Figure 5.1: Gaussian fit on calcification standard with 2.3% carbonate 
substitution. 
The width and position of the Gaussian fit was then examined for 
measurements (n=5) on each of the samples. The mean peak position for each 
of the bare standard samples (n=5) was plotted against the calcification 
substitution percentage (figure 5.2 in green).  
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Figure 5.2: Relation of the carbonate substitution and the position of the 960 cm-1 
band. 
A logarithmic function was fit to these points (Figure 5.2): 
                      
Equation 5: Fit of the relationship between the carbonate concentration (x) of the 
calcification standard and the location of the 960 cm-1 band (y). 
The samples were buried in porcine soft tissue (tissue thickness = 3.6 mm, 
overall thickness 5.6 mm) and again a Gaussian was fitted to the data. The 
mean values for the buried calcifications (n=3) are depicted in the figure 5.2 in 
red. Equation 4 was used to provide a prediction for amount of carbonate 
substitution for the samples based on the peak positions of the 960 cm-1 band. 
It can be seen that the buried calcification standards have peak positions within 
a standard deviation of each other (shown with error bars). The actual versus 
the predicted carbonate substitution was plotted in Figure 5.3. Table 5.1 shows 
the root-mean-square-error of these predictions.  
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Figure 5.3: Actual versus predicted carbonate substitution based upon the 
position of the 960 cm-1 band. 
Carbonate 
substitution 
according to supplier 
(quoted as ± 1%) 
Mean predicted carbonate 
percentage through tissue 
(± std) 
Root mean square error 
of prediction  
(% carbonate) 
0.5% 0.51 ±0.04 0.03 
1.4% 1.79 ±0.23 0.43 
2.0% 2.91 ±0.37 0.96 
2.3% 2.80 ±0.46 0.63 
3.5% 3.61 ±0.05 0.12 
6.0% 6.77 ±1.23 1.26 
11.0% 14.88 ±3.85 4.99 
Table 5.1: Prediction of the percentage carbonate substitution based on the 
location of the peak. 
There is some subtle variability in the position of the phosphate peak 
between measurements from different areas of the same sample. It is 
thought to be due to the heterogeneous nature of the apatite standards used. 
Also, a systematic difference in width between bare and buried samples can 
be observed which is believed to be caused by the SNR of the buried 
samples. When signal was acquired for a longer period of time these 
differences were not observed. The region of interest (clinically relevant 
area) is between 0.5% and 2.5% and is based on work of Baker (2010) which 
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indicated that calcifications corresponding to benign pathology have an 
average carbonate substitution around 2%. This percentage is lower for 
calcifications corresponding to in situ and invasive pathology; where the 
amount of carbonate substitution is ~1.7% and ~1.4% on average, 
respectively. The data of these three pathology groups show a spread from 
0.5 to 2.5% carbonate substitution and in this clinically relevant area the 
relationship between the carbonate substitution and the band position of the 
phosphate band is semi-exponentional. 
Additional samples were kindly provided by Prof. Tecklenburg’s group 
(Central Michigan University, Michigan, USA). The samples had a range of 
B-type carbonate substitution, and some which exhibited both A- and B-type 
subsitution. Raman spectra measured on the Raman microscope system 
(Renishaw 1000 system, 60s accumualation time, n=5) are shown in figure 
5.4. The phosphate band shifts to a higher wavenumber depending on the 
relative amount of A- and B-type substitution and not with the total amount of 
carbonate substitution. Therefore, the band position of the phosphate band 
can only be used if the relative amount of A- and B-type carbonate 
substitution are marker for disease and not to measure the total amount of 
carbonate substitution.  
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Figure 5.4: Band position of the phosphate band depends on the relative amount 
of A- and B-type carbonate substitution and not on the amount of carbonate 
substitution.  
 
5.1.2  Width of the 960 cm-1 band 
The mean peak width for the fitted Gaussian of each of the bare standard 
samples (n=5) was plotted against the calcification substitution percentage in 
figure 5.5 in green. The width of the phosphate band increases with 
carbonate inclusion due to reduction of the crystallinity. Error bars show the 
uncertainty in the carbonate substitution value provided by the manufacturer 
(x axis) and the standard deviation of the replicate values of the spectral 
peak width (y axis). 
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Figure 5.5: Peak with 960 cm-1 band versus carbonate substitution. 
A linear function was fit to the width of the bare standards:  
                  
Equation 6: Fit of the relationship between the carbonate concentration (x) of the 
calcification standard and the width of the 960 cm-1 band (σ). 
The mean values for the buried calcifications (n=3) are also depicted in red 
in figure 5.5.  The buried calcification standards have peak widths within a 
standard deviation of each other (shown with error bars). Equation 5 was 
used to provide a prediction of the carbonate substitution percentage of the 
buried standards (tissue thickness = 3.6 mm, overall thickness 5.6 mm mm). 
Figure 5.6 shows the results plotted against actual concentration determined 
by the manufacturer with FTIR, the root-mean-square-error of the prediction 
is depicted in Table 5.2. Similar results were obtained for sample with an 
overall thickness of 16 mm (data not shown).  
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Figure 5.6: Predicted versus actual carbonate substitution of the buried material 
based on the width of the 960 cm-1 band. 
Carbonate substitution 
according to supplier 
(quoted as ± 1%) 
Mean predicted 
carbonate percentage 
through tissue  (± std 
dev) 
Root mean square error 
of prediction (% 
carbonate) 
0.5% 1.22 ±0.14 0.75 
1.4% 1.83 ±0.39 0.54 
2.0% 2.55 ±0.33 0.61 
2.3% 2.51 ±0.07 0.22 
3.5% 3.78 ±0.53 0.52 
6.0% 5.51 ±0.17 0.50 
11.0% 11.68 ±0.50 0.79 
Table 5.2: Prediction of the percentage carbonate substitution based on the 
width of the peak. 
In a later stage of the project, apatite standards were available from Prof. Mary 
Tecklenburg. When comparing the new samples to the other batches (figure 
5.7, samples Tecklenburg lab in blue, Clarkson Chromatography in red, and 
Rogers lab in green) it can be seen the same trend in the width of the Gaussian 
band is followed.  
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Figure 5.7: Gaussian fit on 960 cm-1 phosphate band on batches of apatites from 
different suppliers (Tecklenburg lab, Clarkson Chromatography, Rogers lab). 
 
5.2 SNR limits for using the pseudo marker 
In order to understand the limitations of this model, the signal to noise ratio is 
evaluated to understand what level of SNR is needed to predict a correct 
amount of carbonate substitution. 
In figure  5.8, a measurement is shown in which a block of tissue with two 
buried calcification standards. When translating the specimen, apatite bands will 
appear and disappear when a calcification standard is measured.   
The Gaussian fitting routine will try to fit a Gaussian to every single 
measurement. As can be seen in figure 5.8, this will not yield a valid answer in 
every case. For example, the measurement at 8mm does not show a peak in 
the spectrum to which a Gaussian can be fitted. A fit to this data will result to an 
answer with a high error bar.  
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Figure 5.8: Spatial resolution experiment. The sample contains two calcification 
standards and is translated in steps of 1 mm (60 seconds accumulation time). 
Spectra of the 960 cm-1 band (850-1000 cm-1 region depicted) are shown for each 
step. 
For every measurement the SNR was calculated and displayed against the grid 
position (Figure 5.9). By selecting data with a sufficient SNR, Gaussian fits will 
be a better representation of the spectrum and error bars will be smaller. 
    
Figure 5.9: Mean SNR of measurements (n=5) versus the position. 
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The figure indicates that two regions of interest are passed (the maxima) and it 
can be seen that pixel 8, in which spectrum the 960 cm-1 band was not readily 
identified, shows a local minimum. The two maxima correspond to the cuvettes 
(high amount of apatite) and the minimum to the walls of the cuvettes and the 
area between them (low amount of apatite).  
The carbonate substitution was evaluated based on the width of the 960 cm-1 
band. Measurements of the bare standards were used to create a model. When 
the mean of steps 2-4, which have the highest SNR of the first feature, was 
evaluated a carbonate substitution of 1.4% was found, the same value was 
supplied by the manufacturer. The average of steps 14-17, the highest SNR for 
the second feature, indicated a carbonate substitution of 2.1%. The carbonate 
substitution quoted by the supplier was 2%.  
To investigate the SNR limitation for using the pseudo marker calcifications 
standards were measured in front of a tissue block with a short accumulation 
time. By combining different spectra, as described in section 2.3.3.2, the SNR 
will increase. In table 5.3, the mean SNR is shown with the mean carbonate 
substitution and the predicted range in carbonate substitution for each amount 
of spectra averaged. 
# of 
spectra 
averaged  
# of 
combinations 
Predicted      
CO3 range  
CO3 mean (std)  Mean SNR (std)  
1  12 0-16.1%  6.5% (6.3)  3.43 (0.69)  
2  66  0-15.6%  6.4 % (4.0)  4.20 (1.14)  
3  220  0-14.4%  6.3% (3.1)  4.72 (1.16)  
4  495  0.1-13.2%  6.3% (2.5)  5.15 (1.21) 
5  792  0.7-12.2%  6.3% (2.1)  5.52 (1.28)  
6  924  1.3-11.2%  6.3% (1.7)  5.83 (1.29)  
7  792  2.0-10.2%  6.2% (1.5)  6.10 (1.30)  
8  495  2.8-9.2%  6.2% (1.2)  6.32 (1.24)  
9  220  3.7-8.5%  6.2% (1.0)  6.51 (1.14)  
10  66  4.6-7.7%  6.2% (0.8)  6.66 (0.98)  
11  12  5.4-7.1%  6.2% (0.5)  6.74 (0.67)  
12  1  6.2%  6.2 % 6.81  
Table 5.3: The predicted carbonate range, mean carbonate substitution and SNR 
for each combination of spectra. 
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In general, the higher the SNR value the closer the value found for carbonate 
substitution is to the 6% quoted by the supplier. This is more readily displayed 
in figure 5.10, in which the calculate amount of carbonate substitution is plotted 
versus the SNR. The extreme values in carbonate substitution are found with 
the lowest SNR value and the highest SNR values indicate a carbonate 
substitution level closest to what the supplier quoted. The value quoted by the 
supplier is indicated by a red line and the range quoted by dotted red lines. 
 
Figure 5.10: Predicted amount of carbonate substitution versus the SNR. 
When nine measurements are averaged, the calculated carbonate substitution 
has a standard deviation equal to the range quoted by the supplier. Averaging 
nine measurements gives a SNR of 6.5.  
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5.3 Theatre project deep Raman spectroscopy on breast 
As a proof of principle study for detection of calcifications in breast, breast 
tissue that was excised during (wire guided) local excisions was measured with 
the transmission Raman setup. X-ray images of the specimens (appendix E3) 
were used as a golden standard for the presence of calcifications.  
Due to the nature of the samples, a range of different properties are observed 
such as thickness, and the presence of skin or blue dye  within the sample 
group.  
From all these measurements transmission spectra could still be measured. In 
figure 5.12, the mean spectra of the specimens with and without blue dye are 
plotted. 
 
Figure 5.11: Mean spectra of specimens with (blue) and without blue dye (green). 
Both mean spectra show the same spectral features.  
The mean spectra of both groups are shown in figure 5.13. No 960 cm-1 band 
was detected in the calcification rich (red) spectrum which could be due to 
several limitations of the study.  
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Figure 5.12: Mean spectra of calcification rich (red) and calcification poor (blue) 
specimens. 
Due to the thickness of the samples, the intensity of the calcification bands will 
be limited. PCA was performed on the dataset in an attempt to pick up small 
variations between the calcification rich and calcification poor group. In figure 
5.14 below, the loads of principal component one to twelve are displayed. 
 
Figure 5.13: Loads of principal component one to twelve. 
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The scores of each principal component are then plotted versus the next 
principal component for both specimens with (red) and without (blue) 
calcifications. A minimal separation was found when plotting principal 
component one versus principal component two. 
 
Figure 5.14: Principal component 1, 2, and PC scores of PC1 and PC2 of 
calcification rich (red) and calcification poor (blue) specimens. 
It was then attempted to further improve the separation by increasing the 
amount of groups the data is split in to four: a group with no calcifications, a 
‘unknown’ group in which it is unsure from the X-ray images whether or not the 
specimens do contain calcifications, a group in which calcifications are present, 
and a group in which the calcification density is high. Mean spectra of all four 
groups are displayed in figure 5.16 below.  
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Figure 5.15: Mean spectra of specimens without calcifications (blue), specimens 
of which it is unsure whether they contain calcification (green), specimens with 
calcifications present (red) and specimens with a high amount of calcifications 
(cyan). 
For each group (no calcifications in green, unknown in blue, calcifications in 
yellow and a high amount of calcifications in red) the scores for each PC were 
plotted versus the next PC. Examples are shown in figure 5.16 below.  
 
Figure 5.16: PC score versus the PC score for the next principal component for 
specimens without calcifications (green), unknown (blue), calcifications (yellow) 
and high amounts of calcifications (red). 
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The group without calcifications (in green) can be separated from the group with 
a high amount of calcification (in red) when plotting principal component 1 
versus principal component 2 which is more readily displayed in figure 5.18. 
 
Figure 5.17: Plot of principal component 1 versus principal component 2 for 
specimens without calcifications (green) and specimens with a high amount of 
calcifications (red). 
When feeding the PCA information into linear discriminant analysis (LDA) a 
linear combination of PCA features is used to discriminate both groups. The 
PCA-LDA result of the group without calcifications (displayed in green) and the 
group with a high amount of calcifications present (red) is shown in figure 5.19. 
Transmission Raman spectroscopy can pick up calcifications in the breast when 
measuring through a considerable amount of tissue (3-25 mm).  
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Figure 5.18: PCA LDA separation of specimens without calcifications (green) and 
specimens with a high amount of calcifications (red). 
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6 Discussion 
6.1 Study of breast calcifications  
6.1.1 Study of calcification standards 
The FTIR and Raman measurements of the calcification standards were in 
agreement with existing literature. The position of the band in the 870 cm-1 - 880 
cm-1 region is different for both types of carbonate inclusion, type A and B. 
Curve-fitting procedures are sometimes used on bands in this region to 
estimate the relative proportion of the carbonate species, but the accuracy of 
such a method can be questioned. According to Rey et al. (2007), these 
techniques have not been verified by other types of analyses. Fleet and Liu 
(2007) state that the 873 cm-1, characteristic for B-type substitution, is not 
proportional to the content of B-type substituted carbonate in all apatites. In 
their study the samples were measured with both X-ray diffraction and FTIR. In 
all FTIR spectra the B-type substituted carbonate was dominant; while X-ray 
structures showed that in some samples the A-type substitution was more 
abundant than B-type substitution. 
Transmission FTIR measurements of calcified materials are easily saturated 
which is not always obvious. ATR FTIR and Raman measurements do not show 
this saturation due to the limited thickness probed (ATR FTIR) and much 
weaker Raman effect (Raman measurements). When plotting the position and 
area under the curve of the phosphate band over a line scan across a 
calcification standard, a band shift is observed relating to the position on the 
calcification. This indicates the observed shift could be an artefact since the 
composition of the standard is expected to be similar over a grain of sample 
prepared in laboratory.  Although band shifts were observed between different 
samples with similar levels but different types of carbonate substitution it is 
unsure whether this can be used to distinguish between samples with different 
types of carbonate substitution.  
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6.1.2 Comparison of spectroscopic techniques with staining 
Most of the breast calcifications observed in the investigated samples were 
found in the ducts of the breast, although calcifications were distributed over the 
whole of the specimen in the invasive samples. In general, samples with 
invasive pathology contained most calcifications, followed by in situ and benign 
pathology (invasive>in situ> benign). However, making clinical decisions based 
on clustering (the amount of calcifications per unit area), or numbers of 
calcifications remains controversial. Park et al. (2000) indicated that the 
significance of clustering is lower than 50%, which means that clustering alone 
does not necessarily suggest malignancy. 
In the benign samples FTIR imaging identified more calcification than both the 
AR and the VK staining. The finding of additional calcifications by FTIR analysis 
could be due to a higher sensitivity of the technique for calcifications that are 
forming or due to the small size of the calcifications which may result in them 
not being present in each of the slices of the samples. However, if differences 
between staining and FTIR were due to physical size of the calcifications 
resulting in the presence or absence in a certain slide, then it would be 
expected that also the reverse would be observed: i.e. positive staining by AR 
and/or VK and no spectroscopic sign of calcifications being present. 
The location of AR and VK staining matched for the majority of the samples 
although AR stains a more extended area than VK and thus more readily 
visible. The area stained by VK matches the FTIR imaging and is thus thought 
to give a better indication of the size of the calcifications than AR staining. This 
size is important since it is thought to correlate to disease (Buchbinder et al., 
2002). However, VK staining alone is not sufficient to identify and/or quantify 
bone like materials in cell cultures (Bonewald et al., 2003). It is proposed that 
techniques such as X-ray diffraction, electron microscopy or FTIR spectroscopy 
be applied. Furthermore it is suggested that in cases where there is no access 
to these techniques, both Alizarin Red and von Kossa staining should be used 
(Bonewald et al., 2003).  
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From the in vitro mineralisation time course study it becomes clear that the VK 
stain consistently lags the AR staining in the calcification formation process, 
which means that although calcium is present, hydroxyapatite has not 
crystallised. This means that caution should be exercised, when only employing 
one stain. For example, in many hospitals AR is used to show the presence of 
calcification in cartilage, whereas it is actually showing just the calcium 
distribution. Regions stained with AR appear to cover larger areas than the 
calcifications measured in this study and sometimes in early phases of 
calcification formation appear to stain when there are no calcifications apparent. 
When using stains, the use of at least two specific stains is therefore necessary. 
Raman and FTIR maps yield similar results so either one of these techniques 
would be sufficient to identify the presence of microcalcifications or to provide 
more detailed compositional information relating to the pathology, such as the 
amount of carbonate substitution. In pathology samples, FTIR will be preferable 
since the paraffin signal can be a problem when using Raman (Faoláin et al., 
2005). However, in vivo measurements of breast calcification compositions will 
most likely require the use of Raman spectroscopy. Deep Raman developments 
show the most promise as an in vivo clinical tool for probing breast 
calcifications. Since the target for deep Raman measurements are 
mammographic calcifications, it should be noted that the resolution of histology 
for calcification detection is much higher than that of mammography. However, 
the spatial resolution of deep Raman spectroscopy is low and depends strongly 
on the thickness of the interrogated tissue.  
 
6.1.3 Synchrotron FTIR imaging of breast calcifications 
Previously, synchrotron FTIR measurements on breast calcifications were only 
described by Baker (2009) who included a study of three maps on frozen tissue 
in her PhD thesis. Baker observed a lower amide concentration in the 
calcification than in the surrounding tissue, which is under scribed by the 
studies presented in this thesis. This indicates that the features observed by 
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Baker et al. are genuinely caused by the chemical composition of the 
calcifications and rules out higher amide concentrations in the surrounding 
tissue and pixel crosstalk. In the benign specimens amide bands were not 
observed at all. An interesting finding presented here is that in the benign 
specimens bands were observed relating to A-type substitution and no bands 
related with B-type substitution, while both types were found in the samples with 
in situ pathology. This probably has to do with the formation and maturation 
processes of the calcifications and may be related to the tumour acidifying its 
surroundings. Carbonate is known to act as a buffer when the pH changes. The 
decreasing amount of carbonate substitution in the apatite lattice could then be 
explained by the carbonate being used to stabilise pH and the differences in 
substitution type by the preferential carbonate substitution (formation) or 
dissolving at that pH. The ratio of A- and B-type substitution should be further 
studied to find out if this feature can be used as a marker for disease.  
In one of the specimens with invasive pathology a band was observed at 990 
cm-1. This band position is characteristic for whitlockite which can be observed 
in vitro together with apatite depending on the experimental variables and is 
observed in for example urinary calculi, prostatic deposits, cartilage and bone 
(Lagier and Baud, 2003) and might act as a seed for calcification. It would 
therefore be interesting to work backwards from the finding to the breast 
calcification environment. The amount of specimens and calcifications 
presented here is not enough for a quantitative study (although a qualitative 
study still fills a hole in literature), but the data obtained at the IRENI beamline 
will fill this gap. 
 
6.1.4 ATR imaging of breast calcifications 
During the ATR measurements a lower amount of amide was found in the 
calcification than in the surrounding tissue which is in agreement with the 
synchrotron measurements performed by Baker (2009). However, this could be 
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due to height differences caused by the slicing (the calcifications being higher 
than the surrounding tissue) which may cause a lack of tissue signal. The ATR 
FTIR measurements need more attention in order to understand the limitations 
and to understand which findings are genuinely caused by the chemical 
differences within the specimens and which by limitations of the system and 
specimens. The observed band shift between samples with different amounts of 
A- and B-type substitution could be due to the location of the measurements. 
When measuring at the middle of a grain calcification standard, a lower wave 
number position was found compared to measurements at the edge of a grain 
calcification standard.  However, this is a really exciting proof of principle study 
for ATR FTIR measurements of breast calcifications. In other breast tissue ATR 
FTIR studies calcifications were not measured (Rehman et al., 2010; Walsh et 
al., 2012) and ATR FTIR might be an interesting technique to understand more 
of the environment of the calcifications and the formation and maturation 
processes.  
 
6.1.5 Raman imaging of breast calcifications 
In the past, Raman mapping on pathology samples has always been limited by 
the presence of paraffin. However, the paraffin removal protocol applied in this 
study was sufficient and no paraffin bands or fluorescence was observed. This 
gives way to more extensive studies. Raman mapping can be done in 1 µm 
steps with the Streamline software, which is similar to the ATR FTIR 
measurements performed and a huge improvement compared to the benchtop 
transmission FTIR system. Raman spectroscopy is less prone to artefacts 
observed with FTIR such as band shifts and therefore an interesting avenue to 
explore. An interesting study would be to measure maps over calcifications with 
a higher exposure time (thus improving the SNR) and evaluating the amount of 
carbonate over the calcifications and investigate if the amount of carbonate 
substitution is equally distributed over the calcifications or not.  
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6.2 Deep Raman system evaluation 
6.2.1 Comparison porcine soft tissue and human mammary  
During the system construction and evaluation, porcine soft tissue was used as 
a model for human mammary tissue. Porcine soft tissue is a valid model since 
the properties are similar, as is the Raman spectra of both types of tissue.  
 
6.2.2 Sample thickness limits when using transmission Raman 
setup 
During the theatre project 41 samples were measured on the transmission 
Raman setup which were compressed between 3 and 25 mm. The SNR 
decreases exponentially with increasing thickness. The calcification bands 
might not be visible when a low SNR is obtained and measurements with 
insufficient SNR could therefore give incorrect feedback on the composition of 
the specimens. Caution should be practised when basing judgements on 
measurements with a low SNR. 
To achieve a SNR high enough to correctly assign the amount of carbonate 
substitution, a maximum thickness of 10 mm can be used with the current 
setup. The average thickness for compressed breast during the horizontal view 
is 54.1 mm ± 0.2 mm and 56.8 mm ± 0.2 mm for the oblique view (Robinson 
and Kotre, 2008). The SNR can be improved by employing a higher laser power 
and increasing the accumulation time of the measurements. In case the beam is 
defocused on the surface, the power is spread over a larger area and the laser 
power could be enhanced significantly without health risks. Furthermore, it 
should be noted that the breast can be compressed locally instead of the whole 
of the breast which would yield a lower sample thickness and thus higher SNR. 
Deep Raman measurements were performed through a tissue block of 45-50 
mm thickness by using a combination of SERS and SORS. The combination of 
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SERS and SORS opens up an interesting parallel avenue for probing organs 
with nanoparticles conjugated to specific antibodies to detect disease, 
ultimately, nanoparticles with different antibodies and reporter molecules (e.g. 
each disease is coded with a specific reporter molecule). Detection of several 
reporter molecules (the Raman label) simultaneously and separation of the 
signals makes it possible to indicate the origin of the signal; both in disease 
nature and its location. This capability would permit the use of the technique in 
a variety of medical fields such as cancer detection and the monitoring of 
treatments. In order to do this the target molecules needs to be known in order 
to tag the correct antibodies to the nanoparticles. To date, no studies have been 
performed on the excretion and toxicity of the nanoparticles used in this 
technique which can therefore not be used in vivo. It would however be possible 
to inject nanoparticles in excised tissue with tags to test for example the 
oestrogen and progesterone receptor status and HER2 expression. The whole 
of the specimen can be tested in this way instead of a few levels. Deep Raman 
techniques could in general be used to do an overall measurement of a 
specimen and used to warn a pathologist more levels of the specimen should 
be evaluated if one does not show abnormalities.   
 
6.2.3 Lateral spreading in transmission Raman measurements 
Due to lateral spreading of the photons, calcification signals will not only be 
measured right behind the calcification when aiming the beam right at the 
calcification, but also when the beam of the laser is placed slightly next to the 
calcification area. Lateral spreading might be utilised during interrogation of the 
breast by decreasing the amount of measurements in a grid and thus speeding 
up the procedure. 
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6.2.4 The originating depth and spatial resolution of transmission 
Raman signal 
Transmission Raman spectroscopy does not make a distinction between 
signals originating from different depths. Other deep Raman techniques such as 
spatially offset Raman spectroscopy (SORS) do have this capability but have a 
more limited range of sample thicknesses for which they can be used. However, 
when using transmission Raman as an adjunct to mammography, the 
mammography will give spatial information whilst the transmission Raman 
measurements can be used for chemical information.  
 
6.2.5 Measurements through skin 
Measurements through skin were performed on human mammary tissue with 
attached skin. Although measurements through tissue and skin show a lower 
SNR than measurements through tissue only, it can be concluded that 
transmission Raman measurements can be done through skin. This is an 
important requirement for a non-invasive technique.  
The measurements performed in this study are the first performed on mammary 
tissue with skin. In previous studies within the group (Baker et al., 2007; 
Matousek and Stone, 2007; Stone and Matousek, 2008; Stone et al., 2007) 
porcine soft tissue models were used and in other groups (Dingari et al., 2012; 
Saha et al., 2011) core biopsies without skin which also are much thinner than 
bulk tissue.  
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6.3 Deep Raman spectroscopy on breast calcifications and 
tissue 
6.3.1 Use of a pseudo marker to estimate the amount of carbonate 
substitution 
In this study, the use of the 960 cm-1 phosphate band as a pseudo marker for 
the amount of carbonate substitution was evaluated. The position of the band is 
not related to the amount of carbonate phosphate since this did not hold up 
when introducing new samples from different origin. The position is however 
related to the type of carbonate substitution. In contrast, the width of the 
phosphate band which is a marker for the amount of carbonate substitution. 
This 960 cm-1 phosphate band is the strongest in the apatite spectrum and not 
as easily obscured by shot noise as the other bands with which the carbonate 
content can be evaluated. Earlier studies (Haka et al., 2002) postulated a higher 
amount of carbonate within calcifications surrounded by tissue with benign 
pathology which was confirmed by Baker et al. (2010). This feature of the 
calcifications can now be exploited when measuring them through tissue. 
Measuring the amount of carbonate substitution through tissue gives way to a 
monitoring use of the deep Raman system. In certain cases monitoring would 
be preferable to invasive surgery, for example in older women where breast 
cancer may not advance in their lifetime. It might be interesting to study the type 
of carbonate substitution in a new study to investigate if there is a link with this 
feature and pathology grade. Another interesting possibility would be to study 
the calcifications change in time to shine light upon the formation and 
maturation process which is yet unknown. 
 
6.3.2 SNR limits for using the pseudo marker 
In this study it was evaluated that the measurement should have a SNR of 6.5 
before applying the Gaussian fitting routine to correctly establish the amount of 
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carbonate substitution. This is an important study since a wrongly estimated 
amount of carbonate substitution, relating to the pathology of the surrounding 
tissue (Baker et al., 2010), might in the future lead to inappropriate judgements 
regarding treatment versus monitoring. It should be noted that for evaluation of 
the calcification type (i.e. type I or type II) a lower SNR could be used since the 
spectra are more distinct than type II calcifications with different amounts of 
carbonate substitution.  
 
6.3.3 Theatre project deep Raman spectroscopy on breast 
During the theatre studies, transmission Raman spectra were measured on 
fresh human breast tissue. Breast calcification signals could be picked up 
during these studies, which is an important step forward. Previous studies within 
the group were all based on porcine soft tissue models with mock up 
calcifications. Studies recently published by other groups (Dingari et al., 2012; 
Saha et al., 2011) were done on core biopsies and although they target natural 
human breast calcifications, lack the thickness component of the studies 
described in this writing. In order to move towards non-invasive screening 
techniques based around Raman spectroscopy, which would give chemical 
information in contrast to the commonly used mammography, measuring 
through several centimetres of human tissue and skin is of paramount 
importance. Hence, this study is the first in its kind to detect human breast 
calcifications within tissue. As stated before, this technique could be used as an 
adjunct to mammography before taking biopsies or to interrogate bulk 
specimens and in case abnormalities are detected this could be flagged up to 
the pathology department. More levels of the specimen should then be 
evaluated by the pathologist if one does not show abnormalities. Another 
application might be to use a deep Raman probe in the cavity left after a biopsy, 
to interrogate the margins.  
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7 Conclusion 
7.1 Study of breast calcifications 
Known calcification standards were studied with FTIR and Raman to 
understand the relationship between chemical differences and spectral 
differences. The observed spectral differences were in agreement with the 
literature. Vibrational spectroscopy was then compared to routine staining 
procedures. From the time series experiments it is evident calcium builds up 
before the apatite is formed. Calcification formation was detected by FTIR (both 
synchrotron and benchtop instruments) at the same formation stage as Raman 
mapping and in a similar size area. VK staining gives a better indication of the 
calcification size than AR staining. The staining experiments also indicated that 
most of the calcifications were located in the ducts of the breast and it is 
plausible that formation takes place there.  
During the synchrotron experiments it transpired that amide is present in the 
centre of calcifications. Furthermore, a band shift was observed in the 1400-
1500 cm-1 region, depending on the pathology grade, which is related to the 
type of carbonate substitution. It is therefore hypothesised that not only the 
amount of carbonate substitution can act as a marker for disease, but also the 
type of carbonate substitution within the breast calcifications.  
Also, evidence for maturation was found in the shape and position of the 
phosphate band. In one of the calcifications a whitlockite core was observed 
which might act as a seed for the calcification.  
Both ATR FTIR and Raman imaging are worth pursuing, since the phosphate 
bands are not as easily saturated and the spatial resolution much higher than 
that achieved with benchtop FTIR. Raman mapping seems more promising than 
ATR FTIR since larger areas could be interrogated, the specimen was not 
disrupted and information from higher wavenumbers could be obtained. 
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7.2 Deep Raman system evaluation 
A deep Raman system was built which could be used in both SORS and 
transmission mode. Initial measurements were performed on porcine soft tissue 
to investigate the performance and limitations of the developed system. The 
amount of light coming through fresh human breast tissue decreases 
exponentially with thickness. An additional approach such as mammography 
should be used in parallel to complement the chemical information derived from 
deep Raman spectroscopy with spatial information. The presence of skin 
introduces an extra source of photon scattering which results in signal spread 
and diminishment. Although the SNR was lower for samples with skin than for 
samples without, satisfactory measurements could be performed on all 
specimens. 
 
7.3 Deep Raman spectroscopy on breast calcifications and 
tissue 
The performance of the 960 cm-1 phosphate band as a pseudo marker for the 
amount of carbonate substitution was tested. The width of the band changes 
linearly with increasing carbonate substitution. In contrast, the observed shift in 
position is not related to the amount but to the type of carbonate substitution. 
This band shift might be another marker for disease. Measurements were 
performed on calcification standards buried in both a porcine soft tissue model 
and human breast tissue. For an accurate estimation of carbonate substitution a 
SNR of at least 6.5 should be obtained.  
Furthermore, a proof of principle study using 41 fresh human breast tissue 
specimens was presented. Measurements could also be performed on 
specimens with blue dye and/or attached skin. Specimens with many 
calcifications could be separated from specimens without any calcifications 
using a PCA-LDA model. This finding is an important step towards transmission 
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Raman spectroscopy as a non-invasive tool to probe the calcifications within the 
breast. 
 
7.4 Recommendations for further work 
The sample thickness used in the Diamond experiments resulted in saturation 
of the calcification bands in the FTIR spectra. Similar features were seen at the 
IRENI beamline, although the saturation problems were less significant. For 
future work, a lower sample thickness is suggested for Diamond experiments (< 
3 micrometers). Originally, it was feared that slicing thinner sections would force 
out calcifications and therefore thicker sections were used. However, a 
pathology sample with a thickness of one micron was tested subsequently on 
the benchtop systems and it was observed that is still contained calcifications. It 
should be noted that the signals of the surrounding tissue will decrease 
significantly when doing transmission measurements on thinner samples. 
Raman mapping showed great potential after removing the paraffin on the 
pathology samples. Part of the calcification patches were removed by applying 
the protocol so it would be useful to test the effect of different paraffin removal 
procedures. The protocol which removes the paraffin sufficiently and damages 
pathology samples the least should then be used to set up a Raman mapping 
study. In this thesis, only a proof of principle study is shown and in future 
studies it would be desirable to increase the sample numbers. Also it would be 
interesting to pay attention to the location of the carbonate inclusions in the 
calcifications since in the proof of principle study the amount of carbonate at the 
centre of the calcification was found to be higher than in the rest of the 
calcification.   
The deep Raman study of fresh human specimens was limited by time and a 
more extensive study would be beneficial. To improve the detection of 
calcifications it is suggested that larger areas are interrogated using higher laser 
powers with defocused beam (maintaining the same power density). 
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Furthermore it would be beneficial to have a direct access to X-ray images 
instead of receiving these afterwards because the time each sample can be 
taken out of the clinical pathway is limited and insufficient to map the entire 
sample. When X-ray images are taken when the specimens are already 
compressed the resolution of the image will increase and would it be easier to 
target specific locations during the deep Raman measurements. A translation 
system in the xy- plane would save time and it could also be used for additional 
measurements. Furthermore, it would be easier to position samples on a 
horizontal platform (i.e. laying them down and pointing the laser down through 
the sample) than mounting them upright as in our experiments. The sample 
holder can compress samples down to 10 mm and an extension of the range to 
lower thicknesses would be helpful for the sample study although not necessary 
for thicker samples such as whole breast. 
 
 
 
171 
 
REFERENCES 
Adibelli, Z.H., Oztekin, O., Gunhan‐Bilgen, I., Postaci, H., Uslu, A., Ilhan, E., 
2010. Imaging Characteristics of Male Breast Disease. The Breast 
Journal 16, 510–518. 
Antonakos, A., Liarokapis, E., Leventouri, T., 2007. Micro-Raman and FTIR 
studies of synthetic and natural apatites. Biomaterials 28, 3043–3054. 
Apfelbaum, F., Diab, H., Mayer, I., Featherstone, J.D.B., 1992. An FTIR study of 
carbonate in synthetic apatites. Journal of Inorganic Biochemistry 45, 
277–282. 
Awonusi, A., Morris, M.D., Tecklenburg, M.M.J., 2007. Carbonate assignment 
and calibration in the Raman spectrum of apatite. Calcif Tissue Int 81, 
46–52. 
Aydin, H.M., Hu, B., Sulé Suso, J., El Haj, A., Yang, Y., 2011. Study of tissue 
engineered bone nodules by Fourier transform infrared spectroscopy. 
Analyst 136, 775. 
Baker, R., Matousek, P., Ronayne, K.L., Parker, A.W., Rogers, K., Stone, N., 
2007. Depth profiling of calcifications in breast tissue using picosecond 
Kerr-gated Raman spectroscopy. Analyst 132, 48–53. 
Baker, R., Rogers, K.D., Shepherd, N., Stone, N., 2010. New relationships 
between breast microcalcifications and cancer. Br J Cancer 103, 1034–
1039. 
Baker, R.N., 2009. Spectroscopic Analysis Of Breast Tissue Microcalcifications. 
Cranfield University. 
Bellahcène, A., Castronovo, V., 1995. Increased expression of osteonectin and 
osteopontin, two bone matrix proteins, in human breast cancer. Am J 
Pathol 146, 95–100. 
Bellahcène, A., Castronovo, V., 1997. Expression of bone matrix proteins in 
human breast cancer: potential roles in microcalcification formation and 
in the genesis of bone metastases. Bull Cancer 84, 17–24. 
Blamey, R.W., 2000. ABC of breast diseases: Screening for breast cancer. BMJ 
321, 689–693. 
Boczar, M., Wojcik, M.J., Szczeponek, K., Jamroz, D., Zieba, A., Kawalek, B., 
2003. Theoretical modeling of infrared spectra of aspirin and its 
deuterated derivative. Chemical Physics 286, 63–79. 
Bonewald, L.F., Harris, S.E., Rosser, J., Dallas, M.R., Dallas, S.L., Camacho, 
N.P., Boyan, B., Boskey, A., 2003. Von Kossa Staining Alone Is Not 
Sufficient to Confirm that Mineralization In Vitro Represents Bone 
Formation. Calcif Tissue Int 72, 537–547. 
Bonucci, E., 2007. Biological calcification: normal and pathological processes in 
the early stages. Springer. 
Boskey, A.L., Mendelsohn, R., 2005. Infrared spectroscopic characterization of 
mineralized tissues. Vibrational Spectroscopy 38, 107–114. 
Boyd, N.F., Guo, H., Martin, L.J., Sun, L., Stone, J., Fishell, E., Jong, R.A., 
Hislop, G., Chiarelli, A., Minkin, S., Yaffe, M.J., 2007. Mammographic 
References 
172 
 
Density and the Risk and Detection of Breast Cancer. New England 
Journal of Medicine 356, 227–236. 
Buchbinder, S.S., Leichter, I.S., Lederman, R.B., Novak, B., Bamberger, P.N., 
Coopersmith, H., Fields, S.I., 2002. Can the Size of Microcalcifications 
Predict Malignancy of Clusters at Mammography? Academic Radiology 
9, 18–25. 
Cancer Research UK, 2012a. CancerStats Incidence 2009 - UK. 
Cancer Research UK, 2012b. 
  www.cancerresearchuk.org/cancerstats/incidence/commoncancers. 
Cancer incidence for common cancers, accessed 19 July 2012. 
Cassidy, J., Bissett, D., Spence OBE, R.A.J., Payne, M. (Eds.), 2006. Oxford 
Handbook of Oncology, second edition. ed. Oxford University Press. 
Cheng, H.D., Cai, X., Chen, X., Hu, L., Lou, X., 2003. Computer-aided detection 
and classification of microcalcifications in mammograms: a survey. 
Pattern Recognition 36, 2967–2991. 
Chiou, H.-J., Hung, S.-C., Lin, S.-Y., Wei, Y.-S., Li, M.-J., 2010. Correlations 
among mineral components, progressive calcification process and 
clinical symptoms of calcific tendonitis. Rheumatology 49, 548 –555. 
Clark, R.J.H., 2002. Pigment identification by spectroscopic means: an 
arts/science interface. Comptes Rendus Chimie 5, 7–20. 
Cox, R., 2011. Cellular and molecular basis of mammary microcalcifications 
(PhD). Royal College of Surgeons in Ireland, Dublin. 
Cox, R.F., Hernandez-Santana, A., Ramdass, S., McMahon, G., Harmey, J.H., 
Morgan, M.P., 2012. Microcalcifications in breast cancer: novel insights 
into the molecular mechanism and functional consequence of mammary 
mineralisation. Br J Cancer 106, 525–537. 
Dekker, R.J., De Bruijn, J.D., Stigter, M., Barrere, F., Layrolle, P., Van 
Blitterswijk, C.A., 2005. Bone tissue engineering on amorphous 
carbonated apatite and crystalline octacalcium phosphate-coated 
titanium discs. Biomaterials 26, 5231–5239. 
Dessombz, A., Bazin, D., Dumas, P., Sandt, C., Sule-Suso, J., Daudon, M., 
2011. Shedding Light on the Chemical Diversity of Ectopic Calcifications 
in Kidney Tissues: Diagnostic and Research Aspects. PLoS ONE 6, 
e28007. 
Dey, P., Bundred, N., Gibbs, A., Hopwood, P., Baildam, A., Boggis, C., James, 
M., Knox, F., Leidecker, V., Woodman, C., 2002. Costs and benefits of a 
one stop clinic compared with a dedicated breast clinic: randomised 
controlled trial. BMJ 324, 507. 
Dingari, N.C., Barman, I., Saha, A., McGee, S., Galindo, L.H., Liu, W., Plecha, 
D., Klein, N., Dasari, R.R., Fitzmaurice, M., 2012. Development and 
comparative assessment of Raman spectroscopic classification 
algorithms for lesion discrimination in stereotactic breast biopsies with 
microcalcifications. Journal of Biophotonics n/a–n/a. 
Duffy, S.W., Tabar, L., Olsen, A.H., Vitak, B., Allgood, P.C., Chen, T.H.H., Yen, 
A.M.F., Smith, R.A., 2010. Absolute numbers of lives saved and 
overdiagnosis in breast cancer screening, from a randomized trial and 
References 
173 
 
from the Breast Screening Programme in England. J Med Screen 17, 
25–30. 
Eckel, R., Huo, H., Guan, H.-W., Hu, X., Che, X., Huang, W.-D., 2001. 
Characteristic infrared spectroscopic patterns in the protein bands of 
human breast cancer tissue. Vibrational Spectroscopy 27, 165–173. 
Elmore, J.G., Armstrong, K., Lehman, C.D., Fletcher, S.W., 2005. Screening for 
breast cancer. JAMA 293, 1245–1256. 
Elston, C. w., Ellis, I. o., 1991. pathological prognostic factors in breast cancer. 
I. The value of histological grade in breast cancer: experience from a 
large study with long-term follow-up. Histopathology 19, 403–410. 
Estepa, L., Daudon, M., 1997. Contribution of Fourier transform infrared 
spectroscopy to the identification of urinary stones and kidney crystal 
deposits. Biospectroscopy 3, 347–369. 
Evans, A., 2003. The diagnosis and management of pre-invasive breast 
disease: Radiological diagnosis. Breast Cancer Res 5, 1–4. 
Evans, A., Pinder, S., Wilson, R. (Eds.), 2002. Breast calcification: A 
diagnostive manual. Greenwich Medical Media. 
Evans, A.J., Wilson, A.R.M., Burrell, H.C., Ellis, I.O., Pinder, S.E., 1999. 
Mammographic features of ductal carcinoma in situ (DCIS) present on 
previous mammography. Clinical Radiology 54, 644–646. 
Everall, N., Matousek, P., MacLeod, N., Ronayne, K.L., Clark, I.P., 2010. 
Temporal and Spatial Resolution in Transmission Raman Spectroscopy. 
Applied Spectroscopy 64, 52–60. 
Faibish, D., Gomes, A., Boivin, G., Binderman, I., Boskey, A., 2005. Infrared 
imaging of calcified tissue in bone biopsies from adults with 
osteomalacia. Bone 36, 6–12. 
Fandos-Morera, A., Prats-Esteve, M., Tura-Soteras, J.M., Traveria-Cros, A., 
1988. Breast tumors: composition of microcalcifications. Radiology 169, 
325–327. 
Faoláin, E.Ó., Hunter, M.B., Byrne, J.M., Kelehan, P., Lambkin, H.A., Byrne, 
H.J., Lyng, F.M., 2005. Raman Spectroscopic Evaluation of Efficacy of 
Current Paraffin Wax Section Dewaxing Agents. Journal of 
Histochemistry & Cytochemistry 53, 121 –129. 
Fleet, M.E., 2009. Infrared spectra of carbonate apatites: ν2-Region bands. 
Biomaterials 30, 1473–1481. 
Fleet, M.E., Liu, X., 2007. Coupled substitution of type A and B carbonate in 
sodium-bearing apatite. Biomaterials 28, 916–926. 
Fleisch, H., 1998. Bisphosphonates: Mechanisms of Action. Endocrine Reviews 
19, 80–100. 
Fleischmann, M., Hendra, P.J., McQuillan, A.J., 1974. Raman spectra of 
pyridine adsorbed at a silver electrode. Chemical Physics Letters 26, 
163–166. 
Fondrinier, E., Lorimier, G., Guerin-Boblet, V., Bertrand, A.-F., Mayras, C., 
Dauver, N., 2002. Breast Microcalcifications: Multivariate Analysis of 
Radiologic and Clinical Factors for Carcinoma. World Journal of Surgery 
26, 290–296. 
References 
174 
 
Foschini, M.P., Fornelli, A., Peterse, J.L., Mignani, S., Eusebi, V., 1996. 
Microcalcifications in ductal carcinoma in situ of the breast: histochemical 
and immunohistochemical study. Hum Pathol 27, 178–183. 
Frank, C.J., McCreery, R.L., Redd, D.C.B., 1995. Raman Spectroscopy of 
Normal and Diseased Human Breast Tissues. Analytical Chemistry 67, 
777–783. 
Frank, C.J., Redd, D.C.B., Gansler, T.S., McCreery, R.L., 1994. 
Characterization of human breast biopsy specimens with near-IR Raman 
spectroscopy. Analytical Chemistry 66, 319–326. 
Frappart, L., Boudeulle, M., Boumendil, J., Lin, H.C., Martinon, I., Palayer, C., 
Mallet-Guy, Y., Raudrant, D., Bremond, A., Rochet, Y., Feroldi, J., 1984. 
Structure and composition of microcalcifications in benign and malignant 
lesions of the breast: Study by light microscopy, transmission and 
scanning electron microscopy, microprobe analysis, and X-ray diffraction. 
Human Pathology 15, 880–889. 
Frappart, L., Remy, I., Lin, H.C., Bremond, A., Raudrant, D., Grousson, B., 
Vauzelle, J.L., 1986. Different types of microcalcifications observed in 
breast pathology. Correlations with histopathological diagnosis and 
radiological examination of operative specimens. Virchows Arch A Pathol 
Anat Histopathol 410, 179–187. 
Furedi, H., Walton, A.G., 1968. Transmission and Attenuated Total Reflection 
(ATR) Infrared Spectra of Bone and Collagen. Appl. Spectrosc. 22, 23–
26. 
Gadaleta, S.J., Gericke, A., Boskey, A.L., Mendelsohn, R., 1996a. Two-
dimensional infrared correlation spectroscopy of synthetic and biological 
apatites. Biospectroscopy 2, 353–364. 
Gadaleta, S.J., Paschalis, E.P., Betts, F., Mendelsohn, R., Boskey, A.L., 1996b. 
Fourier transform infrared spectroscopy of the solution-mediated 
conversion of amorphous calcium phosphate to hydroxyapatite: New 
correlations between X-ray diffraction and infrared data. Calcif Tissue Int 
58, 9–16. 
Galkin, B.M., Muir, H.D., Feig, S.A., Soriano, R.Z., Frasca, P., 1983. 
Photomicrographs of breast calcifications. Radiographics 3, 450–477. 
Griffiths, P., De Haseth, J.A., 2007. Fourier Transform Infrared Spectrometry. 
John Wiley & Sons. 
Guinebretiere, J.M., Menet, E., Tardivon, A., Cherel, P., Vanel, D., 2005. 
Normal and pathological breast, the histological basis. Eur J Radiol 54, 
6–14. 
Gulley-Stahl, H.J., Haas, J.A., Schmidt, K.A., Evan, A.P., Sommer, A.J., 2009. 
Attenuated Total Internal Reflection Fourier Transform Infrared 
Spectroscopy: A Quantitative Approach for Kidney Stone Analysis. Appl. 
Spectrosc. 63, 759–766. 
Gulsun, M., Demirkazik, F., Ariyurek, M., 2003. Evaluation of breast 
microcalcifications according to breast imaging reporting and data 
system criteria and Le Gal’s classification. European Journal of 
Radiology 47, 227–231. 
References 
175 
 
Haka, A.S., Shafer-Peltier, K.E., Fitzmaurice, M., Crowe, J., Dasari, R.R., Feld, 
M.S., 2002. Identifying microcalcifications in benign and malignant breast 
lesions by probing differences in their chemical composition using 
Raman spectroscopy. Cancer Res 62, 5375–5380. 
Haka, A.S., Shafer-Peltier, K.E., Fitzmaurice, M., Crowe, J., Dasari, R.R., Feld, 
M.S., 2005. Diagnosing breast cancer by using Raman spectroscopy. 
Proceedings of the National Academy of Sciences of the United States of 
America 102, 12371–12376. 
Haka, A.S., Volynskaya, Z., Gardecki, J.A., Nazemi, J., Lyons, J., Hicks, D., 
Fitzmaurice, M., Dasari, R.R., Crowe, J.P., Feld, M.S., 2006. In vivo 
margin assessment during partial mastectomy breast surgery using 
Raman spectroscopy. Cancer Res 66, 3317–3322. 
Haka, A.S., Volynskaya, Z., Gardecki, J.A., Nazemi, J., Shenk, R., Wang, N., 
Dasari, R.R., Fitzmaurice, M., Feld, M.S., 2009. Diagnosing breast 
cancer using Raman spectroscopy: prospective analysis. J Biomed Opt 
14, 054023. 
Hirschmugl, C.J., Gough, K.M., 2012. Fourier Transform Infrared 
Spectrochemical Imaging: Review of Design and Applications with a 
Focal Plane Array and Multiple Beam Synchrotron Radiation Source. 
Applied Spectroscopy 66, 475–492. 
Horsnell, J., 2012. The use of Raman spectroscopy for the intra-operative 
assesment of axillary lymph nodes in breast cancer. Cranfield University. 
James, J.J., Evans, A.J., Pinder, S.E., Macmillan, R.D., Wilson, A.R.M., Ellis, 
I.O., 2003. Is the Presence of Mammographic Comedo Calcification 
Really a Prognostic Factor for Small Screen-detected Invasive Breast 
Cancers? Clinical Radiology 58, 54–62. 
Johnson, J.M., Dalton, R.R., Wester, S.M., Landercasper, J., Lambert, P.J., 
1999. Histological correlation of microcalcifications in breast biopsy 
specimens. Arch Surg 134, 712–5; discussion 715–6. 
Kalager, M., Adami, H.-O., Bretthauer, M., Tamimi, R.M., 2012. Overdiagnosis 
of Invasive Breast Cancer Due to Mammography Screening: Results 
From the Norwegian Screening Program. Ann Intern Med 156, 491–499. 
Kazarian, S.G., Chan, K.L.A., 2006. Applications of ATR-FTIR spectroscopic 
imaging to biomedical samples. Biochimica et Biophysica Acta (BBA) - 
Biomembranes 1758, 858–867. 
Keller, M.D., Majumder, S.K., Mahadevan-Jansen, A., 2009. Spatially offset 
Raman spectroscopy of layered soft tissues. Opt Lett 34, 926–928. 
Keller, M.D., Vargis, E., De Matos Granja, N., Wilson, R.H., Mycek, M.-A., 
Kelley, M.C., Mahadevan-Jansen, A., 2011. Development of a spatially 
offset Raman spectroscopy probe for breast tumor surgical margin 
evaluation. Journal of Biomedical Optics 16, 077006–077006–8. 
Kerssens, M.M., Matousek, P., Rogers, K., Stone, N., 2010. Towards a safe 
non-invasive method for evaluating the carbonate substitution levels of 
hydroxyapatite (HAP) in micro-calcifications found in breast tissue. 
Analyst 135, 3156–3161. 
Kontoyannis, C.G., Bouropoulos, N.C., Koutsoukos, P.G., 1997. Use of Raman 
Spectroscopy for the Quantitative Analysis of Calcium Oxalate Hydrates: 
References 
176 
 
Application for the Analysis of Urinary Stones. Appl. Spectrosc. 51, 64–
67. 
Kopans, D.B., 2007. Breast imaging. Lippincott Williams & Wilkins. 
Kriege, M., Brekelmans, C.T.M., Boetes, C., Besnard, P.E., Zonderland, H.M., 
Obdeijn, I.M., Manoliu, R.A., Kok, T., Peterse, H., Tilanus-Linthorst, 
M.M.A., Muller, S.H., Meijer, S., Oosterwijk, J.C., Beex, L.V.A.M., 
Tollenaar, R.A.E.M., Koning, H.J. de, Rutgers, E.J.T., Klijn, J.G.M., 2004. 
Efficacy of MRI and mammography for breast-cancer screening in 
women with a familial or genetic predisposition. N Eng J Med 351, 427–
437. 
Kuhl, C.K., Schrading, S., Leutner, C.C., Morakkabati-Spitz, N., Wardelmann, 
E., Fimmers, R., Kuhn, W., Schild, H.H., 2005. Mammography, breast 
ultrasound, and magnetic resonance imaging for surveillance of women 
at high familial risk for breast cancer. J Clin Oncol 23, 8469–8476. 
Kukreti, S., Cerussi, A., Tromberg, B., Gratton, E., 2008. Intrinsic near-infrared 
spectroscopic markers of breast tumors. Dis. Markers 25, 281–290. 
Kumar, G.L., Kiernan, J.A. (Eds.), 2010. Special stains and H&E, Second 
edition. ed. Dako North America, Carpinteria, California. 
Lagier, R., Baud, C.-A., 2003. Magnesium Whitlockite, a Calcium Phosphate 
Crystal of Special Interest in Pathology. Pathology - Research and 
Practice 199, 329–335. 
Lee, A.H.S., Ellis, I.O., 2008. The Nottingham Prognostic Index for Invasive 
Carcinoma of the Breast. Pathol. Oncol. Res. 14, 113–115. 
Leroy, G., Penel, G., Leroy, N., Bres, E., 2002. Human Tooth Enamel: A Raman 
Polarized Approach. Appl. Spectrosc. 56, 1030–1034. 
Liberman, L., Abramson, A.F., Squires, F.B., Glassman, J.R., Morris, E.A., 
Dershaw, D.D., 1998a. The breast imaging reporting and data system: 
positive predictive value of mammographic features and final 
assessment categories. AJR Am J Roentgenol 171, 35–40. 
Liberman, L., Evans, W.P., Dershaw, D.D., Hann, L.E., Deutch, B.M., 
Abramson, A.F., Rosen, P.P., 1994. Radiography of microcalcifications in 
stereotaxic mammary core biopsy specimens. Radiology 190, 223 –225. 
Liberman, L., Gougoutas, C.A., Zakowski, M.F., LaTrenta, L.R., Abramson, 
A.F., Morris, E.A., Dershaw, D.D., 2001. Calcifications highly suggestive 
of malignancy: comparison of breast biopsy methods. Am J Roentgenol 
177, 165–172. 
Liberman, L., Smolkin, J.H., Dershaw, D.D., Morris, E.A., Abramson, A.F., 
Rosen, P.P., 1998b. Calcification retrieval at stereotactic, 11-gauge, 
directional, vacuum-assisted breast biopsy. Radiology 208, 251–260. 
Lin, X.-M., Cui, Y., Xu, Y.-H., Ren, B., Tian, Z.-Q., 2009. Surface-enhanced 
Raman spectroscopy: substrate-related issues. Analytical and 
Bioanalytical Chemistry 394, 1729–1745. 
Margolin, F.R., Kaufman, L., Jacobs, R.P., Denny, S.R., Schrumpf, J.D., 2004. 
Stereotactic Core Breast Biopsy of Malignant Calcifications: Diagnostic 
Yield of Cores with and Cores without Calcifications on Specimen 
Radiographs1. Radiology 233, 251 –254. 
References 
177 
 
Matousek, P., 2007. Deep non-invasive Raman spectroscopy of living tissue 
and powders. Chem Soc Rev 36, 1292–1304. 
Matousek, P., Everall, N., Littlejohn, D., Nordon, A., Bloomfield, M., 2011. 
Dependence of Signal on Depth in Transmission Raman Spectroscopy. 
Appl. Spectrosc. 65, 724–733. 
Matousek, P., Stone, N., 2007. Prospects for the diagnosis of breast cancer by 
noninvasive probing of calcifications using transmission Raman 
spectroscopy. J Biomed Opt 12, 024008–1–024008–8. 
Matousek, P., Stone, N., 2009. Emerging concepts in deep Raman 
spectroscopy of biological tissue. Analyst 134, 1058–1066. 
Maurice-Estepa, L., Levillain, P., Lacour, B., Daudon, M., 2000. Advantage of 
zero-crossing-point first-derivative spectrophotometry for the 
quantification of calcium oxalate crystalline phases by infrared 
spectrophotometry. Clinica Chimica Acta 298, 1–11. 
McNay, G., Eustace, D., Smith, W.E., Faulds, K., Graham, D., 2011. Surface-
Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance 
Raman Scattering (SERRS): A Review of Applications. Applied 
Spectroscopy 65, 825–837. 
McPherson, K., 2000. ABC of breast diseases: Breast cancer---epidemiology, 
risk factors, and genetics. BMJ 321, 624–628. 
Miller, L.M., Smith, R.J., 2005. Synchrotrons versus globars, point-detectors 
versus focal plane arrays: Selecting the best source and detector for 
specific infrared microspectroscopy and imaging applications. Vibrational 
Spectroscopy 38, 237–240. 
Miller, L.M., Vairavamurthy, V., Chance, M.R., Mendelsohn, R., Paschalis, E.P., 
Betts, F., Boskey, A.L., 2001. In situ analysis of mineral content and 
crystallinity in bone using infrared micro-spectroscopy of the [nu]4 PO43- 
vibration. Biochimica et Biophysica Acta (BBA) - General Subjects 1527, 
11–19. 
Mohlenhoff, B., Romeo, M., Diem, M., Wood, B.R., 2005. Mie-Type Scattering 
and Non-Beer-Lambert Absorption Behavior of Human Cells in Infrared 
Microspectroscopy. Biophys J 88, 3635–3640. 
Moreira, L.M., Silveira Jr., L., Santos, F.V., Lyon, J.P., Rocha, R., Zângaro, 
R.A., Villaverde, A.B., Pacheco, M.T.T., 2008. Raman spectroscopy: A 
powerful technique for biochemical analysis and diagnosis. Spectroscopy 
22, 1–19. 
Morgan, M.P., Cooke, M.M., Christopherson, P.A., Westfall, P.R., McCarthy, 
G.M., 2001. Calcium hydroxyapatite promotes mitogenesis and matrix 
metalloproteinase expression in human breast cancer cell lines. Mol 
Carcinog 32, 111–117. 
Morgan, M.P., Cooke, M.M., McCarthy, G.M., 2005. Microcalcifications 
associated with breast cancer: an epiphenomenon or biologically 
significant feature of selected tumors? Journal of Mammary Gland 
Biology and Neoplasia 10, 181–187. 
Mun, H.S., Shin, H.J., Kim, H.H., Cha, J.H., Kim, H., 2013. Screening-detected 
calcified and non-calcified ductal carcinoma in situ: Differences in the 
imaging and histopathological features. Clinical Radiology 68, e27–e35. 
References 
178 
 
Nasse, M.J., Walsh, M.J., Mattson, E.C., Reininger, R., Kajdacsy-Balla, A., 
Macias, V., Bhargava, R., Hirschmugl, C.J., 2011. High-resolution 
Fourier-transform infrared chemical imaging with multiple synchrotron 
beams. Nat Meth 8, 413–416. 
Nguyen, C.V., Albarracin, C.T., Whitman, G.J., Lopez, A., Sneige, N., 2010. 
Atypical Ductal Hyperplasia in Directional Vacuum-Assisted Biopsy of 
Breast Microcalcifications: Considerations for Surgical Excision. Annals 
of Surgical Oncology 18, 752–761. 
Nishino, M., Yamashita, S., Aoba, T., Okazaki, M., Moriwaki, Y., 1981. The 
Laser-Raman Spectroscopic Studies on Human Enamel and Precipitated 
Carbonate-containing Apatites. Journal of Dental Research 60, 751 –
755. 
Nover, A.B., Jagtap, S., Anjum, W., Yegingil, H., Shih, W.Y., Shih, W.-H., 
Brooks, A.D., 2009. Modern breast cancer detection: a technological 
review. International Journal of Biomedical Imaging 2009, 902326. 
Orel, S.G., Schnall, M.D., 2001. MR imaging of the breast for the detection, 
diagnosis, and staging of breast cancer. Radiology 220, 13–30. 
Pampena, D.A., Robertson, K.A., Litvinova, O., Lajoie, G., Goldberg, H.A., 
Hunter, G.K., 2004. Inhibition of hydroxyapatite formation by osteopontin 
phosphopeptides. Biochem J 378, 1083–1087. 
Parham, D.M., Anderson, N., Buley, I., Pinder, S.E., Robertson, A.J., Wells, C., 
Alexander, J., Hussein, K.A., Kissen, L., Lesna, M., McCutcheon, J., 
Nicholas, D.S., Rasbridge, S.A., D’Sousa, L., Van der Horst, C., Haider, 
S., Hickling, M., 2010. Experts and performance in histopathology—A 
study in breast pathology. Pathology - Research and Practice 206, 749–
752. 
Park, J.M., Choi, H.K., Bae, S.-J., Lee, M.-S., Ahn, S.-H., Gong, G., 2000. 
Clustering of Breast Microcalcifications: Revisited. Clinical Radiology 55, 
114–118. 
Patnick, J. (Ed.), 2011. NHS Breast Screening Programme 2011 Annual 
Review. 
Penel, G., Delfosse, C., Descamps, M., Leroy, G., 2005. Composition of bone 
and apatitic biomaterials as revealed by intravital Raman 
microspectroscopy. Bone 36, 893–901. 
Penel, G., Leroy, G., Rey, C., Bres, E., 1998. MicroRaman Spectral Study of the 
PO4 and CO3 Vibrational Modes in Synthetic and Biological Apatites. 
Calcif Tissue Int 63, 475–481. 
Penel, G., Leroy, G., Rey, C., Sombret, B., Huvenne, J.P., Bres, E., 1997. 
Infrared and Raman microspectrometry study of fluor-fluor-hydroxy and 
hydroxy-apatite powders. Journal of Materials Science: Materials in 
Medicine 8, 271–276. 
Peroos, S., Du, Z., De Leeuw, N.H., 2006. A computer modelling study of the 
uptake, structure and distribution of carbonate defects in hydroxy-apatite. 
Biomaterials 27, 2150–2161. 
Popli, M., 2002. Pictorial essay : Breast calcification. Indian J Radiol Imaging 
12, 33–36. 
References 
179 
 
Proia, A.D., Brinn, N.T., 1985. Identification of calcium oxalate crystals using 
alizarin red S stain. Arch. Pathol. Lab. Med. 109, 186–189. 
Puchtler, H., Meloan, S.N., Terry, M.S., 1969. On the History and Mechanism of 
Alizarin and Alizarin Red S Stains for Calcium. J Histochem Cytochem 
17, 110–124. 
Purdie, C.A., McLean, D., 2009. Benign microcalcification and its differential 
diagnosis in breast screening. Diagnostic Histopathology 15, 382–394. 
Rakha, E.A., El-Sayed, M.E., Lee, A.H.S., Elston, C.W., Grainge, M.J., Hodi, Z., 
Blamey, R.W., Ellis, I.O., 2008. Prognostic Significance of Nottingham 
Histologic Grade in Invasive Breast Carcinoma. JCO 26, 3153–3158. 
Raman, C.V., Krishnan, K.S., 1928. A new type of secondary radiation. Nature 
121, 501–502. 
Rankov, V., 2005. An Algorithm for image stitching and blending. SPIE, pp. 
190–199. 
Rehman, I., Bonfield, W., 1997. Characterization of hydroxyapatite and 
carbonated apatite by photo acoustic FTIR spectroscopy. Journal of 
Materials Science: Materials in Medicine 8, 1–4. 
Rehman, S., Movasaghi, Z., Darr, J.A., Rehman, I.U., 2010. Fourier Transform 
Infrared Spectroscopic Analysis of Breast Cancer Tissues; Identifying 
Differences between Normal Breast, Invasive Ductal Carcinoma, and 
Ductal Carcinoma In Situ of the Breast. Applied Spectroscopy Reviews 
45, 355. 
Ren, B., Liu, G.-K., Lian, X.-B., Yang, Z.-L., Tian, Z.-Q., 2007. Raman 
spectroscopy on transition metals. Analytical and Bioanalytical Chemistry 
388, 29–45. 
Rey, C., Combes, C., Drouet, C., Lebugle, A., Sfihi, H., Barroug, A., 2007. 
Nanocrystalline apatites in biological systems: characterisation, structure 
and properties. Mat.-wiss. u. Werkstofftech. 38, 996–1002. 
Rey, C., Renugopalakrishman, V., Collins, B., Glimcher, M., 1991a. Fourier 
transform infrared spectroscopic study of the carbonate ions in bone 
mineral during aging. Calcified Tissue International 49, 251–258. 
Rey, C., Shimizu, M., Collins, B., Glimcher, M.J., 1991b. Resolution-enhanced 
fourier transform infrared spectroscopy study of the environment of 
phosphate ion in the early deposits of a solid phase of calcium 
phosphate in bone and enamel and their evolution with age: 2. 
Investigations in thev 3 PO4 domain. Calcif Tissue Int 49, 383–388. 
Robinson, M., Kotre, C.J., 2008. Trends in Compressed Breast Thickness and 
Radiation Dose in Breast Screening Mammography. Br J Radiol 81, 214–
218. 
Saha, A., Barman, I., Dingari, N.C., McGee, S., Volynskaya, Z., Galindo, L.H., 
Liu, W., Plecha, D., Klein, N., Dasari, R.R., Fitzmaurice, M., 2011. 
Raman spectroscopy: a real-time tool for identifying microcalcifications 
during stereotactic breast core needle biopsies. Biomedical Optics 
Express 2, 2792. 
Sainsbury, J.R.C., 2000. ABC of breast diseases: Breast cancer. BMJ 321, 
745–750. 
References 
180 
 
Scouten, C.W., Cunningham, M., 2012. Freezing Biological Samples. 
www.leica-microsystems.com white paper. 
Seregin, V.V., Coffer, J.L., 2006. Bias-assisted in vitro calcification of calcium 
disilicide growth layers on spark-processed silicon. Biomaterials 27, 
3726–3737. 
Shafer-Peltier, K.E., Haka, A.S., Fitzmaurice, M., Crowe, J., Myles, J., Dasari, 
R.R., Feld, M.S., 2002. Raman microspectroscopic model of human 
breast tissue: implications for breast cancer diagnosis in vivo. Journal of 
Raman Spectroscopy 33, 552–563. 
Shimoda, S., Aoba, T., Moreno, E. c., Miake, Y., 1990. Effect of Solution 
Composition on Morphological and Structural Features of Carbonated 
Calcium Apatites. Journal of Dental Research 69, 1731 –1740. 
Shoji, K., 1993. [Alizarin red S staining of calcium compound crystals in synovial 
fluid]. Nippon Seikeigeka Gakkai Zasshi 67, 201–210. 
Sickles, E.A., 1982. Mammographic detectability of breast microcalcifications. 
American Journal of Roentgenology 139, 913–918. 
Singh, N., Theaker, J.M., 1999. Calcium oxalate crystals (Weddellite) within the 
secretions of ductal carcinoma in situ–a rare phenomenon. Journal of 
Clinical Pathology 52, 145–146. 
Ślósarczyk, A., Paluszkiewicz, C., Gawlicki, M., Paszkiewicz, Z., 1997. The 
FTIR spectroscopy and QXRD studies of calcium phosphate based 
materials produced from the powder precursors with different CaP ratios. 
Ceramics International 23, 297–304. 
Smekal, A., 1923. Zur Quantentheorie der Dispersion. Naturwissenschaften 11, 
873–875. 
Stolik, S., Delgado, J.A., Pérez, A., Anasagasti, L., 2000. Measurement of the 
penetration depths of red and near infrared light in human “ex vivo” 
tissues. Journal of Photochemistry and Photobiology B: Biology 57, 90–
93. 
Stomper, P.C., Geradts, J., Edge, S.B., Levine, E.G., 2003. Mammographic 
Predictors of the Presence and Size of Invasive Carcinomas Associated 
With Malignant Microcalcification Lesions Without a Mass. AJR 181. 
Stone, N., Baker, R., Rogers, K., Parker, A.W., Matousek, P., 2007. Subsurface 
probing of calcifications with spatially offset Raman spectroscopy 
(SORS): future possibilities for the diagnosis of breast cancer. Analyst 
132, 899–905. 
Stone, N., Faulds, K., Graham, D., Matousek, P., 2010. Prospects of Deep 
Raman Spectroscopy for Noninvasive Detection of Conjugated Surface 
Enhanced Resonance Raman Scattering Nanoparticles Buried within 25 
mm of Mammalian Tissue. Analytical Chemistry 82, 3969–3973. 
Stone, N., Kerssens, M., Lloyd, G.R., Faulds, K., Graham, D., Matousek, P., 
2011. Surface enhanced spatially offset Raman spectroscopic 
(SESORS) imaging – the next dimension. Chem. Sci. 2, 776–780. 
Stone, N., Matousek, P., 2008. Advanced transmission Raman spectroscopy: a 
promising tool for breast disease diagnosis. Cancer Research 68, 4424–
4430. 
References 
181 
 
Tabar, L., Tony Chen, H., Amy Yen, M.F., Tot, T., Tung, T., Chen, L., Chiu, Y., 
Duffy, S.W., Smith, R.A., 2004. Mammographic tumor features can 
predict long‐term outcomes reliably in women with 1–14‐mm invasive 
breast carcinoma. Cancer 101, 1745–1759. 
Terkeltaub, R.A., 2001. Inorganic pyrophosphate generation and disposition in 
pathophysiology. Am J Physiol Cell Physiol 281, C1–11. 
Tfayli, A., Gobinet, C., Vrabie, V., Huez, R., Manfait, M., Piot, O., 2009. Digital 
Dewaxing of Raman Signals: Discrimination Between Nevi and 
Melanoma Spectra Obtained from Paraffin-Embedded Skin Biopsies. 
Applied Spectroscopy 63, 564–570. 
Thouverey, C., Bechkoff, G., Pikula, S., Buchet, R., 2009. Inorganic 
pyrophosphate as a regulator of hydroxyapatite or calcium 
pyrophosphate dihydrate mineral deposition by matrix vesicles. 
Osteoarthritis and Cartilage 17, 64–72. 
Tse, G.M., Tan, P.-H., Cheung, H.S., Chu, W.C.W., Lam, W.W.M., 2007. 
Intermediate to highly suspicious calcification in breast lesions: a radio-
pathologic correlation. Breast Cancer Res Treat 110, 1–7. 
Vardaxis, N.J., Brans, T.A., Boon, M.E., Kreis, R.W., Marres, L.M., 1997. 
Confocal laser scanning microscopy of porcine skin: implications for 
human wound healing studies. J Anat 190, 601–611. 
Vestergaard, P., Fischer, L., Mele, M., Mosekilde, L., Christiansen, P., 2011. 
Use of Bisphosphonates and Risk of Breast Cancer. Calcified Tissue 
International 88, 255–262. 
Vesty, S., 2013. Private communication. 
Volmer, M., Bolck, A., Wolthers, B., De Ruiter, A., Doornbos, D., Van der Slik, 
W., 1993. Partial least-squares regression for routine analysis of urinary 
calculus composition with Fourier transform infrared analysis. Clin Chem 
39, 948–954. 
Walsh, M.J., Kajdacsy-Balla, A., Holton, S.E., Bhargava, R., 2012. Attenuated 
total reflectance Fourier-transform infrared spectroscopic imaging for 
breast histopathology. Vibrational Spectroscopy 60, 23–28. 
Weaver, D.L., Rosenberg, R.D., Barlow, W.E., Ichikawa, L., Carney, P.A., 
Kerlikowske, K., Buist, D.S.M., Geller, B.M., Key, C.R., Maygarden, S.J., 
Ballard‐Barbash, R., 2006. Pathologic findings from the Breast Cancer 
Surveillance Consortium. Cancer 106, 732–742. 
Wilson, E.V., Bushiri, M.J., Vaidyan, V.K., 2010. Characterization and FTIR 
spectral studies of human urinary stones from Southern India. 
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 
77, 442–445. 
Wopenka, B., Pasteris, J.D., 2005. A mineralogical perspective on the apatite in 
bone. Materials Science and Engineering: C 25, 131–143. 
Xie, H., Stevenson, R., Stone, N., Hernandez-Santana, A., Faulds, K., Graham, 
D., 2012. Tracking Bisphosphonates through a 20 mm Thick Porcine 
Tissue by Using Surface-Enhanced Spatially Offset Raman 
Spectroscopy. Angewandte Chemie International Edition n/a–n/a. 
References 
182 
 
Xu, C., Karan, K., Yao, X., Wang, Y., 2009. Molecular structural analysis of 
noncarious cervical sclerotic dentin using Raman spectroscopy. Journal 
of Raman Spectroscopy 40, 1780–1785. 
Zonderland, H.M., Coerkamp, E.G., Hermans, J., Vijver, M.J. van de, 
Voorthuisen, A.E. van, 1999. Diagnosis of breast cancer: contribution of 
US as an adjunct to mammography. Radiology 213, 413–422. 
 
183 
 
APPENDICES 
Appendix A FTIR band assignments calcified 
materials (750-4000 cm
-1
) 
Band 
(cm-1) 
Band 
assignment 
Tissue/ material Reference 
770  Urates (Estepa and Daudon, 
1997) 
780 Water COM and COD (Maurice-Estepa et al., 
2000) 
852 HPO4
2- Octacalcium phosphate (Dekker et al., 2005) 
856 CO3 HAP (Antonakos et al., 2007) 
866 CO3 Labile carbonated 
apatite 
(Fleet, 2009), (Rey et al., 
2007) 
866 HPO4
2- Carbonated apatite (Apfelbaum et al., 1992) 
871 CO3 Type B carbonated 
apatite 
(Fleet, 2009) 
873 CO3 Type B carbonated 
apatite 
(Rey et al., 2007) 
875 CO3 (B) Carbonated apatite (Apfelbaum et al., 1992) 
877 CO3 HAP (Rehman and Bonfield, 
1997) 
878 CO3 Type A carbonated 
apatite 
(Fleet, 2009) 
878 CO3 (A) Carbonated apatite (Apfelbaum et al., 1992) 
880 CO3 Type A carbonated 
apatite 
(Rey et al., 2007) 
906 HPO4
2- Octacalcium phosphate (Dekker et al., 2005) 
912  COD (Maurice-Estepa et al., 
2000) 
947 TCP* Biphasic calcium 
phosphate 
(Victor and Kumar, 2007) 
948  COM (Maurice-Estepa et al., 
2000) 
948 CO3 Type A carbonated 
apatite 
(Antonakos et al., 2007) 
961 PO4 Carbonated apatite (Rehman and Bonfield, 
1997) 
962 PO4 HAP (Antonakos et al., 2007) 
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986 TCP* Biphasic calcium 
phosphate 
(Victor and Kumar, 2007) 
987  Brushite (Rey et al., 1991b)  
1000  Urates (Estepa and Daudon, 
1997) 
1004 Sodium 
hydrogen 
monohydrate 
Calcification in kidney 
tissue 
(Dessombz et al., 2011) 
1004  Brushite (Rey et al., 1991b) 
1006  Type B carbonated 
apatite 
(Rey et al., 1991b) 
1015  AB carbonated apatite (Antonakos et al., 2007) 
1018 PO4 Poorly crystalline non-
stoichiometric apatites 
(Chiou et al., 2010) 
1023  Type B carbonated 
apatite 
(Rey et al., 1991b) 
1023 PO Octacalcium phosphate (Dekker et al., 2005) 
1025 Whitlockite Calcification in kidney 
tissue 
(Dessombz et al., 2011) 
1028 PO4 Resting phase (Chiou et al., 2010) 
1029 PO4 Type B carbonated 
apatite 
(Antonakos et al., 2007) 
1029 PO4 HAP (Antonakos et al., 2007) 
1031 PO4 Matured crystalline 
stoiciometric apatite, 
resorptive phase 
(Chiou et al., 2010) 
1041 PO4 Carbonated apatite (Rehman and Bonfield, 
1997) 
1042 PO4 HAP (Rehman and Bonfield, 
1997) 
1044  Type B carbonated 
apatite 
(Rey et al., 1991b) 
1045  AB carbonated apatite (Antonakos et al., 2007) 
1058  Brushite (Rey et al., 1991b) 
1060 PO4 Type B carbonated 
apatite 
(Antonakos et al., 2007) 
1065 PO4 Brushite (Estepa and Daudon, 
1997) 
1070 PO Octacalcium phosphate (Dekker et al., 2005) 
1072  Type B carbonated 
apatite 
(Rey et al., 1991b) 
1079  Brushite (Rey et al., 1991b) 
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1080 Whitlockite Calcification in kidney 
tissue 
(Dessombz et al., 2011) 
1091 PO4 HAP (Rehman and Bonfield, 
1997) 
1092 PO4 AB carbonated apatite (Antonakos et al., 2007) 
1100 PO Octacalcium phosphate (Dekker et al., 2005) 
1102 Amorphous 
silica 
Calcification in kidney 
tissue 
(Dessombz et al., 2011) 
1104  Type B carbonated 
apatite 
(Rey et al., 1991b) 
1108  Brushite (Rey et al., 1991b) 
1110  Newly precipitated 
apatite 
(Rey et al., 1991b) 
1119 Octacalcium 
and carbatite 
Calcification in kidney 
tissue 
(Dessombz et al., 2011) 
1122 TCP* Biphasic calcium 
phosphate 
(Victor and Kumar, 2007) 
1124  Brushite (Rey et al., 1991b) 
1125  Newly precipitated 
apatite 
(Rey et al., 1991b) 
1133  Brushite (Rey et al., 1991b) 
1135 PO4 Brushite (Estepa and Daudon, 
1997) 
1140  Urates (Estepa and Daudon, 
1997) 
1145 Acid 
phosphate 
Bone (Miller et al., 2001) 
1225-
1235 
Amide III, β-
sheet 
structure 
Tissue (Socrates, 2001) 
1240-
1255 
Amide III, 
random chain 
Tissue (Socrates, 2001) 
1270-
1300 
Amide III, α-
helix 
Tissue (Socrates, 2001) 
1316 CC stretch Urinary stone (Wilson et al., 2010) 
1316 CO stretch COM (Maurice-Estepa et al., 
2000) 
1324 CO stretch COD (Maurice-Estepa et al., 
2000) 
1321 CO3 Carbonated apatite (Rehman and Bonfield, 
1997) 
1324  COM (Maurice-Estepa et al., 
2000) 
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1345  Ammonium hydrogen 
urate 
(Estepa and Daudon, 
1997) 
1410 CO3 Type B carbonated 
apatite 
(Fleet, 2009) 
1417 CO3 Carbonated apatite and 
HAP 
(Rehman and Bonfield, 
1997) 
1420 CO3 (B) Carbonated apatite (Apfelbaum et al., 1992) 
1420 CO3 A+B carbonated apatite (Apfelbaum et al., 1992) 
1427  Type B carbonated 
apatite 
(Antonakos et al., 2007) 
1435  Struvite (Estepa and Daudon, 
1997) 
1444  Type A carbonated 
apatite 
(Antonakos et al., 2007) 
1450  Type A carbonated 
apatite 
(Fleet, 2009) 
1450  Type B carbonated 
apatite 
(Antonakos et al., 2007) 
1454 CO3 Carbonated apatite and 
HAP 
(Rehman and Bonfield, 
1997) 
1455  Type B carbonated 
apatite 
(Fleet, 2009) 
1460 CO3 (B) Carbonated apatite (Apfelbaum et al., 1992) 
1460 CO3 (A) Carbonated apatite (Apfelbaum et al., 1992) 
1460 CO3 A+B carbonated apatite (Apfelbaum et al., 1992) 
1472 CO3 Type B carbonated 
apatite 
(Antonakos et al., 2007) 
1495  Type A carbonated 
apatite 
(Antonakos et al., 2007) 
1520-
1525 
Amide II 
(extended 
chain) 
Proteins and peptides (Socrates, 2001) 
1525 
(sh) 
 Type A carbonated 
apatite 
(Antonakos et al., 2007) 
1540-
1550 
Amide II 
(folded) 
Proteins and peptides (Socrates, 2001) 
1545 
(sh) 
 Type A carbonated 
apatite 
(Fleet, 2009) 
1550 CO3 (A) Carbonated apatite (Apfelbaum et al., 1992) 
1550 CO3 A+B carbonated apatite (Apfelbaum et al., 1992) 
1620 CO stretch COM (Maurice-Estepa et al., 
2000) 
1620  δ OH Urinary stone (Wilson et al., 2010) 
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1640 CO stretch COD (Maurice-Estepa et al., 
2000) 
1645-
1655 
Amide I, α-
helix 
Tissue (Socrates, 2001) 
1648 CO3 HAP (Rehman and Bonfield, 
1997) 
1649  Brushite (Estepa and Daudon, 
1997) 
1650 CO3 Carbonated apatite (Rehman and Bonfield, 
1997) 
1660-
1670 
Amide I, 
random chain 
Tissue (Socrates, 2001) 
1665-
1675 
Amide I, β-
sheet 
structure 
Tissue (Socrates, 2001) 
2345 
(sh) 
OH + NH4
+ Struvite (Estepa and Daudon, 
1997) 
3485 water COM and COD (Maurice-Estepa et al., 
2000) 
3570 OH HAP (Rehman and Bonfield, 
1997) 
3571 OH Carbonated apatite (Rehman and Bonfield, 
1997) 
3600 OH Sodium hydrogen urate (Estepa and Daudon, 
1997) 
3600 Sodium 
hydrogen 
urate 
monohydrate 
Calcification in kidney 
tissue 
(Dessombz et al., 2011) 
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Appendix B Raman band assignments calcified 
materials (400 – 2000 cm-1) 
Band 
(cm-1) 
Band assignment Tissue/ material Reference 
427 PO4 Enamel (Nishino et al., 1981) 
430 PO4 Bone (Penel et al., 2005) 
432 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
432 PO4 Dentine and bone (Penel et al., 1998) 
433 PO4 HAP (Penel et al., 1998) 
433 PO4 Enamel (Penel et al., 1998) 
440 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
442 PO4 Enamel (Nishino et al., 1981) 
445 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
448 PO4 HAP (Penel et al., 1998) 
450 PO4 Dentine and enamel (Penel et al., 1998) 
450 PO4 Bone (Penel et al., 2005) 
452 PO4 Bone (Penel et al., 1998) 
502 OCO bend COM (Kontoyannis et al., 
1997) 
508 OCO bend COD (Kontoyannis et al., 
1997) 
572 PO4 Enamel (Nishino et al., 1981) 
579 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
579 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
579  PO4 Enamel (Penel et al., 1998) 
580 PO4 HAP (Penel et al., 1998) 
580 PO4 Dentine (Penel et al., 1998) 
584 PO4 Bone (Penel et al., 1998) 
587 PO4 Bone (Penel et al., 2005) 
588 PO4 Enamel (Nishino et al., 1981) 
589 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
590 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
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590 PO4 Dentine and bone (Penel et al., 1998) 
591 PO4 HAP (Penel et al., 1998) 
604 PO4 Bone (Penel et al., 2005) 
605 PO4 Enamel (Nishino et al., 1981) 
607 PO4 HAP (Penel et al., 1998) 
608 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
608 PO4 Enamel (Penel et al., 1998) 
609 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
610 PO4 Dentine (Penel et al., 1998) 
611 PO4 Bone (Penel et al., 1998) 
614 PO4 HAP (Penel et al., 1998) 
630  Type A carbonated 
apatite 
(Penel et al., 1998) 
665 C-S Bone (Penel et al., 2005) 
675 CO3 Type A carbonated 
apatite 
(Penel et al., 1998) 
686 CO3 Enamel (Nishino et al., 1981) 
708 CO3 Enamel (Nishino et al., 1981) 
720  Bone (Penel et al., 2005) 
727 CH Breast tissue (Frank et al., 1994) 
750 CO3 Enamel (Nishino et al., 1981) 
756 CO3 (B) Bone (Penel et al., 2005) 
765 CO3 Type A carbonated 
apatite 
(Penel et al., 1998) 
782 C-C-O Bone (Penel et al., 2005) 
813 C-C, C-O-C Bone (Penel et al., 2005) 
849  Breast tissue (Frank et al., 1994) 
853 C-C-H (aromatic) Bone (Penel et al., 2005) 
870  Breast tissue (Frank et al., 1994) 
873 P-OH stretch Dentine and bone (Penel et al., 1998) 
874 CC (amino acids) 
 
Bone (Penel et al., 2005) 
890  Breast tissue (Frank et al., 1994) 
892  Bone (Penel et al., 2005) 
896 CC stretch COM (Kontoyannis et al., 
1997) 
912 CC stretch COD (Kontoyannis et al., 
1997) 
920  Dentine (Penel et al., 1998) 
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920 P-OH Bone (Penel et al., 2005) 
924  Bone (Penel et al., 1998) 
947 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
956 PO4 Enamel (Nishino et al., 1981) 
957 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
959 PO4 Enamel and dentine (Penel et al., 1998) 
960 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
961 PO4 Bone (Penel et al., 1998) 
964 PO4 HAP (Penel et al., 1998) 
972 =CH Breast tissue (Frank et al., 1994) 
1002 HPO4
2- Enamel (Penel et al., 1998) 
1003 HPO4
2- Dentine (Penel et al., 1998) 
1003 HPO4
2-, Phe Bone (Penel et al., 2005) 
1005 HPO4
2- Bone (Penel et al., 1998) 
1018 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
1021 CO3, PO4 Enamel (Nishino et al., 1981) 
1026 PO4 Enamel (Penel et al., 1998) 
1029 PO4 HAP (Penel et al., 1998) 
1030 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
1031 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
1031 PO4 Dentine (Penel et al., 1998) 
1032 PO4 Bone (Penel et al., 1998) 
1034 PO4 HAP (Penel et al., 1998) 
1035 PO4 Bone (Penel et al., 2005) 
1040 CO3, PO4 Enamel (Nishino et al., 1981) 
1041 PO4 HAP (Penel et al., 1998) 
1043 PO4 Enamel (Penel et al., 1998) 
1044 PO4 Bone (Penel et al., 1998) 
1045 PO4 Type B carbonated 
apatite 
(Penel et al., 1998) 
1046 PO4 Dentine (Penel et al., 1998) 
1048 PO4 HAP (Penel et al., 1998) 
1057 PO4 HAP (Penel et al., 1998) 
1059 PO4 Type A carbonated 
apatite 
(Penel et al., 1998) 
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1064 PO4 HAP (Penel et al., 1998) 
1066 CO3, PO4 Enamel (Nishino et al., 1981) 
1066 C-C stretch Breast tissue (Frank et al., 1994) 
1069 PO4 Dentine (Penel et al., 1998) 
1069 CO3 (B) Dentine (Penel et al., 1998) 
1070 CO3 Type B carbonated 
apatite 
(Penel et al., 1998) 
1071 PO4 Enamel and bone (Penel et al., 1998) 
1071 CO3 (B) Enamel and bone (Penel et al., 1998) 
1073 PO4, CO3 (B) Bone (Penel et al., 2005) 
1077 PO4 HAP (Penel et al., 1998) 
1079 C-C stretch Breast tissue (Frank et al., 1994) 
1100  Enamel (Nishino et al., 1981) 
1102 CO3 (A) Dentine (Penel et al., 1998) 
1103 CO3 (A) Enamel and bone (Penel et al., 1998) 
1107 CO3 Type A carbonated 
apatite 
(Penel et al., 1998) 
1119 C-C stretch Breast tissue (Frank et al., 1994) 
1176 COC, Tyr, Phe, 
Tyr 
Bone (Penel et al., 2005) 
1204 Tyr Bone (Penel et al., 2005) 
1242 Amide III Bone (Penel et al., 2005) 
1243 Amide III Bone (Penel et al., 1998) 
1245 Amide III Dentine (Penel et al., 1998) 
1260  Dentine (Penel et al., 1998) 
1262  Bone (Penel et al., 1998) 
 
1265 =CH  Breast tissue (Frank et al., 1994) 
1303 CH2 Breast tissue (Frank et al., 1994) 
1340 Amide III Bone (Penel et al., 2005) 
1398 Heme Bone (Penel et al., 2005) 
1439 CH2 Breast tissue (Frank et al., 1994) 
1449  Bone (Penel et al., 1998) 
1450 CH2/CH3 
protein/lipid 
Bone (Penel et al., 2005) 
1450  Dentine (Penel et al., 1998) 
1455 CH2 Breast tissue (Frank et al., 1994) 
1462 CO stretch COD (Kontoyannis et al., 
1997) 
1477 CO stretch COM (Kontoyannis et al., 
1997) 
1489 CO stretch COD (Kontoyannis et al., 
1997) 
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1585 CCH aromatic ring Bone (Penel et al., 2005) 
1629 CO stretch COM (Kontoyannis et al., 
1997) 
1632 CO stretch COD (Kontoyannis et al., 
1997) 
1654 C=C stretch Breast tissue (Frank et al., 1994) 
1660 Amide I Dentine (Penel et al., 1998) 
1662 Amide I Bone (Penel et al., 1998) 
1743 C=O stretch Breast tissue (Frank et al., 1994) 
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Appendix C Additional images FTIR imaging 
compared to staining 
C.1 Benign specimens 
 
Figure C-1: A) White light image of benign sample with overlaid the intensity fit 
of the hydroxyapatite; B) Alizarin Red staining of adjacent slide; C) H&E staining 
of adjacent slide; D) von Kossa staining of adjacent slide. 
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Figure C-2: A) White light image of benign sample with overlaid intensity of 
apatite fit; B) Alizarin Red staining adjacent slide; C) H&E staining adjacent slide; 
D) von Kossa staining adjacent slide, calcification highlighted by circle. 
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C.2 In situ specimens 
 
Figure C-3: A) Sample with in situ pathology; A) White light image with overlaid 
apatite fit; B) Alizarin Red stain on adjacent slide; C) H&E stain on adjacent slide; 
D) von Kossa staining adjacent slide. 
 
Figure C-4: A) Sample with in situ pathology; A) Apatite fit, each pixel is 6.25 µm; 
B) Alizarin Red staining on adjacent slide; C) H&E staining on adjacent slide; D) 
Von Kossa staining on adjacent slide. 
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C.3 Invasive specimens 
 
Figure C-5: A) White light image with biochemical fit apatite overlaid; B) Alizarin 
Red staining on adjacent slide; C) H&E staining on adjacent slice; D) von Kossa 
staining (counterstain van Gieson) on adjacent slide. 
 
Figure C-6: A) White light image with overlaid the apatite fit; B) Alizarin Red stain 
on adjacent slide; C) H&E staining on adjacent slide; D) Von Kossa staining on 
adjacent slide with van Gieson as counterstain. 
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Figure C-7: A) White light image with overlaid the apatite fit; B) Alizarin Red 
staining on adjacent slide; C) H&E staining adjacent slide; D) Von Kossa staining 
adjacent slide with counterstain van Gieson. 
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Appendix D Paraffin removal 
In order to perform Raman imaging on tissue sections from blocks in storage, 
the paraffin has to be removed as it generates excessive interfering 
fluorescence. In this section the chemical removal of paraffin with paraffin oil 
and hexane is evaluated by FTIR measurements before and after applying the 
de-paraffin protocol described in section 2.1.4. 
Pathology samples are normally stored in paraffin blocks. When these are 
sectioned and measured a paraffin signal will be present in addition to the 
signal of the specimen itself. In FTIR spectroscopy the paraffin signal contains 
of one strong band ~1472 cm-1 and a weaker band ~1463 cm-1. This obscures 
some of the carbonate bands of the apatite, but measurements are still 
valuable. The Raman spectrum of paraffin is however more disruptive. In figure 
D-1 the Raman spectrum of paraffin is shown. Also, the paraffin induces a 
strong fluorescence background on the Raman measurements. 
 
Figure D-1: Raman spectrum of paraffin wax (Faoláin et al., 2005). 
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Paraffin can be removed by chemical treatments, such as xylene or hexane 
dewaxing, or commercial products such as histoclear and trilogy (Faoláin et al., 
2005). Another possibility is ‘digital dewaxing’ in which paraffin signals are 
removed during the data analysis (Tfayli et al., 2009). Faoláin et al (2005) report 
that from all chemical removal protocols tested, hexane removes most of the 
paraffin. Therefore, it was decided to use a hexane based protocol to remove 
paraffin of a pathology sample for a proof of concept Raman mapping study. 
In figure D-2, a sample is shown before applying the protocol. In panel A, the 
white light image is shown with in red the area (2000x300 µm) measured with 
FTIR. In panel B, the biochemical fit of apatite is shown with three distinct areas 
of calcifications which are visible in the white light image (panel A) as dark 
patches. The same fit is shown in panel C with a threshold of 1 applied. The 
spectra corresponding to the white pixels in panel C are shown in panel D. The 
spectra show the characteristic phosphate band (~1030 cm-1), amide bands in 
the 1500-1700 cm-1, and paraffin bands.  
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Figure D-2: Sample before de-paraffin protocol A) White light image; B) 
Biochemical fit for apatite on area highlighted in panel A; C) Biochemical fit for 
apatite with threshold 2; D) Spectra correlated to white pixels in panel C. 
After applying the de-paraffin protocol the structure of the tissue changes 
dramatically, which can be seen in the white light image shown in panel A of 
figure D-3. The calcifications previously visible as darker patches are less 
distinctive after the protocol has been applied. In panel B and C the biochemical 
fit for apatite is shown for the same region as the data shown in figure D-2. In 
panel C, a threshold on 1 is applied. The spectra corresponding to the white 
pixels in panel C are displayed in panel D.  
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Figure D-3: Sample after de-paraffin protocol A) White light image; B) 
Biochemical fit for apatite on area highlighted in panel A; C) Biochemical fit for 
apatite with threshold 2; D) Spectra correlated to white pixels in panel C 
Compared to the measurement done before applying the de-paraffin protocol, 
less and smaller areas of calcification were found. In panel D, less of the 
characteristic paraffin bands can be seen, which is more readily displayed in 
figure D-4, in which the mean spectrum of the spectra shown in panel D of both 
figure D-2 and D-3 are displayed.  
Characteristic paraffin bands in FTIR are found ~1378, 1463, and 1472 cm-1. In 
figure D-4, these positions are highlighted by dotted lines. After the de-paraffin 
protocol (depicted in green) these bands disappear and the 1450 cm-1 band 
characteristic for carbonate become visible.  
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Figure D-4: Mean spectra of the spectra showed in panel D of figure 4.23 and 4.24 
(relating to white pixels in panels C). Locations of the characteristic paraffin 
bands are highlighted with dotted lines.  
In figure D-5, the chemical fit for paraffin is showed for both FTIR 
measurements. While paraffin is abundant before applying the de-paraffin 
protocol, the chemical fit scores close to zero in the map measured after the de-
paraffin protocol. 
 
Figure D-5: Chemical fit of paraffin in panel A) Before de-paraffin protocol; B) 
After de-paraffin protocol 
207 
 
Appendix E Deep Raman on theatre samples 
E.1 Consent form 
 
Figure E 1: Consent form used in the deep Raman study. 
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E.2 Patient information leaflet 
 
Figure E 2: Patient information leaflet used in the deep Raman study (page 1). 
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Figure E 3: Patient information leaflet used in the deep Raman study (page 2). 
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E.3 Raw deep Raman data and X-ray images of the 
specimens 
An overview of the deep Raman measurements on the theatre specimens is 
shown and compared to the X-ray images obtained in theatre. Deep Raman 
measurements were done in transmission mode, 3x60s, with the cosmic ray 
removal function on. On each specimen five measurements were performed on 
different locations.  
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Table E 1: Raw deep Raman data and X-ray images of fresh human breast 
specimens used in the study. 
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Appendix F Scientific output 
F.1 Publications 
F.1.1 Peer reviewed journals 
 Nicholas Stone, Marleen Kerssens, Gavin Rhys Lloyd, Karen Faulds, 
Duncan Graham, and Pavel Matousek, 2011. Surface enhanced spatially 
offset Raman spectroscopic (SESORS) imaging- the next dimension. 
Chemical Science, 2, pp.776-780. DOI: 10.1039/c0sc00570c 1 
 Marleen M. Kerssens, Pavel Matousek, Keith Rogers, and Nicholas 
Stone. 2010. Towards a safe non-invasive method for evaluating the 
carbonate substitution levels of hydroxyapatite (HAP) in micro-
calcifications found in breast tissue. Analyst, 135, pp. 6156-6161. DOI: 
10.1039/C0an00565g 
 
F.1.2 Other  
 M. Kerssens, R. Fullerton, P. Matousek, K. Rogers, N. Stone, 2011. 
Detecting breast cancer by probing micro calcifications with deep-
Raman. Lasers in Medical Science, 26, pp. 721 (published abstract). 
DOI: 10.1007/s10103-011-0967-1 
 Marleen M. Kerssens, Rachel F. Cox, Pavel Matousek, Keith D. Rogers, 
Maria P. Morgan and Nicholas Stone. New methodologies for 
identification of breast calcifications. Breast cancer research, 
(submitted) 
 Marleen M. Kerssens, Pavel Matousek, Nick Stone. Detecting breast 
microcalcifications in theatre: transmission Raman spectroscopy 
                                            
1 This paper was accompanied by a press release: ‘Raman imaging gives new hope for 
cancer diagnosis’, RSC website, February 10, 2011 
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measurements on freshly excised surgical breast specimens. (in 
preparation) 
 Marleen M. Kerssens, Robert Scott, Pavel Matousek, Keith D. Rogers, 
Nick Stone. FTIR synchrotron studies on human breast calcifications. (in 
preparation) 
 Marleen M. Kerssens, Alina B. Zoladek, Pavel Matousek, Keith D. 
Rogers, Sergei Kazarian, Nick Stone. ATR FTIR studies on human 
breast calcifications, a proof of principle. (in preparation) 
 
F.2 Conference contributions (oral presentations) 
 ‘Transmission Raman spectroscopy on freshly excised breast pathology 
specimens’, SciX 2012, Kansas City, Missouri, USA, September 30 – 
October 5  
 ‘High resolution imaging of breast calcification’, SciX 2012, Kansas City, 
Missouri, USA, September 30 – October 5 
 ‘Study of calcification formation and disease diagnostics utilising 
advanced vibrational spectroscopy’, Cranfield Health Postgraduate 
Conference, September 19 2012 
  ‘Non invasive breast cancer detection using Raman spectroscopy’, 
RCaH (Research Complex at Harwell) PhD Symposium Day, 
September 7 2012 
 ‘Exploring deep Raman spectroscopy for real-time non-invasive 
diagnosis of breast cancer’, Lasers for Science Facility User Meeting, 
Abingdon, April 24-26 2012 
 ‘Spectroscopic evaluation of breast calcifications’, Translational 
Medicine Day, Cranfield University, March 29 2012 
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 ‘Towards in vivo application of Deep-Raman to detect breast cancer: 
capability vs. clinical requirements’, FACSS 2011, Reno, Nevada, USA, 
October 2-7 (invited) 
 ‘Detecting breast cancer by probing micro calcifications with Deep-
Raman’, British Medical Laser Association (BMLA) Annual 
Conference, Woburn, April 19-20 2011  
 ‘Detecting breast cancer by probing microcalcifications’, Translational 
Medicine day, Cranfield University, March 4 2011 
 ‘Non invasive pathology the ‘Raman style’: detecting breast cancer by 
probing micro calcifications’, FACSS 2010, Raleigh, North Carolina, USA 
October 17 – 21 
 
F.3 Conference contributions (poster presentations) 
 ‘Transmission Raman spectroscopy on freshly excised breast pathology 
specimens’, SciX 2012, Kansas City, Missouri, USA, September 30 – 
October 5  
 ‘Comparison of breast calcification staining versus FTIR and Raman 
spectroscopy’, ICORS, Bangalore, India, August 12-17 2012 (presented 
by Prof Nick Stone) 
 ‘The use of deep Raman spectroscopy in the NHS breast screening 
programme’, SET for Britain 2012, London, March 12 and RCaH PhD 
Symposium Day September 7 20122 
 ‘Elucidating the relationship between breast calcifications and breast 
disease’, FACSS 2011, Reno, Nevada, USA, October 2-7 (poster prize) 
and Cranfield postgraduate conference September 23  
                                            
2
 This poster was accompanied by a press release: ‘Taking science to parliament’, Outline (staff 
newsletter GRH), March 2012, pp 20. 
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 ‘Non-invasive pathology with Raman spectroscopy: a potential technique 
for biopsy reduction in the breast screening programme’, Infrared and 
Raman discussion group meeting Christmas 2010, London, 
December 16  
 ‘Shining light on pathology: Towards a simple non-invasive method for 
evaluating the carbonate substitution levels of HAP’, SPEC 2010, 
Manchester, June 26-July 1 
 ‘Breast screening with Raman spectroscopy’, Public engagement 
symposium, Rutherford Appleton Laboratory, May 19 2010  
 
F.4 Prizes and awards 
 Coblentz Society Student Award, 20123 
 FACSS Student Poster Prize (3rd place), 2011 
 British Medical Laser Association Educational Award, 2011  
 Science and Technology Facility Council Science in society small award, 
2010 (£4k) 
 Finalist Biotechnology YES (Young Entrepreneur Scheme) 2009 
 Smith Nephew prize ‘Best medical technology’ Biotechnology YES 
(Young entrepreneur Scheme) 2009 
 
F.5 Public Engagement  
 Cheltenham Science Festival 2012 Optical Diagnostics session 
 Rainbow project, Chestnuts day nursery, May 2012 
 SET for Britain, 2012  
 
                                            
3
 This award was accompanied by a press release: ‘International prize for ‘no needles’ breast 
cancer diagnosis technique’, www.stfc.ac.uk, October 1, 2012. 
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 Cheltenham Science Festival 2011 Optical Diagnostics session4 
 Volunteer Cheltenham Science Festival 2010 
                                            
4
 This was publicised in the following article: ‘Hands-on in Cheltenham’, Fascination (STFC 
newsletter), issue 7, pp. 6-7, August 2011 
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